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Abstract 
Mammalian ABC (ATP-binding cassette) transporters are integral membrane proteins that 
translocate allocrites across biological membranes using ATP as a substrate. 
 
ABCB1 is a polyspecific efflux pump which can confer multidrug resistance in cancer. 
ABCB1 is also expressed in a variety of normal tissues where it functions to prevent the 
accumulation of toxic allocrites. Direct inhibition of ABCB1 can therefore have 
detrimental effects on patients. Identification of ABCB1-interacting partners that influence 
trafficking or function would therefore provide alternative targets for therapy which may 
be cell- or tissue-type specific. The “split-ubiquitin” yeast two-hybrid system, that can 
detect protein:protein interactions at the plasma membrane, was used to screen for 
ABCB1-interactors in a human liver library. All candidates isolated from the screen 
interacted with ABCB1 in a non-specific manner when subjected to strict testing. 
 
ABCB4, a close relative of ABCB1, is expressed primarily at the hepatocyte canalicular 
membrane where it flops phosphatidylcholine (PC) into the outer leaflet for extraction by 
bile salts. Many ABCB4 non-synonymous mutations have been linked to cholestatic liver 
diseases in humans, but data confirming an impact on ABCB4 function is lacking. 
Transient expression of wild-type (WT) ABCB4 in tissue culture has proved difficult 
because the protein is toxic to HEK293T cells. However, co-expression of the 
phosphatidylserine flippase ATP8B1 (FIC1) and its accessory protein CDC50A allowed the 
cells to tolerate ABCB4. To investigate the impact of SNPs on ABCB4 function, equivalent 
changes were introduced into the ABCB4 cDNA for transient expression in the presence 
or absence of ATP8B1/CDC50A. ABCB4 expression and targeting to the plasma 
membrane were monitored by western analysis and confocal microscopy, respectively, and, 
by “feeding” the transfected cells [methyl-3H]choline, PC efflux to added bile salt acceptor 
was measured. By thus mimicking the situation at the canalicular membrane I report the 
preliminary characterisation of nine variants of ABCB4 that have been linked to cholestatic 
liver disease. 
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HEK293 human embryonic kidney 293 cells 
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MDR  multidrug resistance 
MDR1  multidrug resistance protein 1 
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Met  methionine 
MHC  major histocompatibility complex 
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mRNA  messenger RNA 
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NBD  nucleotide-binding domain 
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OATP  organic anion transporting polypeptide 
OD  optical density 
Orf3a  ORF3a cucumber mosaic virus 
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PA  phosphatidic acid 
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PBC  primary biliary cirrhosis 
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PC  phosphatidylcholine 
PCR  polymerase chain reaction 
Nomenclature 
 
11 
 
PE  phosphatidylethanolamine 
PEG  poly[ethylene glycol]) 
PEI  Polyethyleneimine 
PEMT  phosphatidylethanolamine N-methyltransferase 
PET  positron emission tomography 
PFIC1  progressive familial intrahepatic cholestasis type 1 
PFIC2  progressive familial intrahepatic cholestasis type 2 
PFIC3  progressive familial intrahepatic cholestasis type 3 
P-gp  P-glycoprotein 
Phe  phenylalanine 
PI  phosphatidylinositol 
PKC  protein kinase C 
PLP2  proteolipid protein 2 
PM4-S  5α-pregnan-3α-ol-20-one sulphate 
PM5-S  5α-pregnan-3β-ol-20-one sulphate 
PMSF  phenylmethylsulfonyl fluoride 
pre-mRNA precursor mRNA 
PS  phosphatidylserine 
PSC  primary sclerosing cholangitis 
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RT  room temperature 
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siRNA  small interfering RNA 
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SSR3  signal sequence receptor gamma 
STAT6  signal transducer and activator of transcription 6 
SUR  sulfonylurea receptor 
SU-YTH spli-ubiquitin yeast two-hybrid system 
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TC  taurocholate 
TCA  trichloroacetic acid 
TE  Tris-EDTA 
TF  transcription factor 
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UBP  ubiquitin-specific protease 
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VAPB  vesicle-associated membrane protein-associated protein B 
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YIF1A  Yip1 interacting factor homolog A 
YIP1B  Yip1-interacting factor homolog B 
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1.1 The ABCs of ABCs 
The ATP-binding cassette (ABC) is a superfamily of integral membrane proteins, members 
of which have been found in all organisms studied to date (eukaryotic, eubacteria or 
archaebacteria) (Higgins, 1992). ABC proteins use energy derived from ATP binding 
and/or hydrolysis to drive an array of cellular processes. These range from mRNA export, 
as exemplified by Elf1p in Schizosaccharomyces pombe (Kozak et al., 2002) to double strand 
break repair involving Rad50 (Hopfner et al., 2000) and chromatin remodelling typified by 
SMC (structural maintenance of chromosomes) proteins such as BsSMC in Bacillus subtilis 
and MukB in Escherichia coli (E. coli) (Graumann et al., 1998, Melby et al., 1998). However, 
the vast majority of ABC proteins translocate allocrites1 across a biological membrane 
(Linton and Holland, 2011). 
 
1.2 Mammalian ABC proteins 
The human complement of ABC transporters comprises 48 genes encoding proteins 
primarily involved in the translocation of allocrites across cellular membranes (Linton and 
Holland, 2011). Phylogenetic analysis of the amino acid sequences of the human ABC 
proteins shows that they form seven distinct subfamilies, A to G (Dean et al., 2001). Many 
of the human ABC transporters have important roles in normal physiology and 
consequently their dysregulation or malfunction underlies a number of important diseases. 
This thesis focuses on two related mammalian exporters, ABCB1 and ABCB4, involved in 
drug efflux and lipid flopping into the bile, respectively. In the first chapter, a general 
overview of the structural features of the human ABC proteins is provided with particular 
focus on ABCB1 and ABCB4. In addition, the physiological role of several human ABC 
                                                          
1 The term allocrite was coined by Blight and Holland (Blight and Holland, 1990) to describe a compound 
which is translocated by a transporter protein but is not changed chemically (i.e. a transport substrate). This 
was done to distinguish the transported solute from the “true” ABC substrate which is ATP. 
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proteins is considered to outline the importance of these proteins in human health and 
disease and to highlight the significance of understanding how they function at the 
molecular level. 
1.2.1 Preface to Project 1: ABCB1 and multidrug resistance 
ABCB1 (MDR1/P-glycoprotein) is one of the major proteins involved in the development 
of multidrug resistance (MDR) in cancer patients and poses an obstacle in their 
chemotherapeutic treatment (Gottesman et al., 2002, Higgins, 2007). In normal physiology, 
ABCB1 is responsible for preventing the accumulation of toxic allocrites in the variety of 
tissues in which it is expressed. Therefore direct inhibition of ABCB1 can have detrimental 
effects on patients. In Chapter 3, the use of a modified version of the yeast two-hybrid 
system to screen for ABCB1-interactors is described. The aim of the experimental research 
was to identify ABCB1-interacting partners which influence its trafficking and/or function 
and provide alternative targets for therapy. Unfortunately, all candidates isolated from the 
screen interacted with ABCB1 in a non-specific manner when subjected to strict testing. 
1.2.2 Preface to Project 2: ABCB4 and cholestatic liver disease 
ABCB4 (MDR3 in humans, Mdr2 in mice) has 78% sequence identity (at the amino acid 
level) with ABCB1 (Lincke et al., 1991) but despite the high level of identity, ABCB4 does 
not exhibit broad allocrite specificity [although transport of a small subset of ABCB1 
allocrites has been demonstrated for ABCB4 (Smith et al., 2000)]. ABCB4 is primarily a 
phosphatidylcholine (PC) floppase which is highly expressed in the hepatocyte where it acts 
as one of the key players in bile formation (Smit et al., 1993, Smith et al., 1994). A large 
number of mutations have been reported which implicate ABCB4 in a spectrum of 
cholestatic disease. This ranges from the most severe phenotype, progressive familial 
intrahepatic cholestasis type 3 (PFIC3), to the milder, intermittent forms of cholestasis, e.g. 
benign recurrent intrahepatic cholestasis (BRIC), drug-induced cholestasis (DIC) or 
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intrahepatic cholestasis of pregnancy (ICP). It is important, therefore, to understand the 
effect of such mutations on ABCB4 in order to elucidate the molecular basis of cholestatic 
liver disease.  The approach to investigate the effect of ABCB4 mutations on the level of 
expression, trafficking and functionality of the protein in a mammalian expression system is 
described in Chapters 4 and 5. 
 
1.3 The ABCB subfamily of proteins 
The human ABCB (MDR/TAP) subfamily of proteins is the third largest of the ABC 
subfamilies and comprises 11 members (ABCB1 – ABCB11). ABCB1 is expressed in a 
variety of tissues including the brain, liver, testes, heart, kidneys and intestines (Cordon-
Cardo et al., 1990, Cordon-Cardo et al., 1989, Fojo et al., 1987, Thiebaut et al., 1987, 
Thiebaut et al., 1989) where it acts as a drug efflux pump protecting the organism against 
xenobiotics. ABCB11 is expressed in the liver (Gerloff et al., 1998) and it is the main bile 
salt export pump in humans (Strautnieks et al., 1998). ABCB4 is also expressed in the liver 
(Buschman et al., 1992) where it functions as a phosphatidylcholine floppase (van Helvoort 
et al., 1996). The transporter associated with antigen processing (TAP) heterodimer 
TAP1/2 (ABCB2/ABCB3) functions at the endoplasmic reticulum (ER) where it is 
involved in the cellular immune response via antigen presentation to MHC Class I 
molecules which can then be recognised by cytotoxic T lymphocytes (Lankat-Buttgereit 
and Tampe, 2002). ABCB5 is mainly expressed in pigmented cells (Chen et al., 2005) and it 
is thought to be involved in the development of chemoresistance in human melanomas 
(Frank et al., 2005). ABCB9, the closest homologue of the TAP proteins (Yamaguchi et al., 
1999b), is most highly expressed in the testes where it localises in the lysosomal 
compartments but its function has not yet been elucidated (Zhang et al., 2000). Finally, 
ABCB6, ABCB7, ABCB8 and ABCB10 all localise to the mitochondria where they act as 
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homodimers involved in iron–sulphur (Fe–S) cluster biogenesis and cellular iron 
metabolism (Zutz et al., 2009). 
 
Evidently, the members of the ABCB subfamily cover a diverse spectrum of biological 
functions and are expressed in a variety of tissues in the human body. ABCB1 and ABCB4 
are amongst the largest proteins of the ABCB subfamily (1280 amino acids in length). 
Although they display a high degree of similarity, each protein performs a different 
biological function and displays a distinct tissue expression pattern. As ABCB1 and ABCB4 
are the most pertinent transporters in the context of this report, they are considered in 
more detail in the following sections along with relevant examples drawn from the other 
ABC subfamilies where appropriate. 
 
1.4 Structural organisation of the ABCB1 and ABCB4 proteins 
ABC transporters are ubiquitous and likely to be found in any organism. They have a vast 
variety of allocrites ranging from small inorganic ions and essential amino acids to 
oligopeptides and even whole proteins.  Although they can be very different in their 
physiological roles, all ABC transporters share a common basic structure. This is 
composed, minimally, of four domains (Figure 1-1). Two transmembrane domains (TMDs) 
which span the membrane several times and form the translocation pathway across the 
lipid bilayer, and two nucleotide-binding domains (NBDs) which contain the ABC and 
bind and hydrolyse ATP acting as engines for the conformational changes induced during 
the transport process (Higgins et al., 1986). 
 
ABCB1 and ABCB4 are encoded as a single polypeptide with four domains (2×TMDs with 
2×NBDs) and they both localise to apical membrane of polarised cells (Buschman et al., 
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1992, Hammerle et al., 2000, Petriz et al., 2004). Most of our knowledge on ABCB4 
topology and predicted structure is based on studies of the best characterised member of 
the ABC family, ABCB1. Because of the high sequence homology between ABCB1 and 
ABCB4 (Van der Bliek et al., 1987) , it is reasonable to assume that both proteins adopt a
 
 
Figure 1-1. The core architecture of an ABC transporter. 
The minimal functional unit of an ABC transporter comprises two transmembrane domains (TMDs) 
and two nucleotide binding domains (NBDs). TMDs form the allocrite translocation pathway across 
the membrane and are not conserved across the ABC family. NBDs are the engines of the 
transporter which provide energy via ATP hydrolysis and are highly homologous amongst 
members of the ABC family. The process represented here is for an ABC exporter. Image created 
using the 3ds Max software from Autodesk.  
 
similar conformation and that ABCB4 translocates its allocrite(s) in a manner analogous to 
xenotoxin translocation fulfilled by ABCB1. In fact, as already mentioned, ABCB4 can 
transport drugs albeit with low efficiency (Smith et al., 2000) and ABCB1 has been 
reported to transport several phospholipids (Bosch et al., 1997, Eckford and Sharom, 2005, 
Romsicki and Sharom, 2001). Structure determination of ABC exporters has provided 
insights into the mechanisms of energy and signal transduction between the NBDs and 
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TMDs, which when interpreted in conjunction with biochemical and biophysical data, has 
led to an understanding of the mechanism of allocrite efflux. 
 
 
Figure 1-2. Structures of ABC exporters. 
All structures are shown cartoon format, with TMDs coloured in yellow and blue and NBDs 
coloured in red and grey. (A) Sav1866 (PDB: 2HYD), (B) MsbA (PDB: 3B60) and (C) Abcb1a (PDB: 
3G5U). Modified from (Zolnerciks et al., 2011). 
 
A number of NBD crystal structures now available have revealed the true nature of the 
NBD-NBD dimer which forms the catalytic site for ATP hydrolysis (Chen et al., 2003, 
Hopfner et al., 2000, Karpowich et al., 2001, Obmolova et al., 2000, Schmitt et al., 2003, 
Smith et al., 2002, Verdon et al., 2003, Zaitseva et al., 2006) and is described in Section 
1.4.1. Complementary to these data, are the crystal structures for 3 complete ABC 
exporters (Figure 1-2): the bacterial exporter Sav1866 from Staphylococcus aureus (Dawson 
and Locher, 2006), the lipid floppase MsbA from Salmonella typhimurium, E. coli and Vibrio 
Cholerae (Ward et al., 2007) and the ABCB1 homologue, Abcb1a, from Mus musculus (Aller 
et al., 2009). Abcb1a crystallised in a different conformation in which the NBDs do not 
share an interface. This may represent a different conformation of the transporter adopted 
during the transport cycle, but the physiological relevance remains untested. These 
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structures, notwithstanding their limited number and medium resolution, have revealed a 
TMD structure unique to exporters whose main features are summarised in Section 1.4.2. 
1.4.1 The nucleotide-binding domains (NBDs) 
The NBDs share a high degree of identity throughout the entire ABC family and all 
contain seven conserved motifs (Figure 1-3) (Kerr, 2002). Each NBD has an L-shaped 
topology with two subdomains. The F1-type “core” subdomain contains the Walker A 
(GxxGxGKS[S/T]) and Walker B (φφφφDE) motifs (where X is any amino acid; φ is a 
hydrophobic residue) together with the A-, Q-, D- and H-loops. The α-helical subdomain 
contains the ABC signature (LSGGQ) motif. In a full ABC transporter, the NBDs align in  
 
 
Figure 1-3. Structure of an ABC transporter NBD. 
This view shows one NBD from the perspective of its partner NBD across the NBD-NBD interface. 
The side chains of key amino acids and nucleotide (ADP) are shown in stick format. ADP 
molecules are coloured by atomic element (carbon, green; nitrogen, blue; oxygen, red; 
phosphorus, orange). The seven conserved motifs in each NBD are also highlighted. The core F1-
ATPase-like ATP-binding subdomain contains: the Walker A (yellow) and Walker B (green) motifs, 
the A-loop (red) and the Q- (purple), D- (orange) and H- (dark blue) loops. The α-helical subdomain 
contains the ABC signature (light blue) motif. Adapted from (Zolnerciks et al., 2011). 
 
a “head-to-tail” arrangement such that the Walker A motif (essential for ATP binding and 
hydrolysis) of one NBD is in close association with the ABC signature motif [also known 
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as the C-motif which is unique to the ABC superfamily (Hyde et al., 1990)] of the apposing 
NBD, allowing two ATP molecules to be trapped at the interface (Jones et al., 2009, Rees 
et al., 2009, Zolnerciks et al., 2011). 
1.4.2 The transmembrane domains (TMDs) 
Each of the aforementioned crystal structures obtained for ABC exporters (Figure 1-2) 
comprises six membrane-spanning helices (MSHs) per TMD followed by an NBD. In each 
TMD the MSHs extend significantly (~25 Å) into the cytosolic space. What is most notable 
in the conformation adopted by the bacterial Sav1866 is a phenomenon described as 
domain-swapping (Dawson and Locher, 2006), which was also observed later in the crystal 
structure of the mouse Abcb1a (Aller et al., 2009). In this arrangement, a number of the 
MSHs from one TMD are in close association with a number of MSHs from the other 
TMD. In the case of Sav1866, MSH1-2 from one TMD associate with MSH3-6 from the 
other TMD (Dawson and Locher, 2006). For Abcb1a, the composition of the two helix 
bundles is different but still occurs in a domain-swapped arrangement (MSH4-5 of the first 
TMD associate with MSH1-3 and 6 of the second TMD) (Aller et al., 2009). Domain 
swapping allows each TMD to contact both NBDs via specific architecturally conserved α-
helical loops known as the coupling helices (Locher et al., 2002). The coupling helices form 
non-covalent interactions with the NBDs at their shared interface. This causes the MSHs 
to be tilted significantly in respect to the plane of the membrane so that the TMDs are 
always closed to one side of the membrane and prevent the passive diffusion of allocrites. 
Such arrangement allows the two intracellular loops of each TMD to contact both NBDs 
which may be what allows the inwardly-open conformation observed in a Abcb1a crystal to 
form and be stage of the efflux cycle. Consequently, the TMDs are mechanistically coupled 
to the NBDs in a way that structural rearrangements caused by allocrite binding at the 
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TMDs, is transduced into the NBDs to stimulate ATP binding and hydrolysis, to drive 
translocation of the allocrite, and to reset the transporter (Zolnerciks et al., 2011). 
 
1.5 ABCB1 and ABCB4 topology 
The original topology model of ABCB1 predicted 6 hydrophobic transmembrane α-helices 
per TMD each followed by a hydrophilic NBD on the cytoplasmic face of the plasma 
membrane (Chen et al., 1986) (Figure 1-4). Such topology was later confirmed by Loo and 
Clarke in a mutant form of human ABCB1 whereby specific cysteine residues were 
introduced into the predicted extracellular or cytosolic loops of an otherwise cysteine-less 
protein and assaying for their ability to be biotinylated (Loo and Clarke, 1995a). In 
addition, the crystal structure of the murine ABCB1 homologue, albeit at a medium 
resolution, demonstrates two bundles of 6 MSHs per TMD each followed by a lobular 
NBD (Aller et al., 2009). 
 
 
Figure 1-4. Domain organisation of ABCB1. 
The topology of ABCB1 is illustrated highlighting the arrangement of the transmembrane domains 
(TMDs) and the nucleotide-binding domains (NBDs). The numbered cylinders within the TMDs 
represent the membrane-spanning α-helices. The seven conserved motifs within the NBDs are also 
demonstrated. The linker region, a cytoplasmic stretch of 75 amino acids joining the two TMDs is 
indicated with an asterisk (*). The glycosylation sites (N91, N94 and N99) in the first extracellular 
loop are indicated by the helical lines. 
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Comparison of the primary sequence of ABCB4 with that of ABCB1 reveals an almost 
identical topology for the two proteins (Van der Bliek et al., 1987). Such observation is in 
agreement with the outcome of a prediction algorithm which, based on the incorporation 
of experimental data, calculates that ABCB4 should have a similar topology to ABCB1 
(Tusnady et al., 2006). It is therefore expected that the crystal structure of ABCB4 would 
closely resemble that obtained by Stephen Aller and colleagues for the murine homologue 
of ABCB1 (Aller et al., 2009). 
1.6 The role of the “linker region” in ABCB1 and ABCB4 
The first NBD is joined to the second TMD of ABCB1 by a stretch of 75 amino acids 
(residues 633–709 as predicted by computer-assisted algorithms), commonly known as the 
linker region (Figure 1-4) (Chen et al., 1986, Germann et al., 1996, Hrycyna et al., 1998). 
This region has been shown to be phosphorylated in vivo by protein kinase C alpha (PKCα) 
(Chambers et al., 1990, Ma et al., 1991, Orr et al., 1993). The role of the linker region in 
ABCB1 is yet to be defined but mutagenesis of the residues which are phosphorylated by 
PKCα has no effect on the localisation and function of the transporter (Germann et al., 
1996, Goodfellow et al., 1996) [for a more detailed account of the interaction between 
ABCB1 and PKCα and its role in the development of MDR see Section 1.11.2.1]. 
 
In contrast, a role for the linker region (residues 623-699) on the localisation, function and 
rate of maturation of ABCB4 has been suggested. In a yeast two-hybrid screen using the 
linker region of ABCB4 as bait against a human liver cDNA library, RACK1 (receptor for 
activated C-kinase 1) was identified as a novel binding partner of ABCB4 and confirmed by 
GST (glutathione S-transferase)-pulldown of purified recombinant domains (Ikebuchi et 
al., 2009). RACK1 is a scaffold protein identified through its ability to bind activated PKC 
and this interaction is thought to stabilise activated PKC and facilitate the regulation of the 
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phosphorylation state of target proteins (Mochly-Rosen et al., 1991). In fact, the apical 
localisation of the cystic fibrosis transmembrane conductance regulator (CFTR/ABCC7) 
has been shown to be regulated by RACK1 (Auerbach and Liedtke, 2007, Liedtke et al., 
2002) suggesting that trafficking of ABC proteins can be modulated by RACK1. 
Suppression of endogenous RACK1 by siRNA in HepG2 cells (polarised cells derived 
from human hepatoma), resulted in intracellular retention of ABCB4 as opposed to the 
expected localisation at the bile canalicular membrane of the polarised cells but the 
localisation of ABCB1 was not affected (Ikebuchi et al., 2009). In a HeLa cell line in which 
RACK1 had been stably knocked down, it was shown that the absence of RACK1 
expression affected the rate of maturation of exogenous ABCB4 (Ikebuchi et al., 2009). 
Finally, the level of activity of ABCB4 both in the presence and in the absence of RACK1 
expression was assayed in HeLa cells by measuring the amount of [14C]PC effluxed by 
ABCB4 into the cell medium (Ikebuchi et al., 2009). In this assay, the ABCB4-mediated 
[14C]PC efflux was reduced by the suppression of RACK1 expression (Ikebuchi et al., 
2009). 
 
Collectively, the above data suggest that ABCB1 and ABCB4, despite their high degree of 
identity, can be regulated by different mechanisms. 
 
1.7 Glycosylation 
ABCB1 is a 170 kDa membrane protein featuring N-linked glycosylation with 
oligosaccharides of the “complex” type (Richert et al., 1988, Schinkel et al., 1993). In 
eukaryotes, the consensus site for N-linked glycosylation has the amino acid sequence of 
Asn (asparagine)-X-Thr (threonine)/Ser (serine), where X can be any amino acid except 
proline (Kornfeld and Kornfeld, 1985). Although sequence analysis of ABCB1 predicts 10 
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possible sites for N-linked glycosylation (Chen et al., 1986), only three are exposed to the 
lumen of the endoplasmic reticulum and thus glycosylated (Gribar et al., 2000, Richert et 
al., 1988, Schinkel et al., 1993). All three consensus sites cluster on the first extracellular 
loop of ABCB1 at the amino acid residues Asn91, Asn94 and Asn99 (Figure 1-4) (Schinkel 
et al., 1993). Glycosylation-deficient ABCB1 retains its drug-transport function and 
substrate specificity (Gribar et al., 2000, Schinkel et al., 1993) however, it is expressed at a 
lower level than WT ABCB1 because a greater fraction of the mutant protein misfolds and 
is degraded by the proteasome (Gribar et al., 2000). 
 
ABCB4 has two consensus N-glycosylation sites. However, the effects of glycosylation on 
ABCB4 trafficking and/or function have not been studied extensively. Although 
glycosylation does not appear to have a strong effect on ABCB1 (Gribar et al., 2000, 
Schinkel et al., 1993), disruption of N-linked glycosylation of another ABC protein, 
ABCG2, has been shown to modulate trafficking to the cell membrane, reduce stability and 
enhance proteasomal degradation (Nakagawa et al., 2009). 
 
1.8 The discovery of ABCB1 and its implications in MDR 
In 1973, Dano presented evidence of the active export of daunomycin from a drug 
resistant Ehrlich ascites tumour cell line (Dano, 1973).  Shortly after, work done on 
colchicine resistant Chinese hamster ovary (CHO) cells revealed a 170 kDa cell membrane 
glycoprotein, termed P-glycoprotein (P-gp, also known as MDR1), which could alter the 
permeability of the cells to amphiphilic drugs and could not be detected in wild type (WT) 
cells (Juliano and Ling, 1976). Resistance to daunorubicin was also noted in Ehrlich ascites 
tumour cells (Skovsgaard, 1978). Several lines of evidence correlated the level of resistance 
with the amount of the 170 kDa protein at the membrane (Juliano and Ling, 1976, Kartner 
 Introduction 
 
37 
 
et al., 1983, Riordan and Ling, 1979) and in most of the MDR cell lines studied (human, 
hamster or mouse) an overexpression of P-gp could be observed (Gerlach et al., 1986b, 
Kartner et al., 1983). Successful cloning and isolation of the complete mouse and human 
cDNAs for the MDR1 gene revealed the internal homology of the two halves of the 
protein. Sequence analysis showed homology with conserved bacterial counterparts and so 
P-gp (ABCB1) was assigned to the ATP binding cassette (ABC) family of proteins and it 
was predicted to function as a drug efflux pump (Chen et al., 1986, Gerlach et al., 1986a, 
Gros et al., 1986b, Gros and Shustik, 1991, Ueda et al., 1987). To confirm this theory, 
overexpression of the cDNA encoding ABCB1 was shown to convert drug sensitive cells 
into resistant ones (Gros et al., 1986a, Ueda et al., 1987). 
 
Early photoaffinity labelling experiments carried out in membrane vesicles derived from 
multidrug-resistant KB carcinoma cells, demonstrated that ABCB1 is indeed a drug- and 
ATP-binding protein (Cornwell et al., 1987a, Cornwell et al., 1986, Cornwell et al., 1987b). 
In addition, drug-transport assays performed in plasma membrane vesicles from the same 
KB cell line, showed that ATP hydrolysis was essential for allocrite transport by ABCB1 
and that drug-resistance reversing agents could inhibit ABCB1-dependent efflux (Horio et 
al., 1988). Collectively, these studies established the basic mechanism by which ABCB1 
transports its allocrites. 
 
Further studies using purified ABCB1, from drug-resistant cell lines, which had been 
functionally reconstituted in proteoliposomes, showed that ABCB1 displayed drug-
stimulated ATPase activity and that it could transport drugs across a lipid bilayer against 
their concentration gradient (Ambudkar, 1995, Ambudkar et al., 1992, Shapiro and Ling, 
1994, Sharom et al., 1993). 
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Taken together, these early experiments confirmed that ABCB1 is an ATP-dependent 
drug-efflux pump responsible for multidrug resistance. 
 
1.9 Association of other ABC proteins with MDR 
ABCB1 is not the only protein affecting drug pharmacokinetics. A human small cell lung 
cancer cell line (H69AR) which did not overexpress ABCB1, could develop cross-
resistance to a variety of anti-cancer agents (Cole, 1990, Mirski et al., 1987). The cDNA of 
the gene responsible for this phenotype was cloned from these cells and, based on primary 
sequence analysis, it was concluded that it coded for another protein belonging to the ABC 
family: the multidrug resistance-associated protein 1 (MRP1/ABCC1) (Cole et al., 1992). In 
1998, a third xenobiotic transporter involved in MDR was identified from human breast 
cancer cells (MCF-7/AdrVp) that did not overexpress ABCB1 or ABCC1, but were 
resistant to anthracycline anticancer drugs. When overxpressed in MCF-7 cells, the protein 
was able to confer resistance to mitoxantrone, doxorubicin, and daunorubicin. The protein 
was named breast cancer resistance protein (BCRP). It is also known as mitoxantrone 
resistance protein (MXR) and it is another member of the ABC family of transporters 
designated as ABCG2 (Allikmets et al., 1996, Doyle et al., 1998, Miyake et al., 1999). 
 
1.10 ABCB1 in normal physiology 
ABCB1 is expressed in a variety of normal human tissues including the brain, liver, testes, 
heart, kidneys and intestines (Cordon-Cardo et al., 1990, Cordon-Cardo et al., 1989, Fojo et 
al., 1987, Thiebaut et al., 1987, Thiebaut et al., 1989). Its primary function appears to be to 
pump xenotoxins out of cells against their concentration gradient. This function is best 
exemplified in the Abcb1a/Abcb1b (formerly known as Mdr1a and Mdr1b, the two 
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functional equivalents of ABCB1 in the rodent) knock-out mice. Disruption of either 
(Abcb1a or Abcb1b) or both of the genes generated mice with a normal physiology and 
fertility which displayed a marked alteration in drug sensitivity (Schinkel et al., 1997, 
Schinkel et al., 1994). Absence of the transporter(s), which are highly expressed in capillary 
endothelial cells that form the blood-brain barrier (Cordon-Cardo et al., 1989, Thiebaut et 
al., 1989), resulted in the toxic accumulation of ivermectin, vinblastine and digoxin in the 
brain of Abcb1a/b null mice, ultimately resulting in death (Schinkel et al., 1997, Schinkel et 
al., 1994). In the liver, ABCB1 is involved in the efflux of toxic substrates into the bile as 
demonstrated by the accumulation of vinblastine in the liver of Abcb1-/- mice (Schinkel et 
al., 1997, Schinkel et al., 1994). ABCB1 also functions in the intestine limiting the re-uptake 
of drugs such as paclitaxel (Taxol) into the blood stream. These data are also corroborated 
by studies in humans, in which inhibition of ABCB1 has been shown by PET studies, to 
dramatically alter the distribution of tracer drugs (Gottesman et al., 2002). 
 
Experiments carried out in human haematopoietic stem cells negative for rhodamine 123 
staining (Rh123; a fluorescent dye that accumulates in the mitochondria) revealed high 
levels of ABCB1 expression (Chaudhary and Roninson, 1991). The decreased accumulation 
of Rh123 was attributed to ABCB1-mediated efflux which has led to the suggestion that 
ABCB1 may, physiologically, be involved in the efflux of toxic substrates from progenitor 
cells or, of factors that would otherwise drive their differentiation (Chaudhary and 
Roninson, 1991). 
 
The function of ABCB1 and Abcb1a as floppases of short-chain analogues of endogenous 
membrane lipids has also been described (Bosch et al., 1997, van Helvoort et al., 1996) but 
neither functional Abcb1a nor Abcb1b could compensate for Abcb4 function in Abcb4 null 
mice (Smit et al., 1993). The physiological role of such floppase function for ABCB1 is 
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unclear but there is evidence to support a role in the secretion of short-chain 
phosphocholine signalling molecules. Platelet-activating factor (PAF; 1-O-alkyl-2-acetyl-sn-
glycero-3-phosphocholine) is one such naturally occurring short-chain phosphocholine. It 
is a potent bioactive lipid and is involved in various pathological conditions, such as 
angiogenesis in breast cancers, metastasis and multiple organ failure (Anderson et al., 1991, 
Montrucchio et al., 1998). One of the best characterised roles for PAF is as a mediator of 
cell-cell interactions in the inflammatory response (Prescott et al., 2000). PAF is secreted by 
a variety of cells (e.g. epithelial and endothelial cells) and exerts its function by binding to a 
G-coupled receptor on the extracellular surface of the target cell (Prescott et al., 2000). In 
order for PAF to perform its function, it has to be transported from its site of synthesis in 
the cytosol to the extracellular leaflet of the plasma membrane. It has been demonstrated 
that ABCB1 can translocate PAF from the inner to the outer leaflet of the plasma 
membrane suggesting a role for the glycoprotein in intercellular signalling (Raggers et al., 
2001). 
 
1.11 Why study the ABCB1 interactome? 
ABCB1 presents a major impediment to chemotherapeutic treatments for cancer patients. 
As highlighted in the examples above (Section 1.10), it also has an important physiological 
role in the protection of several pharmacological sanctuaries, such as the brain, testes, liver 
and intestines; from which it effluxes xenotoxins. It may also be involved in intercellular 
signalling. Direct inhibition of ABCB1 can therefore have detrimental effects on cancer 
patients. Consequently, identification of ABCB1-interacting partners that influence 
trafficking or function could provide alternative targets for therapy. 
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ABCB1 has been shown to retain function when purified from insect cells (Tricoplusia ni) 
and reconstituted in proteoliposomes (Sharom et al., 1999). While this indicates that 
ABCB1 can work in isolation it is also known to interact with other proteins during 
folding/trafficking and at the plasma membrane. These interactions are not well 
characterised, and it is likely that the whole ABCB1-interactome has not yet been 
discovered. A number of proteins that have previously been shown to interact with ABCB1 
are described below. 
1.11.1 ABCB1 interactors involved in intracellular trafficking  
The nascent ABCB1 protein has three potential glycosylation sites (residues 91, 94 and 99, 
Figure 1-4) on the first extracellular loop (ECL) (Chen et al., 1986, Schinkel et al., 1993) 
and is synthesised in the ER as a 150 kDa core-glycosylated intermediate. In the ER, 
ABCB1 interacts specifically with four molecular chaperones (calnexin, calreticulin, ERp57 
and Hsc70) which modulate the folding of N-glycosylated polypeptides (High et al., 2000, 
Loo and Clarke, 1994, Loo and Clarke, 1995b). Misfolded ABCB1 is retained in the ER 
and rapidly degraded (Loo and Clarke, 1997) via the 26S proteasome (Goldberg, 2003) 
whereas the correctly folded form translocates to the Golgi where it is further modified to 
a 170 kDa mature glycoprotein (Molinari et al., 1998, Molinari et al., 1994) before transport 
to the plasma membrane. Trafficking of ABCB1 from the Golgi to the apical domain or 
the plasma membrane of polarised and non-polarised cells, respectively, occurs via 
intracellular endosomes (Fu and Roufogalis, 2007, Kipp and Arias, 2000, Wakabayashi et 
al., 2005) and it is thought to involve interactions with actin cytoskeleton (actin disruption 
leads to intracellular accumulation of fluorescently-labelled ABCB1 (Fu and Roufogalis, 
2007). 
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1.11.2 Function-related ABCB1 interactors 
The mature, fully glycosylated form of ABCB1 localises to the apical membrane of 
polarised cells and the plasma membrane of non-polarised cells as shown by confocal 
microscopy (Hammerle et al., 2000, Petriz et al., 2004). Here, ABCB1 has been shown to 
interact with a number of other proteins, such as protein kinase C alpha and caveolin-1, 
both of which are thought to modulate its function. 
1.11.2.1 ABCB1 and protein kinase C 
Protein kinase C (PKC) is a key enzyme in signal transduction and modulation of cell 
growth, cell proliferation, apoptosis and malignant transformation. To date, 11 subspecies 
of PKC have been reported (alpha [α], beta-I [β-I], beta-II [β-II], gamma [γ], delta [δ], 
epsilon [ε], zeta [ζ], eta [η], theta [θ], lambda [Л] and mu [μ]) which differ in their 
expression profiles, biochemical properties, activator requirements and substrate specificity; 
suggesting distinct roles in different signalling pathways (Hug and Sarre, 1993). The 
common PKC isoenzyme alpha (PKCα) is calcium (Ca2+)-dependent and is activated by the 
phospholipid derivative diacylglycerol (DAG) in response to extracellular signals such as 
growth factors and cytokines (Nishizuka, 1995). Activation of PKC can also occur via the 
tumour-promoting phorbol esters (Castagna et al., 1982) and such activation can induce an 
MDR phenotype in a breast cancer cell line (MCF7) (Fine et al., 1988). Detailed studies of 
the PKC isoenzymes involved in MDR revealed that there was a ten-fold increase in PKCα 
expression in drug-resistant MCF7 cells compared to the parental line (Blobe et al., 1993). 
Furthermore, transfection of MCF7 cells with a vector coding for antisense cDNA against 
PKCα increased the drug sensitivity of the cells by three-fold (Ahmad and Glazer, 1993) 
while overexpression of PKCα in BC-19 cells resulted in decreased drug accumulation (Yu 
et al., 1991). 
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The phospholipid-dependent PKC family of serine/threonine kinases has been implicated 
in MDR (Rumsby et al., 1998). In many of the MDR cell-lines studied to date, there is an 
elevated level of both expression and activity of PKC and in most cases the isoenzyme 
involved is PKCα (Fine et al., 1996). Activation of PKC in MDR cells correlates with 
increased ABCB1 phosphorylation and decreased drug accumulation (Bates et al., 1993, 
Blobe et al., 1993, Chambers et al., 1990, Chambers et al., 1992, Hamada et al., 1987). Co-
immunoprecipitation (co-IP) studies revealed a close association PKCα and ABCB1 in 
membrane vesicles from Sf9 insect cells (Ahmad et al., 1994) and in human carcinoma cell 
lines (Yang et al., 1996). All of the above evidence points towards a role for PKCα in the 
regulation of ABCB1 through phosphorylation of its serine residues. Analysis of the 
phosphorylation sites of ABCB1 both in vivo and in vitro showed that ABCB1 is 
phosphorylated on the “linker” region (a highly charged region connecting the two 
homologous halves of the protein) (Chambers et al., 1990, Ma et al., 1991, Orr et al., 1993). 
The major phosphorylation sites comprise a cluster of three serine residues (Ser661, Ser667 
and Ser671) all of which appear to be phosphorylated in vivo (Chambers et al., 1994, 
Chambers et al., 1993) but this phosphorylation appears to have no effect on the 
localisation or the efflux function of the transporter (Germann et al., 1996, Goodfellow et 
al., 1996). 
 
It is not yet clear what effect the association of ABCB1 with PKCα has on ABCB1 
function but there is evidence to suggest a role for PKCα in the transcriptional activation 
of the ABCB1 gene through the Ras (Rat sarcoma) small GTPase (guanosine 
triphosphatase) which is under the positive influence of PKCs (Grunicke et al., 1994). In 
addition, phosphorylation of the “linker” region was shown to affect the interaction of 
ABCB1 with a number of substrates without affecting its ATPase activity (Szabo et al., 
1997). Moreover, a role for PKC-mediated phosphorylation of ABCB1 in the regulation of 
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volume activated chloride channels has been described which implicates ABCB1 in the 
modulation of cell volume (Hardy et al., 1995, Idriss et al., 2000, Vanoye et al., 1999). 
Finally, it has been proposed that ABCB1 affects the trafficking of PKCα (Sardini A., 
personal communication). Activation of PKCα by a phorbol ester resulted in the transport 
of the protein from the cytoplasm to the cell membrane. In the absence of ABCB1, PKCα 
was re-internalised and localised to a perinuclear compartment within 30 minutes of 
exposure of the cells to phorbol ester. When the same experiment was performed in cells 
expressing ABCB1, no re-internalisation was evident even after 120 minutes of exposure 
(Sardini A., personal communication). 
1.11.2.2 ABCB1 and caveolin-1 
“Liquid-ordered” microdomains within the lipid bilayer of the cell membrane are known as 
lipid rafts (Rietveld and Simons, 1998). Such microdomains deviate from the classical 
“liquid crystalline state” of the cellular membrane (Singer and Nicolson, 1972) in that they 
are enriched in cholesterol and sphingolipids as opposed to phospholipids (Simons and 
Ikonen, 1997); a feature that makes them resistant to solubilisation with Triton-X 100 at 
low temperature (4oC) (Moldovan et al., 1995). Lipid rafts are thought to be important in 
transmembrane signal transduction by recruiting receptors to a microenvironment to allow 
faster communication between ligands and effector proteins (Brown and London, 1998, 
Rietveld and Simons, 1998, Simons and Ikonen, 1997, Simons and Toomre, 2000). 
 
Structural protein components can be integrated in lipid rafts changing the morphology 
and function of the microdomains. One such structural component is caveolin-1 
(CAV1/VIP21) (Rothberg et al., 1992, Kurzchalia et al., 1992, Glenney, 1992). CAV1 is a 
22 kDa hairpin-like, palmitoylated (Dietzen et al., 1995) and cholesterol-binding (Murata et 
al., 1995) integral membrane protein with cytoplasmic amino and carboxy termini (Dupree 
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et al., 1993, Monier et al., 1995). Polymerisation of CAV1 monomers results in the 
invagination of lipid rafts and the formation of caveolae: 50- to 100-nm flask-shaped 
plasma membrane invaginations. Caveolae are found in most differentiated cell types with a 
notable abundance in adipocytes, endothelial cells, fibroblasts, muscle cells and type I 
pneumocytes (Cohen et al., 2004, Razani et al., 1999) and complete absence from 
lymphocytes and neurons of the central nervous system (Cameron et al., 1997, Fra et al., 
1994). The main roles of caveolae include vesicular transport (transcytosis/endocytosis), 
cholesterol homeostasis and signal transduction (Cohen et al., 2004, Razani et al., 2002). 
 
CAV1 is upregulated in human MDR cancer cells (Belanger et al., 2003, Lavie et al., 1998, 
Yang et al., 1998). One of the most uniform associations between MDR and the expression 
of ABCB1 is found in patients with acute myelogenous leukaemia (AML) (Leith et al., 
1999) where the CAV1 and ABCB1 genes have been shown by real-time quantitative 
polymerase chain reaction to be coordinately regulated (Pang et al., 2004). This suggests an 
interaction between ABCB1 and CAV1 but it remains to be elucidated whether CAV1 
expression affects ABCB1 function in AML patients. 
 
A number of investigations have demonstrated a physical interaction between Cav1 and 
Abcb1 in isolated brain capillaries or in drug-resistant cancer cell lines (Barakat et al., 2007, 
Demeule et al., 2000, Hawkins et al., 2010, Jodoin et al., 2003). Immunogold cytochemistry 
at the electron microscope level on human and rat brain tissue detected a fraction of 
ABCB1/Abcb1 in plasma membrane invaginations (caveolae) in all cells that constitute the 
blood-brain barrier (BBB), i.e., capillary endothelial cells, pericytes and astrocytes 
(Bendayan et al., 2006). Experiments performed in COS7 cells, have shown that Abcb1 is 
negatively regulated by Cav1 (Jodoin et al., 2003) and siRNA work in RBE4 cells 
demonstrated that Cav1 downregulation stimulates Abcb1 efflux function (Barakat et al., 
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2007). Evidence for a negative regulation of Abcb1 by Cav1 in vivo has also been obtained 
from in situ rat brain perfusion experiments (Hawkins et al., 2010). 
 
In drug-resistant human colon and breast adenocarcinoma cell lines ABCB1 was shown to 
localise in at least two distinct membrane compartments (Lavie et al., 1998). One 
compartment had the physical characteristics of caveolae whereas the other compartment 
was detergent-soluble and it was demonstrated that the expression of CAV1 was not a 
prerequisite of ABCB1 localisation to the caveolae fraction (Lavie et al., 1998). These data 
are in agreement with the results obtained by Jodoin et al. (2003) in an in vitro model for the 
BBB where a large fraction of Abcb1 molecules was found to localise in caveolar fractions 
and to interact with Caveolin-1 in both caveolar and non-caveolar fractions. ABCB1 is 
highly expressed in endothelial cells at the BBB where it plays a protective role against 
brain toxicity (Beaulieu et al., 1997, Demeule et al., 2001, Schinkel, 1999, Schinkel et al., 
1994). Understanding the significance of ABCB1/CAV1 interaction in the caveolar 
compartments will provide alternative means of overcoming ABCB1 drug-efflux function 
and to increase drug passage through the BBB. 
 
1.12 The “split-ubiquitin” yeast two-hybrid system as a means of studying 
the ABCB1 interactome 
The identification of proteins that interact with ABCB1 should enhance our understanding 
of the function of this efflux transporter and its mechanism of action. In an attempt to 
enrich the pool of known ABCB1 interactors, the “split-ubiquitin” yeast two-hybrid (SU-
YTH) system was employed (Stagljar and Fields, 2002) and is described in Chapter 3. The 
system allows for the identification and characterisation of interactions between an integral 
membrane protein of interest, in this case ABCB1, and other integral membrane proteins 
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or membrane-associated proteins or cytosolic proteins. Compared to the conventional 
yeast two-hybrid system (Fields and Song, 1989), the SU-YTH offers the advantage of 
detecting protein:protein interactions between full-length proteins at the cell membrane 
whilst allowing for the preservation of post-translational modifications such as 
glycosylation (Stagljar et al., 1998, Thaminy et al., 2003). 
 
Identification of novel interactors of ABCB1 was achieved through screening of an adult 
human liver cDNA library (Section 3.2.4). Prior to doing so, the expression of ABCB1:Cub 
bait was confirmed by the “NubI/NubG” test (Section 3.2.1.2) and the level of self-
activation of the ABCB1:Cub bait was assayed (Section 3.2.3). A total of 29 putative 
interactors were isolated from the library screen but following strict testing using the 
appropriate controls, none of the candidate proteins was shown to specifically interact with 
ABCB1 (Section 3.2.5) and the underlying reasons for this unsuccessful attempt are 
considered in Section 3.3. 
 
1.13 Canalicular ABC transporters and liver disease 
Many of the human ABC transporters have important roles in normal physiology and 
morbidity (Borst and Elferink, 2002, Linton and Holland, 2011); a number of which are 
involved in the formation of bile. Bile is a complex mixture of bile salts, phospholipids, 
cholesterol, bile pigments, electrolytes and proteins. Bile salts are required for the 
solubilisation of dietary fats and lipophilic vitamins. They are synthesised in the hepatocyte 
and secreted across the canalicular membrane into the biliary tree where they are eventually 
expelled into the small intestine in response to food intake to fulfil their primary role. Bile 
salts are then reabsorbed very efficiently by enterocytes, and secreted into the portal vein 
for return to the liver to complete the enterohepatic cycle. 
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Both the synthesis and enterohepatic cycling of bile salts is under tight control at the 
protein and genetic level to limit their intrahepatic and serum concentrations. Disruption of 
the mechanisms which control bile salt synthesis and circulation, and the mechanisms that 
protect the membranes of the biliary tree can lead to serious disease due to the inherently 
toxic nature of bile salts. In the biliary tree, where high concentrations of bile salts exist, 
phospholipids are secreted to form a mixed micelle with the bile salts and reduce their 
detergent activity. The anabolic enzymes, the transporters, receptors and transcription 
factors involved in bile salt homeostasis are now largely identified and are described in 
detail below. In particular, the role of three transporters responsible for the majority of bile 
flow; ABCB11, ABCB4 and ATP8B1, are highlighted. 
1.13.1 The liver and biliary tract 
The liver, the largest of the internal organs, is involved in a wide range of processes. These 
include bile synthesis and secretion, excretion of bilirubin, amino acid and lipid metabolism 
as well as the elimination of toxins (Aspinall and Taylor-Robinson, 2002). Due to its 
complicated and highly specified functions, the liver has a complex architecture and a 
double blood supply system (Figure 1-6). Oxygenated blood (20%) is provided by the 
hepatic artery branching out from the aorta, while venous blood (80%) from the intestines 
and spleen arrives through the hepatic portal vein (Stevens and Lowe, 2005). 
Approximately 70% of the cells in the liver are hepatocytes (parenchymal cells); whereas 
the remaining 30% are non-parenchymal cells such as the phagocytic Küpffer cells, stellate 
cells (also known as Ito or fat-storing cells), endothelial cells, epithelial cells and 
lymphocytes (Figure 1-6) (Ishibashi et al., 2009). 
 
Secretion of bile by the liver and recycling through the biliary tree (Figure 1-5) is 
physiologically important as this is the main driving force for solute and water movement 
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within the enterohepatic circulation. The liver produces 400 – 600 ml of bile per day (Arias 
et al., 1994) and its secretion depends on the function of membrane transporters on the 
surface of hepatocytes and cholangiocytes (Esteller, 2008). Hepatocytes are responsible for 
the secretion of “primary” bile (bile salts, cholesterol, bilirubin, drug metabolites and heavy 
metals), into the bile canaliculus, or bile ductules that are formed between adjacent 
hepatocyte plates and lined with cholangiocytes. Through secretory and reabsorptive 
processes, cholangiocytes are responsible for the fluidity and pH of bile and account for 
40% of the total bile volume (Strazzabosco, 1997). 
  
 
Figure 1-5. The liver and biliary tract. 
The main organs involved in the synthesis and secretion of bile into the small intestine. Image 
modified from: http://healthbasictips.com/wp-content/uploads/2011/09/Gallbladder1.jpg 
 
Studies on the finer structure of intrahepatic bile ducts of various sizes (large, intermediate 
and small) have shown that they are lined by cholangiocytes that differ both in shape and 
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size. Specifically, they are cuboidal or flattened in small ducts (or ductules) and columnar in 
large ducts (Steiner and Carruthers, 1961). The intrahepatic bile ductules emerging from the 
hepatocytes gradually merge to establish larger ducts and eventually coalesce to form the 
left and right hepatic ducts which join to form the common hepatic duct (Figure 1-5). The 
gallbladder is responsible for concentrating the bile (5- to 10-fold) by the net reabsorption 
of sodium, calcium, chloride and bicarbonate ions followed by the passive movement of 
water (Dietschy, 1966). It is joined to the biliary tree via the cystic duct where it merges 
with the common hepatic duct to form the common bile duct (coledochus; Figure 1-5). 
Following the ingestion of food, the gallbladder contracts and empties its contents into the 
common bile duct in response to the hormone cholecystokinin (CCK) (Spellman et al., 
1979). The common bile duct merges with the pancreatic duct at the ampulla of Vater 
(Figure 1-5) where the release of digestive enzymes into the duodenum is controlled by the 
sphincter of Oddi under the influence of CCK (Wiley et al., 1988). The release of bile into 
the duodenum marks the beginning of the solubilisation of dietary fats. 
 
1.13.2   The hepatocyte 
The main functional cell of the liver is the hepatocyte which displays a high level of 
metabolic activity in three broad categories: 1. lipid metabolism, 2. carbohydrate 
metabolism and 3. protein metabolism (Mitra and Metcalf, 2009). As a consequence of 
these metabolic activities, the hepatocyte performs both an excretory (e.g. bilirubin, drug 
metabolites, antibiotics) and a secretory (e.g. bile acids, phospholipids, cholesterol) function 
(Campbell, 2006).  
 
Although the hepatocytes appear homogenous using light microscopy, they can have 
different metabolic profiles (Katz, 1992) and such differences are dictated by the relative 
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position of a hepatocyte within the functional unit of the liver, i.e. the liver acinus (Figure 
1-6) (Rappaport et al., 1954). Morphologically, the hepatocytes are organised in a hexagonal 
 
 
Figure 1-6. The liver lobule. 
Blood supply to the liver is provided through branches of the hepatic portal vein (from the gut) and 
the hepatic artery (oxygenated blood from the aorta).  Image modified from (Adams and Eksteen, 
2006). 
 
manner forming the liver lobule (Kaplowitz, 1992). In this arrangement, the portal tract 
(made of the terminal portal venule, terminal hepatic arteriole and bile duct) is at each 
corner with the central vein in the middle of the lobule (Ishibashi et al., 2009). Within the 
lobule, the hepatocytes are arranged in one-cell thick plates of 15 – 25 cells which run from 
the central vein to the periphery of the lobule. Blood flowing from the portal tract to the 
central vein fills the space between the liver-cell plates and forms the hepatic sinusoids 
which are lined with fenestrated endothelial cells (Figure 1-6). The space between the 
sinusoidal endothelium and the microvillar surface of the hepatocytes is known as the 
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space of Disse and allows for the exchange of solutes between the blood and the 
hepatocytes (Figure 1-6). 
 
The surface of the hepatocyte comprises distinct domains which differ in functionality and 
molecular composition (Arias et al., 1994). Consequently the polarised hepatocyte plasma 
membrane has three types of cell surface: 1. the basal (or sinusoidal) surface, which is 
covered by microvilli, faces the sinusoids and is involved in the exchange of metabolites 
with the blood, 2. the lateral surface which is formed between adjacent hepatocytes joined 
by epithelial cell junctions (e.g. tight junctions, gap  junctions, desmosomes and adherens 
junctions) and 3. the apical (bile canalicular) surface which is formed by invaginations of 
the apical membrane of apposing hepatocytes and delimited by junctional complexes 
(Figure 1-6). A number of membrane transporters are known to be expressed at the 
sinusoidal and canalicular surface of the hepatocyte (Table 1-1) where they are involved in 
the transport of substrates from the blood to the hepatocyte or from the hepatocyte to the 
bile, respectively. 
 
Membrane transporter Function Reference 
Apical membrane (canalicular) 
ABCB4 (MDR3) PC floppase (van Helvoort et al., 1996) 
ABCB11 (BSEP/SPGP) Bile salt export (Gerloff et al., 1998) 
ATP8B1 (FIC1) PS flippase/microvillus formation 
(Paulusma et al., 2006); (Paulusma 
et al., 2008); (Verhulst et al., 2010) 
ABCG5/ABCG8 Efflux of plant and animal sterols (Berge et al., 2000) 
ABCC2 (MRP2/cMOAT) 
Efflux of conjugated bilirubin and 
organic anions  
(Paulusma et al., 1997) 
ABCB1 (MDR1/PGP) Efflux of xenobiotics (van Asperen et al., 2000) 
ABCG2 (BCRP/MXR) Efflux of xenobiotics (Ando et al., 2007) 
Basolateral membrane (sinusoidal) 
NTCP (SLC10A1) 
Uptake of conjugated and 
unconjugated bile salts from the 
sinusoids 
(Hagenbuch and Dawson, 2004) 
OATPs (SLC21) 
Uptake of unconjugated bile salts, 
organic cations 
(Hagenbuch and Meier, 2003) 
Table 1-1. Membrane transporters expressed on the canalicular and sinusoidal membranes of the 
hepatocyte. 
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The canalicular surface is of particular importance as it plays an integral role in the 
formation and enterohepatic circulation of bile. From the perspective of human cholestatic 
morbidity, three of the hepatocyte canalicular transporters are key. The bile salt export 
pump (ABCB11) and the phosphatidylcholine (PC) floppase (ABCB4), efflux the two main 
components of bile (bile salts and PC). The third protein necessary for bile flow from the 
hepatocyte is a P-type ATPase, ATP8B1 (FIC1). ATP8B1 appears to flip a different lipid, 
phosphatidylserine (PS), in the opposite direction to PC flop by ABCB4 (i.e. it flips PS 
inwardly). The flux of bile salts across the canalicular membrane is what drives bile flow, 
and mutations in any of the three aforementioned transporters lead to cholestatic liver 
disease. It is therefore important to understand the molecular basis for such diseases in 
order to facilitate therapeutic intervention tailored to each individual. Chapters four and 
five in this thesis focus on the characterisation of ABCB4 single-nucleotide polymorphisms 
(SNPs) in an attempt to understand the physiological significance of ABCB4 activity in 
cholestatic liver disease.   
1.13.3 Bile salt synthesis 
The movement of bile acids and bile alcohols from the hepatocytes (their site of synthesis 
in the liver) to the portal circulation, through the biliary tree and the small intestine, is 
known as the enterohepatic circulation. This is a very efficient recycling system in which 
approximately 95% of the bile salts are re-absorbed; the remaining 5% that is lost is 
replaced by de novo synthesis in the liver. Such process allows for the re-utilisation of these 
detergent-like molecules and forms the major route of cholesterol catabolism in mammals. 
 
The bile salt pool comprises a mixture of primary bile salts that are synthesised de novo in 
the hepatocyte and secondary and tertiary bile salts, which result from bacterial catabolism
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Figure 1-7. Solute composition of bile and chemical structure of the major bile salts in healthy 
humans. 
(A). Organic composition (as weight percentage) of bile in healthy adult humans [modified from 
(Esteller, 2008)]. 
†
 The predominant phospholipid is PC. (B). Chemical structure of the major bile 
salts (BS) comprising the human BS pool. The 24-carbon primary bile acids CA and CDCA are 
synthesised in the liver from cholesterol. The rate-limiting step is the C7-hydroxylation of 
cholesterol, catalysed by the microsomal CYP7A1. Secondary bile acids (DCA and LCA) are formed 
in the gut through the 7 α-dehydroxylation of primary bile acids by bacterial enzymes. Together, 
CA, CDCA and DCA form 95% of the total BS pool. Epimerisation of the C7 hydroxyl of CDCA 
results in the formation of 7-oxolithocholic acid, which is further modified in the liver to form the 
more polar and hydrophilic tertiary bile acid UDCA. The carboxyl group (C24) of 99% of BS is 
amidated with either glycine or taurine [adopted from (Nicolaou et al., 2012)]. CA, cholic acid; 
CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; LCA, lithocholic acid; UDCA, 
ursodeoxycholic acid; R, functional group; PC, phosphatidylcholine; PI, phosphatidylinositol; PE, 
phosphatidylethanolamine. 
† 
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of the primary bile salts in the gut (Figure 1-7A). Cholates, deoxycholates, lithocholates, 
chenodeoxycholates, and ursodeoxycholates are the most common bile salts found in 
healthy adult humans and comprise 92% - 99% of the total biliary bile salts (Stellaard et al., 
1985). In humans two primary bile salts termed cholic acid (CA) and chenodeoxycholic acid 
(CDCA) are synthesised in the hepatocytes using cholesterol as a starting material 
(Hofmann and Hagey, 2008). This process involves at least 14 different enzyme activities 
and it begins with a key hydroxylation event catalysed by the cytochrome P450 enzyme, 
CYP7A1 (cytochrome P450 cholesterol 7α-hydroxylase). The expression of CYP7A1 is 
induced by cholesterol (and oxy-sterol metabolites) and repressed by bile salts, providing 
tight control of bile salt synthesis at this rate-limiting step (Russell, 2003). By the action of 
the symbiotic gut microflora, secondary bile salts are formed from primary bile salts. The 
major reaction of physiological significance is 7 α-dehydroxylation of primary bile salts to 
give deoxycholic acid (DCA) and lithocholic acid (LCA) from CA and CDCA, respectively. 
CA, CDCA and DCA comprise about 95% of the total bile salt pool in humans. The 
remainder is mostly LCA and the tertiary bile salt ursodeoxycholic acid (UDCA; which is 
formed by the reduction of 7-oxolithocholic acid by intestinal bacteria and is further 
modified in the liver) (Arias et al., 1994). Bile salts exist mostly in their soluble form in the 
biliary tree as glycine and taurine conjugates; unconjugated bile salts comprise only 0.1% to 
0.4% of the total biliary bile salts (Matoba et al., 1986). Amidation with glycine or taurine at 
carbon-24 (C24; Figure 1-7B) reduces the pKa such that most bile salts ionised at the low 
pH present in the biliary tree (Russell and Setchell, 1992). Amidation thus increases their 
hydrophilicity, making them more effective emulsifying agents, and decreases their toxicity 
(Hofmann, 2009). It also significantly reduces their ability to diffuse passively across cell 
membranes, and influx and efflux systems have evolved to ensure sufficient trancellular 
flux through enterocytes and hepatocytes (Nicolaou et al., 2012). 
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1.13.4 Regulation of bile salt homeostasis in the hepatocyte 
Control of bile salt homeostasis at the genetic level is achieved through a set of nuclear 
hormone receptors: the farnesoid-X receptor (FXR), the retinoid-X receptor (RXR), the 
liver receptor homologue-1 (LRH-1), the small heterodimer partner (SHP) and the liver-X 
receptor (LXR) (Chawla et al., 2000, Russell, 2003). Oxysterols in the liver bind RXR:LXRα 
heterodimers which in turn up-regulate CYP7A1 expression resulting in an increase in bile 
salt synthesis (Peet et al., 1998). Increased bile salts in the hepatocyte bind FXR:RXR 
heterodimers, activating FXR (Makishima et al., 1999), which subsequently induces the 
transcription of SHP (Goodwin et al., 2000, Lu et al., 2000). SHP downregulates the 
expression of CYP7A1 and its own expression by binding and inactivating LRH-1 
(Goodwin et al., 2000, Lu et al., 2000). ABCB4 and ABCB11 are also targeted by FXR and 
their induction leads to increased export of bile salts and PC from the hepatocyte 
(Ananthanarayanan et al., 2001, Huang et al., 2003). 
1.13.5 The enterohepatic circulation 
The enterohepatic cycle (Figure 1-8), as mentioned above (Section 1.13.3), is very efficient 
at recovering bile salts. The cycle begins at the canalicular membrane of the hepatocyte 
where newly synthesised bile salts are effluxed into the canaliculus by the bile salt export 
pump ABCB11. ABCB11, and its cognate transporters ABCB4 and ATP8B1 that are 
necessary for bile flow are described in detail below. The bile collects in the gall bladder 
which, following the ingestion of food contracts and empties its contents into the common 
bile duct in response to CCK secreted by the mucosal epithelium of the small intestine. To 
exit the gastrointestinal tract and return to the hepatocyte the bile salts must cross three 
membranes; the apical and basolateral of the ileocyte, and the basolateral of the hepatocyte 
(Kullak-Ublick et al., 2004, Meier and Stieger, 2002, Trauner and Boyer, 2003). 
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Figure 1-8. The enterohepatic recycling of bile salts (BSs). 
Approximately 95% of the secreted BSs are re-absorbed in the enterohepatic cycle. De novo 
synthesis from cholesterol (chol) in the liver replaces the 5% that is lost in the faeces. Newly 
synthesised BSs are effluxed into the bile canaliculus by the bile salt export pump ABCB11, where 
they form micelles with phosphatidylcholine (PC) flopped to the outer leaflet of the canalicular 
membrane by ABCB4. The action of the phosphatidylserine (PS)-flippase ATP8B1 is thought be 
involved in the maintenance of lipid asymmetry at the canalicular membrane. Once they are 
secreted into the canaliculus, BSs collect in the gall bladder and are episodically released into the 
small intestine in response to hormonal signals. In the distal ileum, apical sodium-dependent bile 
salt transporter (ASBT) imports BSs into the ileocyte in a Na
+
-dependent manner. At the basolateral 
membrane of the ileocyte, BSs are exported by the heterodimeric organic solute transporter 
OST/ into the portal vein and thence to the liver. At the basolateral membrane of the hepatocyte, 
BSs are imported mainly via the Na
+
-dependent taurocholate co-transporting polypeptide (NTCP). 
Members of the organic anion transporting polypeptides (OATPs) also import BSs via either 
facilitated diffusion or an antiport mechanism in exchange for bicarbonate or reduced glutathione 
[adopted from (Nicolaou et al., 2012)]. 
 
1.13.5.1 Trans-ileocyte transport of bile salts 
Trans-ileocyte transport of BSs (Figure 1-8) involves the apical sodium-dependent bile salt 
transporter [ASBT; also known as the ileal bile acid transporter (IBAT)]; the cytosolic ileal 
bile acid binding protein (IBABP); and the basolateral organic solute transporter (a 
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heterodimer of alpha and beta subunits; OSTα/β) (Dawson et al., 2005, Gong et al., 1994, 
Hagenbuch and Meier, 2004, Soroka et al., 2010).  
 
ASBT (SLC10A2) is a member of the SLC10 family of solute carriers (Hagenbuch and 
Dawson, 2004). It is expressed on the apical membrane of the ileocytes lining the distal 
ileum (Coppola et al., 1998, Hagenbuch and Meier, 2004). ASBT concentrates bile salts in 
the ileocyte by a symport mechanism driven by the sodium gradient across the apical 
membrane. Sodium is thus cotransported with the bile salt (the intra-ileocyte sodium 
concentration is kept low by the Na+K+ATPase on the basolateral membrane). 
Translocation of bile salts through the ileocyte to the basolateral membrane is thought to 
involve IBABP, which can bind to the intracellular face of ASBT (Gong et al., 1994, 
Kramer et al., 1995). At the basolateral membrane, OSTα/β exports the bile salts into the 
portal vein. OSTα/β was first described in the skate Leucoraja erinacea (Dawson et al., 2005) 
before the human homologue was cloned in 2003 (Seward et al., 2003). In humans it is 
expressed at high levels in a variety of tissues including liver and small intestine and is the 
primary exporter of bile salts into the systemic circulation (Seward et al., 2003, Soroka et 
al., 2010). OSTα/β works by facilitated diffusion, transporting bile salts (and other organic 
solutes and steroids) down their concentration gradients. After secretion into the portal 
blood, BSs reach the liver where they diffuse into the perisinusoidal space of Disse (Figure 
1-6) and come into contact with the basolateral membrane of the hepatocyte. 
1.13.5.2 Trans-hepatocyte transport of bile salts 
BSs in the portal blood are efficiently taken up from the space of Disse by the hepatocyte’s 
basolateral membrane transporters (Figure 1-8) (Hagenbuch and Meier, 1996). In the 
basolateral membrane there are both Na+-dependent and Na+-independent systems for the 
uptake of bile salts (Dawson et al., 2009, Kullak-Ublick et al., 2000, Meier and Stieger, 
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2002, Trauner and Boyer, 2003). The Na+-dependent taurocholate co-transporting 
polypeptide [NTCP (SLC10A1), another SLC10 family transporter] is the most important, 
contributing 80% of the transport capacity and it is only expressed in the basolateral 
membrane (Hagenbuch and Meier, 1994). NCTP transports both conjugated and 
unconjugated bile salts (bile salts are commonly deamidated in the intestine by bacteria) 
into the hepatocyte (Boyer et al., 1994, Hagenbuch and Meier, 1994, Hagenbuch and Meier, 
2004, Hata et al., 2003, Kramer et al., 1999, Platte et al., 1996) by symport with sodium ions 
[with a stoichiometry of 2 × Na+ ions per bile salt (Schroeder et al., 1998)]. The Na+-
independent system is mediated by the organic anion transporting polypeptides (OATPs) 
which belong to the SLCO (SLC21) family of solute carriers (Hagenbuch and Dawson, 
2004, Kullak-Ublick et al., 2000, Meier, 1995, Trauner and Boyer, 2003). The main human 
OATPs (OATP1A2, OATP1B1, OATP1B3 and OATP2B1) are expressed at the 
basolateral membrane of the hepatocyte and primarily transport unconjugated bile salts 
(Alrefai and Gill, 2007, Hagenbuch and Meier, 2003, Hagenbuch and Meier, 2004, Kullak-
Ublick et al., 2000). OATP1A2 is unique in its substrate specificity in that it can also 
transport organic cations (similar to OSTα/β) (Kullak-Ublick et al., 2001). 
 
Following uptake, the mechanism of translocation through the hepatocyte is not well 
understood but most likely involves carrier proteins. Several cytoplasmic proteins including 
glutathione S-transferases, steroid dehydrogenases and fatty acid binding proteins have 
been shown to have affinity for bile salts but no definitive evidence for a role in intra-
hepatocyte transport has been reported (Agellon and Torchia, 2000). In the hepatocyte, the 
recycled bile salts are added to the pool synthesised de novo and delivered to ABCB11 for 
export across the canalicular membrane. 
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1.13.5.3 Transport across the canalicular membrane 
Our current understanding of this key activity in the intrahepatic cycle stems from 1969, 
when a rare progressive familial intrahepatic cholestatic (PFIC) disease was first described 
by Clayton et al., (Clayton et al., 1969) (the condition is still referred to as Byler disease after 
the eponymous Amish kindred in which it was described). It is now clear that there are at 
least three primary active transport proteins that are necessary for bile flow across the 
canalicular membrane, and each gives rise to a different type of autosomal recessive PFIC. 
All three present similarly as cholestasis early in life, often within the first year (Table 1-2) 
(Clayton et al., 1969). 
 
 ATP8B1 
(OMIM_602397) 
ABCB11 
(OMIM_603201) 
ABCB4 
(OMIM_171060) 
Alternative names FIC1 BSEP, SPGP MDR3 
Function 
PS-flippase 
microvillus formation 
Bile salt export PC-floppase 
Associated PFIC Type 1 Type 2 Type 3 
Cholestatic onset 1
st
 year – adolescence 1
st
 year – adolescence 1
st
 year- early childhood 
Biliary bile acid Very low, PS present Absent Normal but devoid of PC 
Serum 
Bile salts 
γ-GT 
ALT 
Cholesterol 
High 
Normal 
Mild Elevation 
Sometimes elevated 
High 
Normal 
Five times normal levels 
Often elevated 
Normal 
Raised 
Five times normal levels 
Normal 
Liver histology 
Canalicular cholestasis 
Granular bile 
Giant cell hepatitis 
Bile duct proliferation 
and fibrosis 
Pruritus Severe Severe Moderate 
Extrahepatic symptoms 
Diarrhoea, pancreatitis, 
hearing loss 
None None 
Conditions associated 
with partial function 
BRIC1, ICP BRIC2, ICP, DIC, CIC, HC 
(BRIC3?), ICP, DIC, LPAC, 
CIC 
Table 1-2. Diseases associated with mutations in ATP8B1, ABCB11 and ABCB4. 
PFIC, progressive familial intrahepatic cholestasis; PS, phosphatidylserine; PC, 
phosphatidylcholine; -GT, γ-glutamyl transferase; ALT, alanine transaminase; BRIC1/2/3, benign 
recurrent intrahepatic cholestasis type 1/2/3; ICP, intrahepatic cholestasis of pregnancy; LPAC, low 
phospholipid-associated cholelithiasis; DIC, drug-induced cholestasis; CIC, contraceptive-induced 
cholestasis; HC, hepatocellular carcinoma. 
 
Affected individuals absorb dietary fats and fat-soluble vitamins inefficiently, which leads 
to growth restriction and progressive liver damage caused by increased hepatic and serum 
levels of bile salts. Affected individuals also commonly have jaundice and intractable 
pruritus. The condition progresses to end-stage liver disease in the first or second decade. 
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Characterisation of these patients has allowed the genetic aetiology of PFIC to be 
determined and the three transporters that are key to bile flow across the canalicular 
membrane to be identified and characterised. PFIC types 2 and 3 are caused by mutations 
to the transporters that efflux the two major components of bile; bile salts via ABCB11, 
and the lipid PC via ABCB4. PFIC1 (Byler Disease) is caused by mutation of ATP8B1, 
which transports PS in the opposite direction (from the outer to the inner leaflet of the 
membrane). While PFIC3 patients may be differentially diagnosed by raised serum γ-
glutamyl transferase (γ-GT), and immunohistochemistry can be invaluable to establish 
whether specific transporters are implicated in disease aetiology (Knisely and Gissen, 2010), 
definitive clinical diagnosis generally requires genetic testing. It is becoming increasingly 
apparent that there is a spectrum of cholestatic disease caused by mutations in ABCB11, 
ABCB4 and ATP8B1. This ranges from the severe phenotype of PFIC to milder, 
intermittent forms of cholestasis, e.g. benign recurrent intrahepatic cholestasis (BRIC), 
drug-induced cholestasis (DIC) or intrahepatic cholestasis of pregnancy (ICP) (Table 1-2). 
1.13.5.3.1 ABCB11: the bile salt exporter and the etiological root of PFIC2 
In 1991, Nishida et al., described an ATP-dependent system for the transport of 
taurocholate in canalicular membrane vesicles derived from rat liver (Nishida et al., 1991). 
This observation was soon confirmed by three other groups (Adachi et al., 1991, Muller et 
al., 1991, Stieger et al., 1992) and a low stringency hybridisation screen on pig liver cDNA 
identified a novel gene with high sequence identity to the human drug efflux pump ABCB1 
(described in more detail above). This new gene was eventually renamed Abcb11 [earlier 
names include sister of Pgp (spgp), and bile salt export pump (Bsep)] (Childs et al., 1995). 
Successful cloning of the full-length rat homologue showed that Abcb11 could function in 
vitro as a bile salt efflux transporter in the presence of ATP, and northern blot analysis 
revealed that it was primarily expressed in the liver (Gerloff et al., 1998). Positional cloning 
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of the human orthologue was then correlated with a set of mutations linked to PFIC2 
(Strautnieks et al., 1998). This established ABCB11 as the main bile salt export pump in the 
human liver and mapped the ABCB11 gene to chromosome 2q24. Expression of the 140-
150 kDa human ABCB11 in insect cells confirmed its ability to transport bile salts in an 
ATP-dependent manner, with an apparent affinity for different bile salts that reflects the 
composition of the bile salt pool in humans (Byrne et al., 2002, Noe et al., 2002). Knock-
out mice deficient for Abcb11, develop intrahepatic cholestasis, but the phenotype is less 
severe than in PFIC2 patients (Wang et al., 2001). This is considered to be due to the less 
toxic nature of the murine bile salt pool and the compensatory up-regulation of other ABC 
transporters. In Abcb11-/- mice there is a dramatic decrease in the export of cholic acid but 
the total output of bile salts is only slightly reduced (Wang et al., 2001). This unexpected 
observation was later shown to be due to the up-regulation of Abcb1a, which could 
apparently function as bile salt transporter in the absence of Abcb11 (Lam et al., 2005). 
However, no compensatory increase in ABCB1 mRNA has been observed in PFIC2 
patients (Keitel et al., 2005). 
 
ABCB11 mutations have been reported in patients with PFIC2 and benign recurrent 
intrahepatic cholestasis type 2 or BRIC2 (Byrne et al., 2009, Byrne et al., 2002, Chen et al., 
2002, Goto et al., 2003, Jansen et al., 1999, van Mil et al., 2004). Biochemically, PFIC2 is 
characterised by normal γ-GT and normal cholesterol levels in the serum but very low 
biliary bile salts (Davit-Spraul et al., 2009, Morotti et al., 2011). BRIC2 develops usually 
after the first decade and can progress into PFIC2 although it is normally episodic and 
benign (Lam et al., 2006, Noe et al., 2005, van Mil et al., 2004). Mutations in ABCB11 have 
also been linked to ICP (Dixon et al., 2009), DIC (Keitel et al., 2006, Lang et al., 2006, 
Pauli-Magnus et al., 2004b, Pauli-Magnus et al., 2005) and contraceptive-induced 
cholestasis (CIC) (Meier et al., 2008). The association of genetic variation in ABCB11 with 
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ICP and CIC prompted research into the mechanisms by which reproductive hormones 
can impair ABCB11 function. Two sulphated progesterone metabolites have been 
demonstrated to trans-inhibit efflux of bile acids by ABCB11 in an oocyte model system 
(Vallejo et al., 2006). Furthermore, oestrogen 17β-glucuronide has also been demonstrated 
to trans-inhibit ABCB11 in an SF9 cell vesicle system (Stieger et al., 2000). Many of the 
ABCB11 SNPs described have since been shown to affect mRNA splicing, protein stability 
and/or protein function in vitro (Byrne et al., 2009). ABCB11 deficiency is also associated 
with hepatocellular carcinoma in young children (Knisely et al., 2006). 
1.13.5.3.2 ABCB4: The PC flopper and the etiological root of PFIC3 
ABCB4 was first cloned in 1987 by Van der Bliek et al. from a human liver cDNA library 
and named MDR3, due to its high degree of similarity with the third hamster “multidrug 
resistance” (Mdr) gene (Van der Bliek et al., 1987). The ABCB4 gene locus spans 74kb on 
chromosome 7q21.1 and gives four alternatively spliced transcripts (Lincke et al., 1991). 
The high level of expression in the canalicular membrane suggested an important role for 
ABCB4 in the liver (Buschman et al., 1992), which was later confirmed by the generation of 
Abcb4-/- mice (Smit et al., 1993). Mice deficient in Abcb4 developed severe liver disease 
characterised by a complete absence of PC from the bile. Analysis of fibroblasts from 
transgenic mice showed that Abcb4 flops PC from the inner to the outer leaflet of the 
plasma membrane (Smith et al., 1994). The human orthologue was cloned and also shown 
to translocate PC specifically, across the plasma membrane (van Helvoort et al., 1996) and, 
when knocked-in to Abcb4-/- mice, human ABCB4 rescued PC excretion into the bile 
(Smith et al., 1998). In the absence of ABCB4, the detergent activity of bile salts 
transported into the bile by ABCB11 can solubilise cell membranes resulting in biliary 
toxicity (Donovan et al., 1991). Homozygous mutation of ABCB4 causes PFIC3, which 
presents within the first few years of age with pruritus, jaundice and growth restriction 
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(Oude Elferink and Groen, 2002, Pauli-Magnus et al., 2005). Liver histology reveals portal 
fibrosis, which can progress to cirrhosis and ductular proliferation that eventually leads to 
end-stage liver disease (Davit-Spraul et al., 2009, Morotti et al., 2011). Biochemically, 
PFIC3 can be distinguished from PFIC1 and 2 by high levels of γ-GT in the serum and 
complete absence of PC from the bile (Jacquemin et al., 2001). 
 
It is becoming increasingly apparent that mutations of ABCB4 are associated with a 
spectrum of cholestatic diseases. These overlap with ABCB11 phenotypes and include ICP 
(Mullenbach et al., 2003), DIC (Oude Elferink and Paulusma, 2007), CIC and low 
phospholipid associated cholelithiasis [(LPAC), a form of cholesterol gallstone disease 
(Rosmorduc et al., 2001)]. Recently, missense mutations in ABCB4 have also been reported 
in two heterozygous patients with cholangiocarcinoma (a malignant tumour in the biliary 
tract) in two unrelated families (Tougeron et al., 2012). Together, these conditions suggest 
that ABCB4-dependent hepatobiliary disease is common. ICP (also known as obstetric 
cholestasis) presents in the third trimester of pregnancy when oestrogen levels reach their 
peak (Dixon et al., 2009, Eloranta et al., 2002, Gendrot et al., 2003, Jacquemin et al., 1999, 
Mullenbach et al., 2003). Symptoms include severe pruritus and abnormal bile flow in the 
mother, which resolve rapidly after delivery. ICP carries a significant increased risk of 
adverse pregnancy outcome and intrauterine death, and affects 0.6% of births in the British 
Caucasian population. In LPAC, female gender and parity (in agreement with the influence 
of oestrogens in bile flow, as suggested for ICP) are among the major risk factors. LPAC 
patients often also present with raised serum γ-GT, further implicating ABCB4. 
 
In 2004, 18 mutations in ABCB4 had been associated with PFIC3 and 30 mutations were 
linked to induced cholestatic disease, but often only in single or few families (Pauli-Magnus 
et al., 2004b). These include 11 and 16 SNPs, respectively, which encode non-synonymous 
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changes in the protein sequence. The effects of these SNPs on protein trafficking, function 
and response to inducing agents, have not been characterised, so the causal conjunction 
between ABCB4 SNPs remains to be definitively proved for some hepatobiliary diseases 
(particularly the induced forms with a complex aetiology). 
 
Some insights into the functional consequences of ABCB4 mutation have been obtained by 
two groups which have used the closest homologue of ABCB4, ABCB1, to express and 
characterise the effect of mutations identified in patients (Delaunay et al., 2009, Dixon et 
al., 2000). This was achieved by mimicking clinically-relevant mutations in the multidrug 
resistance ABCB1 and measuring the effect on ABCB1 expression and drug efflux. 
However, this approach is limited and only relevant if the particular amino acid is 
conserved in both proteins and performs the same function. This rules out the study of 
amino acid changes that directly influence PC binding or efflux, or responses to hormones 
of pregnancy, contraceptives or other drugs. Biochemical characterisation of ABCB4 SNPs 
directly has, hitherto, been difficult for two reasons: the technical difficulty of measuring 
the flux of PC from the inner to the outer leaflet of the plasma membrane; and because 
expression of functional PC floppase, transiently in vitro, appears to be deleterious to cells 
and leads to cell death. These difficulties have now been overcome and this new data has 
coincidentally shed some light on why ATP8B1 is needed in the canalicular membrane [see 
below (Groen et al., 2011)]. 
1.13.5.3.3 ATP8B1 (FIC1): The PS flipper and the etiological root of PFIC1 
Surprisingly, mutation of neither ABCB11 nor ABCB4, which transport the two major 
components in bile, could explain the original Byler family PFIC pedigree. The third 
transport protein that appears to be necessary for bile flow across the canalicular 
membrane was not discovered until 1998, when Laura Bull identified the ATP8B1 gene on 
 Introduction 
 
66 
 
chromosome 18q21 by positional cloning (Bull et al., 1998). ATP8B1 (also known as FIC1) 
is a P-type ATPase which functions in complex with the accessory protein CDC50A 
(Paulusma et al., 2008). ATP8B1 moves a different membrane phospholipid, PS, in the 
opposite direction to the transport of PC by ABCB4. PS is generally restricted to the inner 
leaflet of the plasma membrane and so is not normally exposed at the cell surface. There 
are three lines of evidence in support of PS-flippase activity for ATP8B1: (a) loss of 
ATP8B1 activity reduces bile flow but causes the appearance of PS in the residual flow; this 
is also true of Atp8b1-deficient mice following taurocholate infusion (Paulusma et al., 
2006); (b) fluorescently-labelled PS analogues are internalised by UPS-1 cells following 
transient expression of ATP8B1 (Paulusma et al., 2008, Ujhazy et al., 2001); and (c) the 
same cells show reduced binding of annexin-V when added extracellularly (annexin-V has a 
high affinity for native PS when the PS headgroup is exposed on the cell surface). 
 
ATP8B1-deficiency is linked to several cholestatic liver diseases, PFIC1 and BRIC1 (Bull et 
al., 1998), and ICP (Mullenbach et al., 2005, Painter et al., 2005). PFIC1 is by far the most 
severe (Klomp et al., 2004). Scanning electron micrographs of bile from patients reveals 
coarse granules [sometimes called “Byler bile” (Clayton et al., 1969)]. Histological 
examination of early liver biopsies revealed relatively mild liver damage, compared to 
PFIC2 and PFIC3, with lobular architecture largely preserved and an absence of giant cells 
(Clayton et al., 1969). Signs of cholestasis are, in fact, largely confined to the canaliculi 
(Clayton et al., 1969). In keeping with these observations, serum levels of hepatic enzymes 
γ-GT and ALT, are only mildly elevated in patients with PFIC1. Nevertheless, the common 
outcome is cirrhosis and end-stage liver disease within the second decade. The presence of 
ATP8B1 at apical membranes of pancreatic acinar cells, enterocytes of the ileum and 
jejunum, and cochlear hair cells of the inner ear means that PFIC1 is a pleiotropic 
condition. Extrahepatic symptoms include intractable diarrhoea (Lykavieris et al., 2003), 
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sensorineural hearing loss (Stapelbroek et al., 2009) and, in a few cases, pancreatitis 
(Tygstrup et al., 1999). 
 
BRIC1 is also associated with ATP8B1 (Klomp et al., 2004). Affected individuals present 
with episodic bouts of cholestasis, pruritus and extrahepatic symptoms such as diarrhoea, 
which may last days, weeks or months but is not progressive. It is considered benign 
because no lasting liver damage occurs and, during remission, patients are biochemically 
normal. However, as is the case with PFIC1, pruritus can be very severe during cholestatic 
episodes and some patients have elected for liver transplantation in order to improve 
quality of life (EASL, 2009). Initial onset of BRIC1 generally occurs early in childhood and 
episodes can occur multiple times within a single year, although there is considerable 
variation and some patients remain in remission for a decade or more (Tygstrup et al., 
1999). Triggers of cholestatic episodes are not well defined but there is anecdotal 
correlation with viral infection and use of the contraceptive pill (de Pagter et al., 1976, 
Tygstrup et al., 1999). BRIC1 is less severe than PFIC1 and it is presumed that the 
mutations associated with BRIC1 have a milder impact on protein function, although this 
has not been demonstrated definitively. 
1.13.6 Are the functions of ABCB4 and ATP8B1 complementary? 
It is well established that the phospholipids in the plasma membrane are arranged 
asymmetrically. For example, the sphingolipids and PC are enriched in the outer leaflet, 
while phosphatidylethanolamine (PE), phosphatidylinositol (PI) and PS are enriched in the 
inner leaflet (Figure 1-9). This lipid asymmetry and the high concentration of sphingolipids 
and cholesterol in the outer leaflet is thought to influence the lipid packing, fluidity and 
barrier function (Elliott et al., 2005, van Meer et al., 2008), and is particularly important at 
the canalicular membrane which is essentially under attack from bile salts that are effluxed 
 Introduction 
 
68 
 
into the canaliculus by ABCB11. ABCB4 flops excess PC into the outer leaflet, which 
might be expected to destabilise the bilayer but is extracted into the bile by the detergent 
activity of the bile salts. ABCG5 and ABCG8 also efflux cholesterol into the bile, 
presumably for the same purpose: to form a bile salt/lipid mixed micelle and reduce the 
detergent nature of the bile salt. If a PS flippase is important for bile flow one must expect 
PS to appear in the outer leaflet. The lipid and bile salt traffic at the canalicular membrane 
means that it is in a continuous state of flux and the ensuing instability may allow PS to 
flop spontaneously into the outer leaflet. Alternatively, it is possible that PS is flopped by 
ABCB4 directly, although there is no evidence for this because analogues of PS were not 
tested in the most comprehensive study of ABCB4 substrate specificity (van Helvoort et 
al., 1996). Whichever the explanation, the presence of PS in the outer leaflet will, along 
with the excess of PC flopped by ABCB4, dilute the relative concentration of sphingolipids 
and cholesterol, thus prevent the leaflet from forming a liquid crystalline phase. This would 
render the canalicular membrane more sensitive to detergent solubilisation. This has led to 
the suggestion that ATP8B1 is required to re-internalise the flopped PS to maintain the 
liquid crystalline order of the canalicular membrane. In the ATP8B1-deficient state this 
does not happen and the membrane is progressively damaged by the liver’s own 
metabolites. 
 
Is there any evidence to support this theory? Data from our own lab and from the lab of 
our collaborator Ronald Oude Elferink strongly suggests that ATP8B1 is critically 
important to cell survival when ABCB4 is present. 
 
It was observed that transient expression of ABCB4 in HEK293T (human embryonic 
kidney 293T) cells was deleterious to the integrity of the membrane and cell survival [cells 
became leaky and released the cytoplasmic enzyme lactate dehydrogenase (LDH) into the
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Figure 1-9. Maintenance and role of lipid asymmetry at the canalicular membrane. 
Lipid asymmetry at the plasma membrane is known to be important for barrier function. Bile salts 
are exported into the bile canaliculus by ABCB11. The PC floppase ABCB4 flops PC into the outer 
leaflet of the canalicular membrane, where it is extracted into the bile by bile salts. Flopping of 
excess PC destabilises the canalicular membrane, causing PS to flop spontaneously into the outer 
leaflet (alternatively, ABCB4 may flop PS directly). The dilution of sphingomyelin in the outer leaflet 
induces a liquid disordered phase and renders the canalicular membrane more sensitive to 
detergent solubilisation. The PS flippase ATP8B1 is therefore required to flip PS back into the inner 
leaflet of the canalicular membrane to maintain its liquid crystalline order (adapted from Nicolaou 
et al., 2012). 
 
culture medium; (Figure 1-9A)] (Groen et al., 2011). ABCB4 protein level in the transiently-
transfected cells was therefore low (Figure 1-9B). However, LDH release could be 
attenuated and ABCB4 expression rescued when ATP8B1 (and its cofactor CDC50A) was 
co-expressed. These cells co-expressing the PC floppase and the PS flippase were able to 
secrete PC in a bile salt-dependent manner (Figure 1-9C). Consistent with this observation, 
double knock-out mice that lacked expression of Abcb4 and Atp8b1 had a milder 
phenotype than Atp8b1-deficient mice suggesting that the phenotype of the latter was at 
least in part due to the cytotoxic effect of unchecked Abcb4 activity on the integrity of the 
canalicular membrane (Groen et al., 2011). 
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Figure 1-10. ATP8B1 is necessary for functional expression of ABCB4. 
(A). ABCB4 expression alone in HEK293T cells is cytotoxic causing lactate dehydrogenase (LDH) 
to be released from the cells. This is rescued by co-expression of ATP8B1 and CDC50A. (B). 
Western analysis showing that transient expression of the ABCB4 PC floppase is only tolerated 
when the ATP8B1/CDC50A PS flippase is co-expressed. (C). Cells co-expressing the PC floppase 
and PS flippase can efflux PC to added taurocholate [adapted from (Groen et al., 2011)]. 
 
1.13.7 Functional studies of ABCB4 in vitro 
As described in Section 1.13.5.3.2, many mutations have been reported which implicate 
ABCB4 malfunction in a spectrum of cholestatic disease. This ranges from the most severe 
 Introduction 
 
71 
 
phenotype, PFIC3, to the milder, intermittent forms of cholestasis, e.g. BRIC, DIC or ICP 
(Table 1-2). Although in PFIC3 the link between mutation and disease is clear, in the 
majority of liver diseases the underlying causes are complex and include diet, physiological 
conditions such as pregnancy or therapeutic drug use, as well as genetics. In these cases, 
association with particular mutations in ABCB4 is suspected but not proved. To investigate 
the aetiology of cholestatic liver disease, I have introduced suspected disease-causing 
mutations into the recombinant transporter for transient expression in HEK293T cells (in 
the presence and absence of the ATP8B1/CDC50A PS flippase). ABCB4 expression and 
trafficking was monitored by western analysis and confocal microscopy, and function was 
measured by 3H- PC efflux to bile salts added to the culture medium. By mimicking the 
situation at the canalicular membrane, an initial characterisation of mutant ABCB4 that are 
associated with cholestatic liver disease has been achieved and reported in chapters 4 and 5 
of this thesis. 
 
1.14 Aims 
The aims of the two projects described in this report are listed below. 
1.14.1 Project 1 (ABCB1) 
The overall aim of Project 1 was to employ the SU-YTH system in yeast to identify 
proteins that interact with ABCB1 and, ultimately, to study their effects on its localisation 
or its ability to efflux drugs. 
1.14.2 Project 2 (ABCB4) 
The aim of Project 2 was to use a transient expression system in which ABCB4 is co-
expressed with the ATP8B1/CDC50A PS flippase in HEK293T cells to investigate the 
aetiology of cholestatic liver disease at the molecular level. 
  
 
Chapter Two 
 
 
 
 
 
 
 
2 Materials and Methods 
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2.1 Cell strains 
The yeast (NMY51), bacterial (XL10-Gold®) and mammalian (HEK293T) cell strains used 
in this investigation are outlined below. 
2.1.1 NMY51 yeast reporter strain 
MATa his3Δ200 trp1-901 leu2-3, 112 ade2 LYS2::(lexAop)4-HIS3 ura3::(lexAop)8-lacZ 
ade2::(lexAop)8-ADE2 GAL4 
2.1.2 XL10-Gold® Ultracompetent E. coli cells 
Tetr Δ (mcrA)183 Δ(mcrCB-hsdSMR-mrr)173 endA1 supE44 thi-1 recA1 gyrA96 relA1 lac 
Hte [F´ proAB lacIqZΔM15 Tn10 (Tetr) Amy Camr] 
2.1.3 HEK293T mammalian cells 
Human embryonic kidney 293 cells (Graham et al., 1977) stably and constitutively 
expressing the SV40 large T antigen (HEK293T) allowing for the expression of transfected 
plasmids containing the SV40 origin of replication were obtained from the Imperial Cancer 
Research Fund, cell production unit. 
 
2.2 Plasmids 
The vectors used for the transformation of yeast and bacteria as well as the transfection of 
mammalian cells are described in Table 2-1. 
 
Vector Auxotrophic Marker (Yeast) Resistance Marker (E. Coli) Source 
SU-YTH Bait Vectors 
pBT3-N LEU2 Kanamycin Dualsystems Biotech 
pBT3-N:CD36 LEU2 Kanamycin J. Wharton, London 
pBT3-N:FATP4 LEU2 Kanamycin J. Wharton, London 
Table 2-1. List of vectors used in the investigation. 
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Vector Auxotrophic Marker (Yeast) Resistance Marker (E. Coli) Source 
SU-YTH Library Vectors 
pPR3-STE TRP1 Ampicillin Dualsystems Biotech 
pPR3-N (NubG-X) TRP1 Ampicillin Dualsystems Biotech 
pDL2xN-SUC (X-NubG) TRP1 Ampicillin Dualsystems Biotech 
pDL2xN-STE (X-NubG) TRP1 Ampicillin Dualsystems Biotech 
SU-YTH Control Prey Vectors 
pCCW-Alg5p LEU2 Kanamycin Dualsystems Biotech 
pAI-Alg5 (NubI) TRP1 Ampicillin Dualsystems Biotech 
pDL2-Alg5 (NubG) TRP1 Ampicillin Dualsystems Biotech 
pPR3-STE:Caveolin TRP1 Ampicillin J. Wharton, London 
pPR3-STE:PKCα TRP1 Ampicillin This study 
Cloning Vectors 
pGEM3®-3Zf(-)  Ampicillin Promega 
pGEM3®-3Zf(-):PKCα Vector 
pGEM3®-3Zf(-):PKCα  Ampicillin This study 
PKCα-GFP Vector 
EGFP-PKCα(cDNA)   A. Sardini, London 
ABCB4 
pcDNA3.1-ABCB4wt  Ampicillin Groen et al. (2011) 
pcDNA3.1-G535D  Ampicillin This study 
pcDNA3.1-M301T  Ampicillin This study 
pcDNA3.1-E528D  Ampicillin This study 
pcDNA3.1-L591Q  Ampicillin This study 
pcDNA3.1-P1161S  Ampicillin This study 
pcDNA3.1-R545C  Ampicillin This study 
pcDNA3.1-A286V  Ampicillin This study 
pcDNA3.1-S320F  Ampicillin 
M. Rodriguez-Romero, 
London 
pcDNA3.1-A546D  Ampicillin 
M. Rodriguez-Romero, 
London 
pcDNA3.1-E558Q  Ampicillin Groen et al. (2011) 
ATP8B1 
pCI-neo-ATP8B1  Ampicillin Groen et al. (2011) 
CDC50A 
pCI-neo-CDC50  Ampicillin Groen et al. (2011) 
CFP/GFP/YFP 
pECFP-C1  Kanamycin Clontech 
pEGFP-C1  Kanamycin Clontech 
pEGFP-C1  Kanamycin Clontech 
Table 2-1. (continued) List of vectors used in the investigation. 
 
2.3 Primer list 
A list of the oligonucleotides used in this investigation is provided in Table 2-2. 
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Name Sequence (5’ – 3’) Source 
Mutagenic Primers 
pGEM3
®
-3Zf(-):PKCα 
PciI-F:PKCα CGGGTGCTGGTGACATGTCTGACGTTTTCCC Sigma-Aldrich 
AgeI-R:PKCα CGCTGGTGAGTTTCAACCGGTACTCTGTAAGAT Sigma-Aldrich 
pcDNA3.1-ABCB4  
G535D GCCCAGCTGAGTGATGGGCAGAAGCAG Sigma-Aldrich 
M301T AAAAAGCTATTTCAGCAAACATTTCCACGGGTATTGCCTTCC Sigma-Aldrich 
E528D GACACCCTGGTTGGAGACAGAGGGGCC Sigma-Aldrich 
L591Q CCACCATTGTGATAGCACACCGACAATCTACGG TCCGAAATGCAG ATGTC Sigma-Aldrich 
P1161S GCCAACATACATCCTTTCATCGAGACGTTGTCCCACAAATATGAAA Sigma-Aldrich 
R545C GGATCGCCATTGCATGTGCCCTGGTTCGC Sigma-Aldrich 
A286V 
GAAAGGTATCAGAAACATTTAGAAAATGTCAAAGAGATTGGAATTAAAAA 
AGCTATT 
Sigma-Aldrich 
S320F CTGGCCTTCTGGTATGGATTCACTCTAGTCATATCAAA Sigma-Aldrich 
A546D CGCCATTGCACGTGACCTGGTTCGCAACC Sigma-Aldrich 
E558Q GATCCTTCTGCTGGATCAGGCGACGTCAGCATTGGAC Sigma-Aldrich 
Sequencing Primers 
pGEM3
®
-3Zf(-):PKCα 
PKCaR1 AGACGCCGTGGAGTCGTT A. Sardini 
PKCaF1 TGCACGAGGTGAAGGACC A. Sardini 
PKCaF2 GTCTGTAGAAAATCTGGG A. Sardini 
PKCaF3 GATAACGTCATGTTGGAT A. Sardini 
PKCaF4 GCTAACATAGACCAGTCT A. Sardini 
pEGFP-C1F1 TCCTGCTGGAGTTCGTGACC A. Sardini 
pUC/M13F CGCCAGGGTTTTCCCAGTCACGAC Promega 
pUC/M13R TCACACAGGAAACAGCTATGAC Promega 
pcDNA3.1-ABCB4 
ABCB4_389F GATTGGGTGCTGGAGTTCTTGTTG Sigma-Aldrich 
ABCB4_918F CATTTCCATGGGTATTGCCTTCCTG Sigma-Aldrich 
ABCB4_1440F GGTGTGGTGAGTCAGGAGCCGGTG Sigma-Aldrich 
ABCB4_1983F GCCCCAAATGGCTGGAAATCTCGC Sigma-Aldrich 
ABCB4_2473F CTTGCCACAGATGCTGCCCAAGTCC Sigma-Aldrich 
ABCB4_2981F CTCTAGGACATGCCAGTTCATTTGC Sigma-Aldrich 
ABCB4_3393F CTGCAGC ATTGCCGAGAATATTGCC Sigma-Aldrich 
ABCB4_491R CAGTGGTGTCATTGATGTCAAACC Sigma-Aldrich 
pPR3-N, pDL2xN-SUC, pDL2xN-STE 
pNubGx GTCGAAAATTCAAGACAAGG Sigma-Aldrich 
pDSL-Nx GTAAGCGTGACATAACTAATTACATG Sigma-Aldrich 
Table 2-2. List of primers used in the investigation. 
The underlined and emboldened letters indicate the single nucleotide change introduced to the WT 
ABCB4 coding sequence.  
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2.4 Yeast transformation solutions and reagents 
All yeast transformation solutions were prepared by dissolving the reagents listed in the 
tables below in the appropriate volume of sterile water. Following preparation, the 
solutions were passed through a sterile filter (0.2 µm) and stored at room temperature. 
PEG (poly[ethylene glycol]) and LiAc (Lithium acetate dehydrate) were aliquoted in 50 ml 
Falcon tubes (SLS, UK), capped tightly and sealed with Parafilm “M” to avoid evaporation. 
It is crucial to avoid evaporation as the concentration of these reagents is a very critical 
parameter to achieve good transformation efficiency. Single-stranded (SS) carrier DNA 
from salmon sperm was prepared by dissolving 200 mg of salmon sperm DNA type III 
sodium salt (Sigma-Aldrich, UK; D1636) in 100 ml sterile water (2 mg ml-1 stock) into a 
250 ml sterile glass beaker. Initially the large chunks of DNA were dissolved by pipetting 
up and down with a 25 ml sterile strippette (Corning Inc., UK) followed by continuous 
stirring for 2 – 3 hours at RT (room temperature) until all DNA was dissolved. 
Subsequently, the DNA was aliquoted into sterile 1.5 ml eppendorf test tubes (Eppendorf, 
UK), boiled on a hot block (DRI Block® DB.2A; Techne LTD, UK) for 5 min at 99oC and 
immediately chilled in an ice/water bath before being stored at -20oC. For small-scale 
transformations the SS DNA was thawed and used directly. For large-scale transformations 
the SS DNA was thawed on ice, boiled again at 99oC for 5 min, chilled immediately on an 
ice/water bath and kept on ice until required.  
  
50% PEG (Poly[ethylene glycol]) 
Reagent For 100 ml Source 
PEG 4000 50 g Sigma-Aldrich 
dH2O 80ml 
 
1 M LiAc (Lithium acetate dihydrate) 
Reagent For 100 ml Source 
LiAc dihydrate 10.2 g Sigma-Aldrich 
 dH2O to 100 ml 
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10 × TE (Tris-EDTA), pH 7.5  
Reagent For 1 L Source 
Tris-Cl pH 7.5 (1 M) 100 ml Sigma-Aldrich 
EDTA pH 7.8 (0.5 M) 20 ml Sigma-Aldrich 
 dH2O to 1 L 
 
2.5 Yeast media 
All selective defined (SD) media were prepared using synthetic drop-out mix lacking Trp 
(tryptophan), Leu (leucine), His (histidine) and Ade (adenine) and supplemented with the 
appropriate amino acid where appropriate. Amino acid stocks were prepared as 
summarised in the table below, passed through a sterile filter (0.2 µm) and kept at 4oC for 
up to one month. All yeast growth media, after preparation, were autoclaved for 15 min at 
121oC and kept at room temperature. Yeast agar plates (90 mm) containing SD or growth 
(YPAD) media were prepared using aseptic techniques and stored at 4oC for up to two 
weeks.  Prior to use, plates were dried and equilibrated at 30oC in an incubator (Sanyo, 
UK). 
 
 
SD Plates 
Supplement Amount/Litre Final Concentration Source 
Yeast Nitrogen base without 
amino acids 
6.7 g 0.7 % ForMedium
TM
 
Dropout Mix 0.6-0.7 g 0.1 % ForMedium
TM
 
D – (+) Glucose  20 g 2 % Sigma-Aldrich 
Bacto agar 20 g 2 % BD Biosciences 
dH2O to 1 L 
 
SD medium (liquid) 
Supplement Amount/Litre Final Concentration Source 
Yeast Nitrogen base without 
amino acids 
6.7 g 0.7 % ForMedium
TM
 
Dropout Mix 0.6-0.7 g 0.1 % ForMedium
TM
 
D – (+) Glucose 20 g 2 % Sigma-Aldrich 
dH2O to 1 L 
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YPAD Plates 
Supplement Amount/Litre Final Concentration Source 
Bacto Yeast extract 10 g 1 % BD Biosciences 
Bacto peptone 20 g 2 % BD Biosciences 
D – (+) Glucose 20 g 2 % Sigma-Aldrich 
Bacto agar 20 g 2 % BD Biosciences 
Adenine Sulphate 40 mg 0.004 % Sigma-Aldrich 
dH2O to 1 L 
 
YPAD medium (liquid) 
Supplement Amount/Litre Final Concentration Source 
Bacto Yeast extract 10 g 1 % BD Biosciences 
Bacto peptone 20 g 2 % BD Biosciences 
D – (+) Glucose 20 g 2 % Sigma-Aldrich 
Adenine Sulphate 40 mg 0.004 % Sigma-Aldrich 
dH2O to 1 L 
 
2× YPAD medium (liquid) 
Supplement Amount/Litre Final Concentration Source 
Bacto Yeast extract 20 g 2 % BD Biosciences 
Bacto peptone 40 g 4 % BD Biosciences 
D – (+) Glucose 40 g 4 % Sigma-Aldrich 
Adenine Sulphate 40 mg 0.004 % Sigma-Aldrich 
dH2O to 1 L 
 
Amino Acid stocks 
Amino Acid Stock Amount/Litre Final Concentration Source 
Tryptophan 10 g/L 2 ml 0.02 g/L Sigma-Aldrich 
Histidine 10 g/L 2 ml 0.02 g/L Sigma-Aldrich 
Leucine 10 g/L 10 ml 0.1 g/L Sigma-Aldrich 
Adenine 5 g/L 8 ml 0.04 g/L Sigma-Aldrich 
 
2.5.1 FK506 YPAD yeast agar plates 
A stock solution of 10 mg ml-1 FK506 (Sigma-Aldrich, UK) was prepared in ethanol 
(Sigma-Aldrich, UK) containing 10% (v/v) Tween 20 (Sigma-Aldrich, UK). 
 
YPAD agar plates containing FK506 at various concentrations (0, 5, 10, 20, 25, 30, 40, 50 
and 100 µg ml-1) were prepared by adding the appropriate volume of FK506 from the stock 
solution to 15 ml of YPAD agar equilibrated to 50oC before pouring into 3 cm petri dishes 
(Fisher Scientific, UK). Control YPAD plates lacking FK506 were also prepared which 
contained ethanol supplemented with Tween 20 at the same concentrations as FK506. 
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2.5.2 3-AT (3-amino-1,2,4-riazole) SD yeast agar plates 
Where necessary yeast cells were grown on basic selection plates (either SD-Trp-Leu-His or 
SD-Trp-Leu-His-Ade) supplemented with 0, 1, 2.5, 5, 7.5 and 10 mM 3-AT (a competitive 
inhibitor of the HIS3 gene product). 
 
A stock solution of 1.0 M (final concentration) 3-AT was prepared by dissolving 8.4 g of 3-
AT (Sigma-Aldrich, UK) in 100 ml sterile water by vortexing (Vortex Genie 2; Scientific 
Industries Inc., Bohemia, NY). The 100 ml stock solution was stored at -20oC in 10 ml 
aliquots. SD-agar plates containing 3-AT at the stated concentrations were prepared by 
adding the 3-AT from the stock solution (thawed on ice) to 100 ml of either SD-Trp-Leu-
His or SD-Trp-Leu-His-Ade liquid medium, equilibrated at 50oC, before pouring into the 
150 mm Petri dishes (VWR, Radnor, PA). 
 
2.6 Bacterial media 
Bacterial media [LB (Lysogeny broth) liquid medium and LB agar] were prepared by 
suspending 20 g of LB powder, Lennox (Fisher Scientific Ltd, UK; BPE1427-500) in 1 L 
of sterile water and autoclaved for 15 min at 121oC. For LB-agar plates, the medium was 
supplemented with 1.5% (w/v) bacto agar (BD Biosciences, UK) prior to autoclaving. 
Where necessary, the medium was allowed to cool down to 55oC before the appropriate 
antibiotic (100 µg ml-1 ampicillin) was added. For “blue/white” screening of recombinant 
constructs, 80 μg ml-1 X-gal (5-bromo-4-chloro-3-indolyl-beta-D-galactopyranoside, 
Fermentas, UK) and 20 mM IPTG (Isopropyl 1-thio-β-D galactopyranoside; Fisher 
Scientific Ltd, UK) were also added at this stage. LB-agar plates were prepared using 
aseptic techniques and stored at 4oC for up to one month. Prior to use, plates were dried 
and equilibrated at 37oC in an incubator (Sanyo, UK). 
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2.6.1 S.O.C. rich medium 
2% tryptone, 0.5% yeast extract, 10 mM NaCl, 2.5 mM KCl, 10 mM MgCl2, 10 mM 
MgSO4, 20 mM glucose (Invitrogen, UK; 15544-034). 
2.6.2 LB (Liquid) 
1% (w/v) NaCl, 1% (w/v) tryptone, 0.5% (w/v) yeast extract (Fisher Scientific Ltd, UK; 
BPE1427-500). 
2.6.3 LB-Agar (Plates) 
1% (w/v) NaCl, 1% (w/v) tryptone, 0.5% (w/v) yeast extract (Fisher Scientific Ltd, UK; 
BPE1427-500), 1.5% (w/v) bacto agar (BD Biosciences, UK). 
 
2.7 Mammalian cell culture 
2.7.1 Media and reagents 
Dulbecco’s Modified Eagle Medium (DMEM; 31053), with 4.5 mg L-1 glucose, but no 
Glutamine, no Phenol Red and no Sodium Pyruvate was purchased from Gibco. TrypLETM 
Express (12604), and L-Glutamine (200 mM; 25030) were also purchased from Gibco. 
Fetal bovine serum (FBS; F7524) and sodium pyruvate (100 mM; S8636) were purchased 
from Sigma-Aldrich. The cationic branched polymer Polyethyleneimine (PEI; 408727) and 
D-(+)-glucose (G7528), used as a transfection reagents, were supplied by Sigma-Aldrich. 
Poly-L-lysine (Mw 70,000-150,000; P4707) was also purchased from Sigma-Aldrich. 
Dulbecco's phosphate buffered saline (DPBS) was obtained from PAA Laboratories.  
2.7.2 Culture conditions 
HEK293T cells were grown as monolayers on 75 cm2 tissue culture flasks (VWR, UK) and 
maintained by regular passage in 15 ml “feeding” medium [phenol red-free DMEM 
supplemented with 10% (v/v) heat-inactivated fetal calf serum, 100 U ml-1 penicillin, 0.1 
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mg ml-1 streptomycin, 0.584 g/L L-glutamine and 1 mM sodium pyruvate], under 5% CO2 
at 37oC with a water vapour saturated atmosphere (Galaxy 170S; New Brunswick Scientific, 
Edison, NJ). All manipulations were performed in a sterile environment, with disposable 
plasticware and glassware reserved specifically for the purpose. 
2.7.3 Transfection reagents 
Cells were transfected with polyethyleneimine (PEI) – DNA complexes (Boussif et al., 
1995, Ehrhardt et al., 2006). PEI was prepared by dissolving 45 mg PEI in 8 ml sterile 
water, corrected to pH 7.2 with dilute HCl, passed through a sterile filter (0.2 µm) and kept 
at RT. Glucose, 5% (w/v), was prepared by dissolving 2.5 g of glucose in sterile water, 
passed through a sterile filter (0.2 µm) and kept at RT. 
 
2.8 Yeast (NMY51) transformation 
Yeast transformation was carried out using the LiAc (Lithium acetate dihydrate)/SS (single-
stranded) carrier DNA/PEG (Poly[ethylene glycol]) method (Gietz and Schiestl, 2007b). 
To ensure efficient transformation, yeast cells used to inoculate YPAD or SD media were 
always picked from colonies not older than 2 weeks. 
2.8.1 Small-scale transformation 
NMY51 yeast cells taken from a fresh YPAD plate were cultured at 30oC overnight (12 – 
16 h) on a rotary shaker (Innova 4000 Benchtop Incubator Shaker; New Brunswick 
Scientific, Edison, NJ) at 200 rpm in 50 ml YPAD to an OD546 (optical density) of 0.6 – 0.8 
(DU® Spectrophotometer; Beckman Coulter, UK). Cultures exceeding OD546 of 0.8 were 
diluted to an OD546 of 0.2 and regrown to an OD546 of 0.6. Prior to harvesting the cells, the 
transformation mix [240 µl 50% (w/v) PEG, 36 µl LiAc 1.0 M, 25 µl SS DNA 2 mg ml-1, 
1.5 µg plasmid DNA; per reaction] was prepared in sterile 1.5 ml eppendorf test tubes 
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(Eppendorf, UK), vortexed briefly (Vortex Genie 2; Scientific Industries Inc., Bohemia, 
NY) and kept on an ice/water bath. The 50 ml culture was harvested by centrifugation for 
5 min at 2500 g (Rotanta; Hettich, DE) and resuspended in 2.5 ml sterile water. 
Resuspended yeast cells (100 µl for each transformation) were added to sterile 1.5 ml 
eppendorf test tubes containing the transformation mix, vortexed for 1 min to thoroughly 
mix all components and incubated in a water bath at 42oC for 45 min. Following the 
incubation, the cell suspensions were pelleted for 5 min at 700 g. After the supernatant was 
removed, the cells were resuspended in 100 µl 0.9% (w/v) NaCl and spread onto 90 mm 
Petri SD plates, lacking the appropriate amino acid(s) (see Section 2.5), using a sterile 
disposable L-shaped spreader (Fisher Scientific Ltd, UK). The plates were then sealed with 
Parafilm “M” and incubated for 3 – 5 days at 30oC until visible colonies were produced. 
2.8.2 Large-scale transformation 
NMY51 yeast cells previously transformed with the ABCB1:Cub (pBT3-N:ABCB1) bait 
vector (as described in Section 2.8.1) were taken from a fresh SD-Leu plate and cultured in 
10 ml SD-Leu medium for 8 h at 30oC on a rotary shaker (Innova 4000 Benchtop 
Incubator Shaker; New Brunswick Scientific, Edison, NJ) at 200 rpm. The entire 10 ml 
culture was then subcultured in 100 ml SD-Leu and grown overnight (12 – 16 h) at 30oC 
with shaking at 200 rpm. On the following day, the OD546 of the overnight culture was 
determined by taking a 1 ml aliquot of the culture, centrifuging it at 2500 g for 5 min, 
resuspending the pellet in 1 ml sterile water and measuring the OD546 (DU
® 
Spectrophotometer; Beckman Coulter, UK) against a water blank. The appropriate volume 
of culture required to return 22.5 OD units was calculated (as instructed by the 
manufacturer; Dualsystems Biotech, Zurich, CH), aliquoted into 50 ml Falcon tubes (SLS, 
UK) and spun down for 5 min at 700 g (Rotanta; Hettich, DE). The pellet was then 
resuspended in 150 ml 2×YPAD (pre-warmed to 30oC) in a sterile 1 L baffled Erlenmeyer 
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flask. [At this stage to ensure that the correct dilution of the culture was achieved, a 1 ml 
aliquot was removed from the flask and spun down at 2500 g for 5 min. The pellet was 
resuspended in 1 ml sterile water and the OD546 was measured against a water blank to 
ensure that it was around 0.15]. Subsequently, the culture was grown at 30oC with shaking 
at 200 rpm to an OD546 of 0.6 – 0.7 (two cell divisions, 3 – 5 h). In the meantime, the 
transformation mixes [LiAc/TE mastermix (528 µl LiAc 1.0 M, 528 µl 10×TE pH 7.5, 
3.744 ml sterile water); PEG/LiAc mastermix (750 µl LiAc 1.0 M, 750 µl 10×TE pH 7.5, 6 
ml 50% (w/v) PEG) per 150 ml cell culture] and SS DNA [1 ml aliquot of SS DNA (see 
Section 2.4 on how to prepare) was thawed on ice, boiled at 99oC for 5 min and 
immediately chilled in an ice/water bath where it was kept until required] were prepared. 
Once the exponentially growing 150 ml cell culture had reached the required OD546, it was 
split in 3×50 ml Falcon tubes and centrifuged for 5 min at 700 g after which the 
supernatant was discarded. Each cell pellet was then resuspended in 30 ml of sterile water 
by vortexing (Vortex Genie 2; Scientific Industries Inc., Bohemia, NY), centrifuged at 700 
g for 5 min and, after the supernatant had been removed, resuspended in 1 ml LiAc/TE 
master mix before transferring into a sterile 1.5 ml eppendorf test tube (Eppendorf, UK). 
The cells were then spun at 700 g for 5 min and, after the supernatant was removed, 
resuspended in 600 µl of LiAc/TE mastermix. Subsequently, each of the 600 µl cell 
suspensions was added to a separate 50 ml Falcon tube containing 7 µg prey vector, 100 µl 
SS DNA and 2.5 ml PEG/LiAc mastermix, vortexed for 1 min to thoroughly mix all the 
components and incubated for 45 min at 30oC with brief mixing every 15 min. At the end 
of the incubation, 160 µl of DMSO (dimethyl sulfoxide) were added to each Falcon tube 
and mixed immediately by shaking followed by a 20 min incubation at 42oC. The cells were 
then pelleted at 700 g for 5 min, resuspended in 3 ml 2×YPAD (pre-warmed to 30oC), 
pooled and allowed to recover for 90 min at 30oC with slow shaking at 150 rpm. 
Subsequently, the cells were pelleted for 5 min at 700g, resuspended in 3.6 ml 0.9% (w/v) 
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NaCl and spread onto the prepared 3-AT selection plates (see Section 2.5.2). A 300 µl 
aliquot of cell suspension was spread on each 150 mm plate (12 plates × 300 µl = 3.6 ml) 
using a sterile disposable L-shaped spreader. The remaining resuspended cells were used to 
prepare 1:100, 1:1000 and 1:10,000 dilutions in a final volume of 1 ml of 0.9% (w/v) NaCl 
and spread (100 µl form each dilution) on separate 90 mm Petri SD-Trp-Leu plates (see 
Section 2.5), using a sterile disposable L-shaped spreader; these plates were used to 
calculate the transformation efficiency. All plates were sealed with Parafilm “M” and 
incubated at 30oC for 4 days. The transformation efficiency was calculated using the 
following formulae: 
 
                                                                 
                          
 
                          (
      
  
   )   
                             
     
 
 
The total number of transformants should be greater than 8×105 as indicated by the 
manufacturer (Dualsystems Biotech, Zurich, CH). 
 
2.9 Bacterial (XL10-Gold® Ultracompetent Cells) transformation 
Plasmid DNA was transformed into XL10-Gold® Ultracompetent cells (Agilent 
Technologies, UK; 200315). 
 
XL10-Gold® Ultracompetent cells were gently thawed on ice. For each sample reaction to 
be transformed, 22.5 µl of bacteria were aliquoted to a prechilled 1.5 ml eppendorf test 
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tube (Eppendorf, UK) followed by chemical treatment with 1 μl  XL10-Gold® β-
mercaptoethanol mix. After gentle mixing, the cells were kept on ice for 10 min and swirled 
every 2 min. Subsequently, 2 µl of plasmid DNA from each sample to be transformed were 
added to separate aliquots of the ultracompetent cells, mixed gently and incubated on ice 
for 30 min. Following heat-shock at 42oC for 30 sec, the reactions were incubated on ice 
for 2 min before 250 µl of preheated (42oC) S.O.C. rich medium (Invitrogen, UK) was 
added to each tube. The cells were then allowed to recover for 1 h at 37oC with shaking at 
225 rpm (Innova 4000 Benchtop Incubator Shaker; New Brunswick Scientific, Edison, NJ) 
before the appropriate volume from each transformation was plated on LB-ampicillin agar 
plates (supplemented with X-gal and IPTG where appropriate for “blue/white” screening). 
Transformation plates were incubated at 37oC for >18 h. 
 
2.10 Mammalian cell (HEK293T) transfection 
2.10.1 For immunoblot analysis 
HEK293T cells (3 × 105) were seeded as a monolayer on 6 round-well plates 
(ThermoFisher Scientific, Waltham, MA; TKT-190-050T) in 2 ml “feeding” medium (see 
Section 2.7.2) 24 h prior to transfection. The transfection mixture [7.5 μg total plasmid 
DNA in 1 µl of 5% (w/v) glucose mixed with 1.5 μl PEI and adjusted to a final volume of 
10 µl with sterile water] was prepared in individual 1.5 ml eppendorf test tubes (Eppendorf, 
UK) on the day of transfection and incubated for 10 min at RT. For the single 
transfections (i.e. with plasmid DNA encoding WT or mutant ABCB4 and empty pCi-Neo 
vector), the transfection mixture contained 2.5 µg of ABCB4-encoding plasmid and 5 µg of 
empty pCi-Neo vector. For the triple transfections (i.e. with three different plasmids 
encoding either WT or mutant ABCB4 or ATP8B1 or CDC50A), the transfection mixture 
contained 2.5 µg of each plasmid. At the end of the 10 min incubation, 1 ml fresh 
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“feeding” medium, pre-warmed to 37oC, was added to each tube and applied to the cells. 
Prior to the application of the transfection mixture (during the 10 min incubation period), 
all the medium was aspirated from each well and replaced with 1 ml fresh “feeding” 
medium pre-warmed to 37oC. The cells were harvested 48 h post transfection (see Section 
2.18.2). 
2.10.2 For cellular efflux of 3H-PC 
Six round-well plates were treated with 1 ml Poly-L-lysine for 1 h at RT and washed 3× in 
1 ml DPBS. Poly-L-lysine improves cell adherence to the surface of the wells and prevents 
cells from being washed off during the subsequent stages of the experiment. 
 
HEK293T cells (3 × 105) were seeded the pre-treated plates 24 h prior to transfection. For 
this assay, only triple transfections were set up as described in Section 2.10.1. During the 10 
min incubation of the transfection mixture, all the medium was aspirated from each well 
and replaced with 600 µl fresh “feeding” medium (see Section 2.10.1) pre-warmed to 37oC. 
The assay was performed as described in Section 2.22. 
2.10.3 For immunocytochemistry 
HEK293T cells (1.2 × 105) were seeded as a monolayer on 12 round-well plates 
(ThermoFisher Scientific, Waltham, MA) in 1 ml “feeding” medium (see Section 2.7.2) 24 
h prior to transfection. Before seeding, sterile coverslips were placed into each well and 
treated with 100 µl Poly-L-Lysine for 1 h at RT followed by 3 washes in 1 ml DPBS. On 
the day of transfection, the same volume of transfection mixture described in Section 
2.10.1 was prepared per transfection, to avoid aliquoting small volumes and run the risk of 
introducing pipetting errors, but only 400 µl was applied to the cells (i.e. 2.5× less than for 
the 6-well plate). The cells were fixed 48 h post transfection (see Section 2.23). 
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2.11 Isolation of plasmid DNA from yeast and E. coli. 
Small-scale (µg-quantities) preparations of plasmid DNA were isolated from both yeast and 
E. coli using the GenEluteTM Plasmid Miniprep Kit (Sigma-Aldrich, UK; PLN350) as 
described by the manufacturer. Slight modifications to the protocol are included within the 
procedures outlined below. Large-scale (mg-quantities) preparations of plasmid DNA were 
isolated from E. coli using the GenEluteTM HP Plasmid Maxiprep Kit (Sigma-Aldrich, UK; 
NA0310) using the vacuum format as described by the manufacturer and outlined below. 
2.11.1 Isolation of plasmid DNA from yeast (NMY51) 
Plasmid DNA was isolated from yeast by mechanical disruption of the yeast cells using 
glass beads. SD-Trp-Leu medium (3 ml) was inoculated with yeast, incubated overnight at 
30oC with shaking at 200 rpm and then harvested by gentle centrifugation for 5 min at 
4000 g. The cells were then resuspended in 200 µl Resuspension Solution (supplemented 
with 10 µg ml-1 RNase A) and transferred into a tube containing ~100 µl of acid-washed 
glass beads (Sigma-Aldrich, UK; G8772). Following vortexing for 5 min (Vortex Genie 2; 
Scientific Industries Inc., Bohemia, NY), the lysate was transferred into a fresh test tube 
and plasmid DNA was purified using the GenEluteTM Plasmid Miniprep Kit (Sigma-
Aldrich, UK; PLN350) as described above (see Section 2.11.2.1) with the following 
modifications; the cleared lysate was applied to the pre-prepared spin columns and 
centrifuged for 1 min at 6000 g followed by 2× wash with nuclease removal buffer (500 µl; 
Optional Wash Solution) and once with Wash Solution (500 µl). The purified plasmid was 
eluded in 50 µl of 10 mM Tris buffer, pH 8.8, stored at -20oC and used for DNA 
sequencing or transformation of E. coli.    
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2.11.2 Isolation of plasmid DNA from E. coli. (XL10-Gold®) 
2.11.2.1 Small-scale preparations 
Bacterial cells (2 ml) from a 5 ml overnight culture (LB broth supplemented with the 
appropriate antibiotic; see Section 2.6) were harvested by centrifugation for 5 min at 12,000 
g. The cell pellet was then resuspended in 200 µl Resuspension Solution. Lysis Solution 
was then added and the solution was mixed by inversion. The alkalinity of the Lysis Buffer 
causes the denaturation of nucleic acids and protein within the lysate. After 5 min 
incubation at room temperature, Neutralization Solution (350 µl) was added, causing the 
aggregation of insoluble genomic DNA and high molecular weight RNA, and the 
precipitation of protein-SDS (sodium dodecyl sulphate) complexes. The lysate was then 
centrifuged for 10 min at 12,000 g. GenElute HP Miniprep Binding Columns were 
prepared by adding 500 µl Column Preparation Solution and centrifuging for 1min at 
12,000 g. The supernatant from the cell lysate was then added to the columns and 
incubated for 1 min at room temperature. Following incubation, the supernatant was 
passed through the columns by centrifugation at 12,000 g for 1 min. The columns were 
washed by adding Wash Solution (500 µl) and centrifuging for 1 min at 12,000 g. The 
eluted Wash Solution was discarded and the columns were centrifuged as before in order to 
remove any traces of Wash Solution. Plasmid DNA was eluted by adding 50 µl of 10 mM 
Tris buffer, pH 8.8 to the column and incubating for 5 min at room temperature, followed 
by centrifugation for 1 min at 12,000 g. The concentration and purity of the plasmid DNA 
was determined by spectrophotometric analysis as described in Section 2.14 and stored at -
20oC. 
2.11.2.2 Large-scale preparations 
A single bacterial colony from a freshly streaked plate was used to inoculate a starter 
culture of 5 ml LB, containing the appropriate antibiotic (see Section 2.6), in a sterile 50 ml 
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Erlenmeyer flask and incubated for 8 h at 37oC with shaking at 225 rpm (Innova 4000 
Benchtop Incubator Shaker; New Brunswick Scientific, Edison, NJ). The starter culture 
was then diluted 1:500 in a suitable volume of LB broth (200 ml), containing the 
appropriate antibiotic, in a sterile 2 L baffled Erlenmeyer flask and incubated at 37oC with 
shaking at 225 rpm for 12 – 16 h. Bacterial cells (200 ml) were harvested by centrifugation 
at 5,000 g for 10 min at 4oC. The cell pellet was resuspended in 12 ml Resuspension/RNase 
A Solution by a combination of pipetting and vortexing (Vortex Genie 2; Scientific 
Industries Inc., Bohemia, NY). Lysis Solution (12 ml) was then added before mixing by 
inversion and incubating for 5min at room temperature. Following the addition (12 ml) of 
ice-cold Neutralization Solution and mixing by inversion, the Binding Solution (9 ml) was 
added, the contents were mixed by inversion, poured into the barrel of the provided filter 
syringe and allowed to settle for 5 min. In the meantime, the GenElute HP Maxiprep 
Binding Column was prepared by placing it onto the Sigma VM20 (Sigma-Aldrich, UK; 
VM20) vacuum manifold, adding 12 ml of Column Preparation Solution and applying 
vacuum until all the liquid had passed through. Subsequently, the cleared lysate from the 
syringe barrel was expelled into the prepared column and allowed to pass through, 
followed by two successive washes; the first with 12 ml of Wash Solution 1 and the second 
with 12 ml Wash Solution 2. Following the wash steps, the GenElute HP Maxiprep 
Binding Column was placed into the 50 ml collection tube provided and spun in a swinging 
bucket rotor (Rotanta; Hettich, DE) for 5 min at 3,000 g to dry the column by removing 
any residual wash solution. The binding column was then transferred into a clean 50 ml 
collection tube and after 3 ml of Elution Solution were added it was centrifuged at 3,000 g 
for 5 min to recover the plasmid DNA. Once the DNA was recovered, it was concentrated 
by NaAc/isopropanol precipitation. NaAc Buffer Solution 3.0 M pH 5.2 (0.1 volumes) and 
isopropanol (0.7 volumes) were added to the solution, mixed well by inversion and 
centrifuged at 15,000 g for 30 min at 4oC. The supernatant was decanted with care not to 
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disturb the pellet and the pellet was washed with 1.5 ml of 70% (v/v) ethanol followed by 
centrifugation at 15,000 g for 10 min at 4oC. The supernatant was then discarded, the pellet 
was air-dried until all residual ethanol had evaporated and then resuspended in 400 µl of 10 
mM Tris buffer, pH 8.8. The concentration and purity of the plasmid DNA was 
determined by spectrophotometric analysis as described in Section 2.14 and stored at -
20oC. 
2.12 Agarose gel electrophoresis of DNA 
Agarose gels [0.7 – 1.5% (w/v)], were prepared by melting the required amount of 
powdered agarose (DNA grade; Invitrogen, UK) in TAE buffer (40 mM Tris-acetate, 1 
mM EDTA), by heating in a microwave oven (Sharp, UK), until clear. The melted solution 
was then allowed to cool down to 55oC, before the ethidium bromide (0.5 µg ml-1) was 
added, poured into the appropriate mould (Owl Separation Systems; Thermo Fisher 
Scientific, UK) and allowed to harden. DNA fragments were separated by electrophoresis 
through a submerged gel. Prior to loading onto the gel, the samples were mixed with the 
appropriate volume of 6× gel-loading buffer (2.5 % Ficoll 400, 11 mM EDTA, 3.3 mM 
Tris-HCl, 0.017 % SDS, 0.15 % Orange G pH 8.0; NEB, UK), loaded into sample wells, 
and electrophoresed at 2 – 10 V cm-1 until the required sesolution was achieved. The DNA 
was visualised using a UV transilluminator and images were recorded using the 
MultiImageTM Light Cabinet (Alpha Innotech Corporation, San Leandro, CA). 
 
2.13 Isolation of DNA from agarose gels 
Linearised DNA was isolated from agarose gels using the PureLinkTM Quick Gel 
Extraction Kit (Invitrogen, UK; K2100-12) which allows rapid and efficient purification of 
DNA fragments from TAE (Tris-acetate-EDTA) agarose gels of various percentages. 
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After completion of agarose gel electrophoresis, the area of the gel containing the desired 
DNA fragment was excised using a scalpel with a clean, sharp blade taking care to 
minimise the amount of agarose surrounding the DNA fragment. The gel slice containing 
the DNA fragment was then weighed and put into a 1.5 ml eppendorf test tube 
(Eppendorf, UK); if the gel slice exceeded 400 mg, it was cut into smaller slices so that no 
one slice would exceed 400 mg and each slice was placed into a separate test tube. Three 
volumes of Gel Solubilization Buffer (L3) were then added per gel volume (e.g. 1.2 ml of 
L3 per 400 mg of agarose gel slice) followed by heating of the test tube containing the gel 
slice on a hot block (DRI Block® DB.2A; Techne LTD, UK) at 50oC for 10 min, inverting 
every 3 min to ensure gel dissolution. After the gel slice had dissolved, the incubation was 
continued for a further 5 min before 1 gel volume of isopropanol was added to the 
dissolved slice and mixed well. A Quick Gel Extraction Column (1 per 400 mg gel slice) 
was attached to the Sigma VM20 (Sigma-Aldrich, UK; VM20) vacuum manifold. The 
dissolved gel slice containing the DNA fragment of interest was then loaded onto the 
centre of the silica membrane of the Quick Gel Extraction Column and vacuum was 
applied until all the liquid had passed through. Wash Buffer (700 µl; W1) was then added to 
the centre of the Quick Gel Extraction Column and vacuum was applied until all the liquid 
had passed through the column, before the column was transferred into a Wash Tube and 
centrifuged at 14,000 g for 3 min to remove any residual W1. The Quick Gel Extraction 
Column was then placed into a Recovery Tube before 50 µl of Elution Buffer (E5; 10 mM 
Tris-HCl, pH 8.5) were added followed by 1 min incubation at RT. The purified DNA was 
recovered by centrifugation for 1 min at 12,000 g. The concentration and purity of the 
plasmid DNA was determined by spectrophotometric analysis as described in Section 2.14 
and stored at -20oC. 
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2.14 Determination of DNA yield and quality 
DNA concentration in nucleic acid preparations was determined by spectrophotometry by 
measuring absorbance at 260 nm using the NanoDrop ND-1000 V3.5 (ThermoFisher 
Scientific, Waltham, MA). The quality of DNA is indicated by the ratio between the 
absorbance at 260 and 280 nm. For pure DNA the A260/A280 ratio should be ~1.8. Smaller 
ratios usually indicate contamination by protein or organic chemicals. As a secondary 
measure of nucleic acid purity, the A260/A230 ratio was also measured which should be in 
the range of 1.8 – 2.2. 
 
2.15 Site-Directed Mutagenesis 
Oligonucleotide-directed mutations were introduced into pcDNA3.1-ABCB4wt (Table 2-1) 
using the “QuikChange II XL’ site-directed mutagenesis kit (Agilent Technologies, UK) 
which allows site-specific mutations in double-stranded plasmids isolated from a dam+ E. 
coli strain. Such DNA is methylated and is a suitable template for mutagenesis. 
2.15.1 Mutagenic Primer Design 
Mutagenic oligonucleotides were designed using the web-based QuickChange Primer 
Design Program available at http://www.stratagene.com/qcprimerdesign and supplied by 
Sigma-Aldrich. 
2.15.2 Mutant Strand Synthesis 
The template plasmid DNA is amplified by PCR using a pair of mutagenic primers. Each 
primer covers the site to mutate but is complementary to opposite strands of the template, 
to generate mutation-containing synthesised DNA. Following amplification, DpnI 
endonuclease digestion (1 µl of 10 U µl-1 DpnI per reaction; for 1 h at 37oC) of methylated 
and hemi-methylated DNA is carried out. Because the template plasmid DNA is generated 
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in a dam+ E. coli strain, whereas the newly-synthesised DNA is unmethylated, the template 
DNA is susceptible to DpnI digestion. This enables selection for the newly synthesised, 
mutation-containing DNA, which can then be used to transform XL10-Gold® 
Ultracompetent Cells as described in Section 2.9. 
 
Thermal cycling reactions were set up in thin-walled PCR tubes (Sigma-Aldrich, UK; 
Z662593), to maximise temperature-cycling performance. Each reaction was set up as listed 
in Table 2-3 and cycled using the parameters outlined in Table 2-4. 
 
 
QuickChange
®
 Reaction Volume (μl) 
Reaction Buffer (10×) 5 μl 
dsDNA Template 1 μl (10 ng) 
Primer #1 1 μl (125 ng) 
Primer #2 1 μl (125 ng) 
dNTP Mix 1 μl 
QuikSolution 3 μl  
ddH2O To 50 μl final volume 
PfuTurbo DNA Polymerase 1 μl (2.5 units) 
Table 2-3. Protocol for the QuickChange
®
 XL site-directed mutagenesis kit (Stratagene, UK). 
This protocol was used to introduce the required mutations to pcDNA3.1-ABCB4wt vector. 
Reaction buffer (1×): 200 mM Tris-HCl (pH 8.8), 20 mM MgSO4, 100 mM KCl, 100 mM (NH4)2SO4, 1% 
Triton
®
 X-100, 1 mg/ml nuclease-free bovine serum albumin (BSA); dNTP mix and QuikSolution 
composition: proprietary (Agilent Technologies, UK).  
 
Time (sec) Temperature (
o
C) No. Of Cycles  
60 95 1 Denaturation 
50 95 (denaturation) 
18 
Cycling 
(Amplification) 
50 60 (annealing) 
540 68 (extension) 
420 68 1 Extension 
Table 2-4. PCR programme used to mutagenise the pcDNA3.1-ABCB4wt vector. 
 
The sequence of the entire mutant cDNA was confirmed as described in Section 2.17.2. 
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2.16 Plasmid Constructions 
2.16.1 pGEM3®-3Zf(-):PKCα 
The PKCα cDNA from the EGFP-PKCα vector (50 ng) was amplified in a mutagenic 
PCR set-up as per Table 2-5 (RoboCycler Gradient 40, Agilent Technologies, UK). The 
mutagenic primers PciI-F:PKCα and an AgeI-R:PKCα were used at a temperature gradient 
(48oC – 62oC), in the thermal cycling summarised in Table 2-6. Through this, a PciI and an 
AgeI restriction site were introduced at the 5’- and 3’-ends, respectively, of the amplified 
product generating PKCα(AgeI/PciI). 
 
Vent PCR Reaction Volume (μl) Final Concentration 
ThermoPol Reaction Buffer (10×) 2.5 μl 1× 
dNTP mix (2 mM) 2.5 μl 200 μM 
PciI-F PKCα  (10 μ M) 1.5 μl 0.15 μM 
AgeI-R PKCα  (10 μ M) 1.5 μl 0.15 μM 
DNA template 50 ng  
VentR® DNA Polymerase 1.0 μl  2 units 
ddH2O To 25 μl final volume  
Table 2-5. Protocol for Vent PCR Reaction used to amplify the PKCα cDNA from the pEGFP-PKCα. 
This protocol was used to introduce the PciI and AgeI restriction sites at 5’- and 3’- ends , 
respectively, of the PKCα cDNA. ThermoPol Reaction Buffer (1×): 20 mM Tris-HCl, 10 mM 
(NH4)2SO4, 10 mM KCl, 2 mM MgSO4, 0.1 % Triton X-100 pH 8.8 @ 25°C. dNTP mix: dATP, dCTP, 
dGTP and dTTP, each at 2 mM. 
 
Time (min) Temperature (
o
C) No. Of Cycles  
2 95 1 Denaturation 
1 95 
30 
Cycling 
(Amplification) 
1 48-62 
1 72 
5 72 1 Extension 
Table 2-6. Programme used in mutagenic PCR to amplify PKCα and define the optimal annealing 
temperature for the reaction. 
 
The blunt-ended, PCR product [PKCα(AgeI/PciI)] was cloned into the polylinker SmaI site 
of the pGEM3®-3Zf(-) vector (Promega, UK; P2261) to generate pGEM3®-3Zf(-):PKCα. 
Prior to the ligation, the digested vector and PCR product were run on a 1% (w/v) agarose 
gel (see Section 2.12) and purified by gel extraction using the PureLink™ Quick Gel 
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Extraction Kit (see Section 2.13). The ligation was carried out using Quick T4 DNA Ligase 
(NEB, UK; M2200L) for 10 min at 25oC.  Vector and insert fragments were used at an 
approximate 1:1 molar ratio. The ligation product was transformed into XL10-Gold® 
Ultracompetent cells (as described in Section 2.9) for “blue/white” screening. White 
colonies, i.e. carrying the pGEM3®-3Zf(-) vector with the PKCα(AgeI/PciI) insert, were 
picked and incubated overnight in 5 ml LB-amp liquid medium at 37oC with shaking (250 
rpm). Plasmid DNA was isolated from the overnight cultures as described in Section 
2.11.2.1. 
 
The presence of the PKCα cDNA (AgeI/PciI) was verified by restriction digest analysis 
using the enzymes HindIII and XmnI (NEB, UK). DNA (400 ng) was digested from each 
individual clone. The digested products were resolved on 1% agarose gel (see Section 2.12). 
 
The integrity of the construct was verified by DNA sequencing using the pUC/M13 
forward and reverse primers as well as several other primers covering the whole length of 
the PKCα cDNA, namely, PKCaR1, PKCaF1, PKCaF2, PKCaF3, PKCaF4 and pEGFP-
C1F1. 
2.16.2 pPR3-STE:PKCα 
pPR3-STE(AgeI/NcoI) and PKCα(AgeI/PciI) were generated by digestion of the pPR3-
STE:Caveolin (Wharton J., personal communication) and the pGEM3®-3Zf(-
):PKCα(AgeI/PciI) (see above 2.16.1) with the appropriate enzymes (NEB, UK). The 
digested products were run on a 1% agarose gel (see Section 2.12) and the fragments 
corresponding to the expected size of the DNA fragment of interest were purified by gel 
extraction (see Section 2.13). Ligation of pPR3-STE(AgeI/NcoI) and PKCα(AgeI/PciI) was 
carried out using Quick T4 DNA Ligase (NEB, UK; M2200L) for 10 min at 25oC. As a 
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control for the self-ligation of the vector, an additional ligation reaction was carried out 
using vector only DNA. The products of the ligation reactions were transformed into 
XL10-Gold® Ultracompetent as described in Section 2.9. Bacterial colonies, transformed 
with the pPR3-STE:PKCα ligation product, were picked and incubated overnight in 5 ml 
LB-amp liquid medium at 37oC with shaking (250 rpm). Plasmid DNA was isolated from 
the overnight cultures as described in Section 2.11.2.1.  
 
The presence of the PKCα insert was verified by digesting the purified plasmid with DraIII 
(NEB, UK). A large-scale preparation of the pPR3-STE:PKCα construct was carried out as 
described in Section 2.11.2.2. 
2.16.3 pcDNA3.1-ABCB4 WT and Mutant plasmids 
pcDNA3.1-ABCB4wt plasmid encoding human ABCB4 as well as the inactive 
ABCB4_E558Q (c.1672G>C) derivative (replacing a conserved glutamate in the Walker B 
motif with a glutamine to prevent ATP hydrolysis) were kindly provided by Dr Marta 
Rodriguez-Romero and have been described elsewhere (Groen et al., 2011). 
ABCB4_A546D (c.1637C>A) and ABCB4_S320F (c.959C>T) were derived by site-
directed mutagenesis from pcDNA3.1-ABCB4wt. They were provided by Dr Marta 
Rodriguez-Romero (personal communication) and confirmed by DNA sequencing (see 
Section 2.17.2). 
2.16.3.1 Site-directed Mutagenesis 
All other ABCB4 mutants were derived from pcDNA3.1-ABCB4wt using the 
QuickChange® XL site-directed mutagenesis kit (see Section 2.15) The primers used to 
derive each mutant were the following: ABCB4_G535D (c.1604G>A), ABCB4_M301T 
(c.902T>C), ABCB4_E528D (c.1584G>C), ABCB4_L591Q (c.1772T>A), 
ABCB4_P1161S (c.3481C>T), ABCB4_R545C (c.1633C>T), ABCB4_A286V (c.857C>T) 
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and their reverse complements (Table 2-2). Colonies from the mutagenesis reaction were 
picked and incubated overnight in 5 ml LB-amp liquid medium at 37oC with shaking (250 
rpm). Plasmid DNA was isolated from the overnight cultures as described in Section 
2.11.2.1. 
2.16.3.2 Restriction Digests 
Putative mutants were screened based on their restriction digest profiles as predicted by in 
silico analysis of the mutated constructs. Specifically 1 µg of template from each candidate 
was digested for 1 h at the appropriate conditions according to the requirements of the 
restriction endonuclease as stated by the manufacturer (NEB, UK). ABCB4_G535D were 
digested with BstXI, ABCB4_M301T with NcoI, ABCB4_E528D with BsmAI, 
ABCB4_L591Q with AccI, ABCB4_P1161S with TthIIII and ABCB4_R545C with both 
PmlI and NheI-HF. The digested products were run on a 1% agarose gel (see Section 2.12) 
and candidates for each mutation with the expected restriction digest profile were 
confirmed either by automated DNA sequencing (see Section 2.17.1; Source BioScience, 
UK) or in-house sequencing (see Section 2.17.2). The primers used were designed to cover 
the whole ABCB4 cDNA, namely, ABCB4_389F, ABCB4_918F, ABCB4_1440F, 
ABCB4_ 1983F, ABCB4_2473F, ABCB4_2981F, ABCB4_3393F, ABCB4_491R (Table 
2-2). 
2.16.4 ATP8B1 and CDC50 Plasmids 
pCI-neo-ATP8B1 and pCI-neo-CDC50 plasmids encoding human ATP8B1 and CDC50A 
respectively were kindly provided by Dr Marta Rodriguez-Romero (Groen et al., 2011). 
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2.17 DNA Sequencing 
2.17.1 Automated DNA sequencing 
Automated DNA sequencing was out sourced and performed by either: 1. The MRC 
Clinical Sciences Centre Genomics Core Laboratory or 2. LifeSciences (Source BioScience, 
UK). 
2.17.2 In-house sequencing 
In-house sequencing was carried out using the BigDye® Terminator v3.1 Cycle Sequencing 
Kit (Invitrogen, UK). 
2.17.2.1 Cycle sequencing on plasmid DNA 
The BigDye Terminator v3.1 Cycle Sequencing Kit provides the required reagent 
components for the sequencing reaction in a pre-mixed format. These reagents are suitable 
for performing fluorescence-based cycle sequencing reactions on single-stranded or 
double-stranded DNA templates and on PCR fragments. 
 
Each reaction mixture was prepared as shown below in Table 2-7. 
 
Reagent Volume (μl) 
Oligonucleotide (3.2 pmol/μl) 1.0 μl 
BigDye® Terminator Buffer (5×)  2.0 μl 
DNA template 1.0 μg 
Ready Reaction Premix 0.5 μl 
ddH2O To 10 μl final volume 
Table 2-7. Reaction mixture preparation for DNA sequencing. 
BigDye
®
 Terminator Buffer and Ready Reaction Premix composition: proprietary (Invitrogen, UK) 
 
Cycle sequencing was performed in the Touchgene Gradient Thermal Cycler (Techne 
LTD, UK) using the protocol summarised in Table 2-8. 
 
 Materials and Methods 
 
99 
 
Time (sec) Temperature (
o
C) No. Of Cycles 
60 96 1 
10 96 
25 5 50 
240 60 
∞ 10 ∞ 
Table 2-8. Termocycling for plasmid DNA sequencing. 
 
2.17.2.2 Ethanol/EDTA precipitation of DNA 
To ensure optimum results, unincorporated dye terminators (which can obscure data) 
should be completely removed prior to electrophoresis. In order to minimise 
unincorporated dyes the ethanol/EDTA (ethylenediaminetetraacetic acid) purification 
method was used. 
 
Initially, the tubes containing the amplified products (in 10 µl volumes) were spun briefly 
before adding 2.5 µl of 125 mM EDTA (25 mM final; Sigma-Aldrich, UK) to each sample 
followed by 30 µl of 100% ethanol (Sigma-Aldrich, UK). The tubes were sealed, mixed by 
inverting 4 times, incubated at RT for 15 min and spun for 20 min at 17000 g at 4oC in a 
fixed-rotor centrifuge (Heraeus Fresco 17; ThermoFisher Scientific, Waltham, MA). 
Following centrifugation, the supernatant was discarded and 30 µl of 70% ethanol were 
added to each sample. The tubes were then spun for 10 min at 17000 g at 4oC and the 
supernatant was discarded. Finally, the samples were allowed to air-dry for 30 min in the 
dark, resuspended in 10 µl Hi-DiTM Formamide (Applied Biosystems, UK) and loaded onto 
a MicroAmp® Optical 96-Well Reaction Plate (Invitrogen, UK).  
2.17.2.3 Sample electrophoresis 
Prior to electrophoresis, the 96-well reaction plate was sealed and the samples were heated 
for 5 min at 96oC on a hot block (DRI Block® DB1.M; Techne LTD, UK) to denature the 
DNA and cooled down rapidly for 1 min on ice.  
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Automated sample electrophoresis and sequencing analysis were performed using the 
instrument protocol “sequencing_600bp_POP7” and analysis protocol “3130 
POP7_BDTU3-KB_DENOVO_V.5.2” on ABI Prism® 3130xl Genetic Analyser (Applied 
Biosystems, UK). 
2.17.2.4 Sequencing data analysis 
Analysis of the electropherograms was performed using the Sequence Scanner V1.0 
(Applied Biosystems, UK). 
 
2.18 Isolation of whole-cell protein content 
2.18.1 Yeast whole-cell extracts 
SD medium (10 ml) was inoculated with several colonies of NMY51 transformed with the 
appropriate vector(s) (see Section 2.8.1) and incubated overnight at 30oC with shaking at 
200 rpm to an OD546 of 0.6-1. The cells (~2.4×10
7 – 4.0×107) were harvested by 
centrifugation at 700 g for 5 min. The pellet was then washed once in 1 mM EDTA in 
water and the cells were lysed in 200 µl 2.0 M NaOH for 10 min on ice. The samples were 
precipitated using TCA (trichloroacetic acid) as described in Section 2.19 and stored at -
80oC. 
2.18.2 HEK293T whole-cell extracts 
Total-cell extracts from mammalian cells for immunoblot analysis (see Section 2.21) were 
prepared 48 h post transfection (see Section 2.10.1). Prior to lysis, cells were washed three 
times in ice-cold phosphate-buffered saline (PBS, Sigma-Aldrich, UK) and lysed on the cell 
culture dish in 300 µl lysis buffer [1% sodium dodecyl sulfate in PBS supplemented with 
150 mM NaCl, 10 mM HEPES, 25 U/µl Benzonase® Endonuclease (Merck Millipore, 
Darmstadt, DE), Protease Inhibitor Coctail (Roche, UK) and 1.0 mM PMSF 
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(phenylmethylsulfonyl fluoride) in ethanol]. The endonuclease was allowed to act for 15 
min at RT before the samples were collected in 1.5 ml eppendorf test tubes (Eppendorf, 
UK) and centrifuged at 17,000 g for 15 min at 4oC to remove any insoluble material. The 
supernatant was collected in fresh tubes and stored at -80oC. 
 
2.19 TCA (trichloroacetic acid) precipitation of protein extracts 
Cell lysates were concentrated using trichloroacetic acid (TCA) precipitation. Sodium 
deoxycholate (0.1 volumes of a 0.15% solution) was added to the protein sample and 
incubated at room temperature for 5 minutes. Following this, 0.1 volumes of 72% 
trichloroacetic acid was added, the sample was mixed and incubated for a 10 minutes at 
RT. The protein was recovered by centrifugation at 20,000 g for 8 min. After the 
supernatant was carefully removed and discarded, the pellet was resuspended in 50 μl 
resuspension buffer (4% SDS, 0.2 M Tris pH 7.4, 0.15 M NaOH). Samples were stored at -
80oC. 
 
2.20 Protein quantitation 
Protein concentration of whole-cell extracts was determined using the Bio-Rad DC Protein 
Assay (Bio-Rad, UK; 500-0116). The assay is based on the Lowry method (Lowry et al., 
1951) and was carried out following the manufacturer’s instructions. The reactions were set 
up in duplicates on 96-well microplates (ThermoFisher Scientific, Waltham, MA). A range 
of BSA concentrations (0, 0.25, 0.5, 1.0, 2.0, 4, 6, 8 and 10 mg ml-1) was used to produce a 
standard curve. 
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2.21 Analysis of protein expression 
2.21.1 General reagents and buffers 
SDS gel-loading buffer (5×): 0.31 M Tris-HCl (pH 6.8), 0.25 M DTT (dithiothreitol), 
0.1% (v/v) bromophenol blue, 50% (v/v) glycerol, 10% (w/v) SDS. Running buffer 
(10×): 0.25 M Tris, 2.5 M glycine (pH 8.3), 1.0% (v/v) SDS. Transfer Buffer (5×): 0.195 
M glycine, 0.24 M Tris base, 0.185% (w/w) SDS. All reagents were supplied by Sigma-
Aldrich, UK. The Running buffer was diluted to 1× with deionised water and used up to 
three times before discarding. The Transfer buffer was diluted to 1× with deionised water 
supplemented with 20% (v/v) methanol and used once. 
2.21.2 Antibodies 
Anti-ABCB1/B4:  C219 (mouse monoclonal; SIG-38710-1000) was obtained from 
Cambridge Bioscience. Anti-Caveolin: pY14 (mouse monoclonal; 611338) was obtained 
from BD Biosciences. Anti-LexA: Lex (2-12) (mouse monoclonal; sc-7544) was obtained 
from Santa Cruz. Anti-tubulin: anti-β-tubulin (mouse monoclonal; E1C601) was obtained 
from EnoGene Biotech. Secondary Anti-Mouse: HRP-conjugated (goat anti-mouse 
polyclonal; P0447) was obtained from Dako. 
2.21.3 SDS-PAGE (sodium dodecyl sulfate polyacrylamide gel electrophoresis) 
Gels were prepared using the discontinuous buffer system devised by Davis (1964), 
Ornstein (1964), and Laemmli (1970) in which the buffer in the sample and the stacking gel 
contain Tris-Cl (pH 6.8) and the resolving gel contains Tris-Cl (pH 8.8). Such buffer 
system has the ability to concentrate the complexes in the samples into a very small volume 
and therefore increase the resolution of the gel. 
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All SDS-PAGE was performed using the Mini-PROTEAN® electrophoresis system from 
Bio-Rad and tris-glycine running buffer (see Section 2.21.1). Proteins were diluted in 5× 
SDS sample buffer (see Section 2.21.1) and denatured briefly (5 min at 70oC) prior to 
loading on a freshly-made 7.5% SDS-polyacrylamide resolving gel (with 5% stacking gel). 
For each sample, 2 µg of total protein extract (protein quantitation was determined as 
described in Section 2.20) was loaded per lane. For yeast whole cell extracts (Section 2.18.1) 
the whole volume (50 µl) of the TCA-precipitated samples (Section 2.19) was loaded per 
lane. A lane containing 10 µl of standard molecular weight marker (Precision Plus Protein 
All Blue Standards; Bio-Rad, UK) was loaded onto each gel to enable the subsequent 
determination of protein molecular weights. Proteins were initially separated using a 
constant voltage (90 V) until the molecular weight marker separation was evident. The 
voltage was then increased to 120 V, and the separation was continued until the dye-front 
had reached the base of the gel. 
2.21.4 Immunoblot analysis 
Western blotting was originally devised by Towbin (1979) and Burnette (1981) and involves 
the transfer of electrophoretically separated proteins from an SDS gel to a solid support 
(polyvinylidene fluoride (PVDF) membrane) and probed with antibodies specific for 
particular amino acid sequences. The bound (primary) antibody is detected by a secondary 
(horseradish peroxidase (HRP)-conjugated) antibody via chemiluminescence. 
 
Following their separation by SDS-PAGE, proteins were transferred onto a PVDF 
membrane (Immobilon-P; Millipore, Billerica, MA), activated with 100% methanol (1 min) 
and washed in deionised water (1 min), for western blotting analysis. The transfer was 
carried out overnight at 20 mV using the Mini-PROTEAN® transfer system and 
accompanying ice-pack from Bio-Rad with constant stirring.  After electroblotting, the 
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PVDF membrane was washed in PBS-T [PBS + 0.1% (v/v) Tween-20 (Sigma-Aldrich, 
UK)] and blocked in 5% (w/v) milk (Marvel, UK) in PBS-T for 1 h at RT on a rocking 
platform. Subsequently, the membrane was probed overnight with the appropriate primary 
antibody at 1:1000 dilution in 5% (w/v) milk in PBS-T inside a heat-sealed bag at 4oC with 
gentle agitation. For β-tubulin, the primary antibody was used at 1:100,000 dilution. The 
membrane was then given three 10 min washes with PBS-T before incubation (1 h at RT 
with gentle agitation in a heat-sealed bag) with secondary HRP-conjugated goat-anti mouse 
antibody (Dako, UK) at 1:1000 dilution in PBS-T. Following three 10 min washes in PBS-
T, bound antibodies were visualized by chemiluminescence (ECL PlusTM, Amersham, 
Piscataway, NJ) and exposed to Hyperfilm ECL (GE Healthcare, Piscataway, NJ). 
 
2.22 Cellular efflux of 3H-PC 
HEK293T cells were subcultured and transfected as described in Section 2.10.2. One hour 
post-transfection, the cells were fed 2 µCi [methyl-3H]choline (PerkinElmer, Waltham, MA) 
and cultured for 48 h. Subsequently, the “feeding” medium was removed and cells were 
washed 3× in 1 ml fresh “feeding” medium pre-warmed to 37oC followed by a 24 h 
incubation in 2 ml “feeding” medium supplemented with 2 mM sodium taurocholate 
hydrate (TC) (Sigma-Aldrich, UK; 86339) in DPBS. After the 24 h incubation, 50 µl of 
culture media from each well were analysed for radioactivity content in a Beckman LS 
6000SC scintillation counter (Beckman Coulter, UK). The cells attached to the dish were 
washed 3× in 1 ml DPBS and lysed in 2 ml 0.5% (v/v) Triton-X 100. An aliquot (50 µl) 
from each lysate was analysed for radioactivity to determine the cellular content. The level 
of [methyl-3H]PC efflux for each ABCB4 variant was calculated as a percentage of the total 
[methyl-3H]PC using the following equation: 
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Each set of transfections was repeated six independent times.Statistical analysis was 
performed by one-way ANOVA (analysis of variance) using the GraphPad PRISM® V5.0 
software. 
 
2.23 Immunocytochemistry 
HEK293T cells were cultured and transfected 24 h post-seeding (see Section 2.10.3). Forty 
eight hours post-transfection, all the medium was aspirated from the wells, the cells were 
washed 3× in 1 ml PBS and then fixed with ice-cold 10% (v/v) acetone in ethanol, for 20 
min at RT. Following 3 washes in PBS, the cells were blocked for 1 h at RT in 1 ml of 5% 
(w/v) BSA (bovine serum albumin; Sigma-Aldrich, UK) in PBS.  Subsequently, the cells 
were washed 3× in 1 ml PBS before incubating the coverslips with 100 µl of the anti-
ABCB4 antibody, P3II-26 [50 µg ml
-1 (Sigma-Aldrich, UK) in 1% (w/v) BSA in PBS] for 1 
h at RT. Following 3 washes in 1 ml PBS, the coverslips were incubated with 100 µl of 
Alexa Fluor® 488 Dye-conjugated goat anti-mouse IgG [2 µg ml-1 (Invitrogen, UK; 
A10680) in 1% (w/v) BSA in PBS] for 1 h at RT; at the same time, nuclei were stained with 
1.5 ng µl-1 DAPI (4’,6-diamidino-2-phenylindole; Invitrogen, UK). Subsequently, the 
coverslips were washed 3× in 1 ml PBS and mounted onto microscope slides using 
FluorSaveTM Reagent (Merck Millipore, Darmstadt, DE; 345789). Cells were viewed using a 
Zeiss LSM710 confocal laser scanning microscope based on an Axiovert inverted 
microscope (Carl Zeiss, DE) with a 63× oil immersion objective with a numerical aperture 
of 1.4. Laser lines 488 nm and 405 nm were used to excite Alexa Fluor® 488 and DAPI, 
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respectively. The pinhole was set to 1 airy unit at 2.0% laser power for all experiments. 
Images were acquired with sequential scanning to allow cross-talk free Alexa Fluor® 488 
and DAPI images to be collected. 
 
2.24 Flow cytometric analysis 
All flow cytometry was performed using a BD FACSAria II flow cytometer (BD 
Biosciences). Polypropylene FACS tubes (5 ml) were purchased from BD Biosciences. 
 
HEK293T cells were triple-transfected as described in Section 2.10.1 replacing pcDNA3.1-
ABCB4wt, pCI-neo-ATP8B1 and pCI-neo-CDC50A with the pECFP-C1, pEGFP-C1 and 
pEYFP-C1 vectors and harvested 48 h post transfection, by brief incubation with TrypLE-
Express (500 µl). TrypLE-Express was neutralised by the addition of 5 ml “feeding” 
medium (Section 2.7.2) prior to collecting the cell suspension. Cells were pelleted for 10 
min at 200 g at 4 oC. The resulting cell pellets were resuspended in 5 ml PBS and subjected 
to flow cytometry. Efficiency of transfection with all three vectors was assessed by 
enhanced cyan fluorescent protein (ECFP), enhanced green fluorescent protein (EGFP) 
and enhanced yellow fluorescent protein (EYFP) fluorescence. The ECFP  fluorophore 
was excited at 450 nm, the EGFP fluorophore was excited at 525 nm and the EYFP 
fluorophore was excited at 582 nm. The emission spectra were measured using the FL-1 
channel. The level of expression of each fluorophore was measured in 10,000 cells of 
normal size and granularity. The ECFP/EGFP/EYFP population was compared to 
untransfected cells. Flow cytometry data were analysed using the FlowJo software package 
(Tree Star, Ashland, OR, USA). 
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2.25 FK506 assay 
Single colonies of NMY51 yeast previously transformed with the ABCB1:Cub- or the 
CD36:Cub (control)-expressing vectors (as described in 2.8.1) were incubated overnight in 
10 ml SD-Leu at 30oC with shaking to an OD600 of 1.0. Serial dilutions were prepared by 
diluting the cultures to an OD600 of 0.2 and further down to an OD600 of 0.02 and 0.002 in 
sterile water. The cell suspension (5 μl) from each dilution was spotted onto the 
appropriate 90 mm Petri YPAD agar plates and growth was monitored after incubation of 
the plates for 2 days at 30oC in the dark. The experiment was repeated at 0, 20, 30, 40 and 
50 μg ml-1 FK506. 
2.26 The NubI/NubG test (control assay) 
Exponentially growing cells at an OD546 of 0.6-0.8 were transformed with 1.5 μg of the 
appropriate prey and bait vectors (see Table 2-9) as described in Section 2.8.1. 
 
Amount of Vector each (μg) Plasmid (Bait) Plasmid (Prey) 
1.5 pBT3-N:ABCB1 pAI-Alg5 (NubI) 
1.5 pBT3-N:ABCB1 pDL2-Alg5 (NubG) 
Table 2-9. List of vectors used in the NubI/NubG test. 
 
Each transformed yeast sample was resuspended in 150 μl 0.9% NaCl. Aliquots (50 µl) 
from each sample were spread on 90 mm SD-Trp-Leu (to select for plasmid maintenance) 
and SD-Trp-Leu-His, SD-Trp-Leu-His-Ade (to select for bait and prey interaction) agar 
plates. The plates were sealed with Parafilm “M” and the percentage of growth under 
selection was assessed after a 4 day incubation at 30oC and calculated using the following 
formula: 
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If the bait is properly expressed and functional in the control assay, then the percentage of 
growth under selection for the pBT3-N:ABCB1/NubI co-expressing cells should be 
between 20% and 100% depending of the expression level of the bait. On the other hand, 
no significant growth should be observed under selection for the pBT3-N:ABCB1/NubG 
co-expressing cells. 
 
2.27 The human adult liver cDNA library screens 
2.27.1 Library complexity assay 
For the NubG-X library this was done using an oligo dT sequence which anneals to polyA+ 
mRNA. As the cDNA synthesis can terminate in any of the three different frames, only 
one-third of the cDNAs will be fused in frame (N-terminally) with the NubG. For the X-
NubG library the use of the oligo dT primers for first-strand synthesis is not possible as 
this would produce cDNAs containing the stop codon of the gene and the 3’-untranslated 
region and. To circumvent this problem, random primers were used by the company 
(Dualsystems Biotech, Zurich, CH) to reverse-transcribe the mRNA and also add a leader 
sequence to the 5’-end to ensure efficient translation of the fusion product. Using this 
approach, two fusion points need to be in-frame with the cDNA clone, and only one-ninth 
of the cDNA clones will carry both the leader sequence (5’) and the NubG sequence (3’) 
in-frame with the cloned cDNA. First-strand synthesis was performed using M-MLV 
(Moloney Murine Leukemia Virus) reverse transcriptase. The first-strand cDNA was then 
purified and amplified by PCR to add an adapter to the 5’- and 3’-end of the cDNA to 
introduce asymmetric SfiI restriction sites allowing for directional cloning into the 
appropriate library vector. 
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To confirm the quality of the cDNA libraries employed; a qualitative test was performed 
on isolated plasmid DNA from randomly selected clones. Plasmid DNA (400 ng) from the 
NubG-X and X-NubG was transformed into XL10-Gold® Ultracompetent cells as 
described in Section 2.9 and transformants were selected by resistance to ampicillin. DNA 
(1 µg) isolated from E. coli (see Section 2.11.2.1) was digested with SfiI (NEB, UK) and run 
on 1% agarose gel at 120 mV until the desired resolution was obtained (see Section 2.12). 
The average insert size was expected to be between 1.2 and 1.3 kb for both libraries (as 
stated by the manufacturer; Dualsystems Biotech, Zurich, CH). 
2.27.2 Optimisation of screening stringency 
The level of the ABCB1:Cub self-activation was tested by assaying the level of growth of 
yeast cells co-transformed with the ABCB1:Cub-expressing vector and the pPR3-N empty 
vector on selective plates. A large-scale transformation was performed as described in 
Section 2.8.2. The concentration of 3-AT (2.5 mM) at which no growth was observed was 
chosen for the library screen. 
2.27.3 The library screens 
The NubG-X (pPR3-N) and X-NubG (pDL2xN-SUC/pDL2xN-STE) adult liver cDNA 
libraries were transformed into exponentially growing NMY51 cells bearing the 
ABCB1:Cub-expressing vector as described in Section 2.8.2 with slight modifications 
highlighted below [note: the quantities described are for one library]. The amount of culture 
required to return 30 OD units was calculated (as instructed by the manufacturer; 
Dualsystems Biotech, Zurich, CH), spun down and re-suspended in 200 ml 2×YPAD. The 
transformation mixtures were prepared as follows: LiAc/TE mastermix (704 µl LiAc 1.0 
M, 704 µl 10×TE pH 7.5, 5 ml sterile water); PEG/LiAc mastermix (1.0 ml LiAc 1.0 M, 
1.0 ml 10×TE pH 7.5, 8 ml 50% w/v PEG), per 200 ml cell culture. A total of 28 μg of 
library plasmid mix was transformed in each culture. Cells were re-suspended in 4.8 ml of 
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0.9% (w/v) NaCl and spread on a total of 16 SD-Trp-Leu-His-Ade plates supplemented 
with 2.5 mM 3-AT (see Section 2.5.2). The plates were sealed with Parafilm “M” and 
incubated at 30oC for 5 days. Following the appearance of colonies, the plates were stored 
at 4oC for a further 4 days and monitored for the development red colouration 
(accumulation of a shunt intermediate product in the ADE2 biosynthetic pathway 
indicative of a false-positive colony). The total number of transformants should be greater 
than 2×106 per transformation reaction (i.e. 4.8 ml of re-suspended culture) on the SD-Trp-
Leu plates (as stated by the manufacturer; Dualsystems Biotech, Zurich, CH). The 
transformation efficiency was calculated using the formula listed in Section 2.8.2. 
2.27.4 Recovery of plasmid DNA from yeast for transformation into bacteria 
The library vector encoding a putative ABCB1-interactor was isolated by mechanical 
disruption of the yeast cells, expressing interacting proteins, using glass beads (see Section 
2.11.1) and then retransformed into E. coli to obtain large amounts of plasmid DNA (see 
Sections 2.9 and 2.11.2.1). 
2.27.5 Sequencing and Analysis of Recovered Plasmid DNA 
Isolated plasmid DNA from E. coli (see Section 2.27.4) was sequenced using the forward 
primer pNubGx for the NubG-X library clones and the reverse primer pDSL-Nx for the 
X-NubG library clones. The retrieved sequence data was analysed using Vector NTI 
AdvanceTM software V11.0 (Invitrogen, UK) and the encoded genes were identified using 
the BLAST algorithm. 
2.27.6 Confirmation of positive interaction and determination of its specificity for 
ABCB1 
2.27.6.1 Confirmation of positive ABCB1-interactors 
Prey plasmid DNA isolated from yeast from the initial screen, was transformed into E. coli 
(Section 2.9), recovered from E. coli (Section 2.11.2.1) and re-transformed into the 
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ABCB1:Cub-bearing yeast strain as described in Section 2.8.1. Each transformation (100 µl) 
was then plated on 90 mm SD-Trp-Leu agar plates, sealed with Parafilm “M” and incubated 
at 30oC until colonies had appeared (3 – 4 days). Single colonies were then picked and 
grown O/N into 5 ml of SD-Trp-Leu medium in individual, CultiFlask® 50 disposable 
bioreactor (Sartorius, UK; DF-050MB-SSH) to an OD546 of 1.0. Exponentially growing cell 
cultures were then diluted to an OD546 of 0.1 in SD-Trp-Leu medium and 10 µl of each was 
spotted SD-Trp-Leu plates and on SD-Trp-Leu-His-Ade plates supplemented with 0, 1, 2, 3, 
or 4 mM 3-AT. Cells carrying the control prey plasmids pAI-Alg5 (NubI) and pDL2-Alg5 
(NubG) were also employed as positive and negative controls, respectively. Growth at 30oC 
was monitored after 3 – 4 days by means of colony-colour (white, pink or red depending 
on the strength of interaction) and colony growth (by eye). 
2.27.6.2 Determination of the specificity of interaction with ABCB1:Cub 
ABCB1:Cub, FATP4:Cub (Wharton J., personal communication) and Alg5p:Cub 
(Dualsystems Biotech, Zurich, CH) vectors were transformed into exponentially growing 
NMY51 yeast cells as described in Section 2.8.1 and grown on SD-Leu plates for 3 – 4 days 
at 30oC. Individual colonies were then used to inoculate the appropriate volume of SD-Leu 
medium (2 ml of yeast culture per bait/prey pair to be assayed) and grown overnight at 
30oC with shaking at 200 rpm to an OD546 of 0.6-0.8. Exponentially growing cells were 
transformed with individual prey plasmids (isolated from the library screen) and 10 µl of 
each was spotted onto SD-Trp-Leu and SD-Trp-Leu-His-Ade plates supplemented with 3.0 
mM 3-AT. Colour development was monitored at 30oC after 2 days on SD-Trp-Leu agar 
plates, and after 3 – 4 days on SD-Trp-Leu-His-Ade agar plates in the presence of 3-AT. 
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2.28 Testing the interaction of ABCB1 with Caveolin-1 and PKCα 
The interaction of ABCB1 with Caveolin-1 and PKCα was tested using the transformation 
protocol outlined in Section 2.8.1. The pPR3-STE:Caveolin and pPR3-STE:PKCα prey 
vectors were transformed into the ABCB1:Cub(bait)-bearing yeast strain. The 
transformants were spread on SD-Trp-Leu-His-Ade plates, sealed with Parafilm “M” and 
assessed for growth density and colour development (where growth was evident) after 4 
days at 30oC. 
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3.1 Introduction 
ABCB1 is a plasma membrane glycoprotein involved in many aspects of the normal human 
physiology. It functions primarily as an efflux pump in the variety of tissues that it is 
expressed (the BBB, liver, testes, heart, kidneys, intestines and stem-like progenitor cells) 
providing a protective role against xenobiotics (Chaudhary and Roninson, 1991, Cordon-
Cardo et al., 1990, Cordon-Cardo et al., 1989, Fojo et al., 1987, Sharom, 2011, Thiebaut et 
al., 1987, Thiebaut et al., 1989). It may also be involved in intercellular signalling (Raggers 
et al., 2001). 
 
Despite its protective role, overexpression of ABCB1 in tumour tissues is one of the major 
impediments to chemotherapeutic treatments for cancer patients (Gottesman et al., 2002). 
This phenomenon is known as multidrug resistance (MDR) and describes the state 
whereby tumours become spontaneously resistant to a variety of therapeutic agents that are 
structurally and/or functionally unrelated, including agents that the cells have not been 
previously exposed to. While direct inhibition of ABCB1 could improve the outcome of 
chemotherapeutic treatment in cancer patients, it imposes a risk for neurological toxicity 
and myelosuppression (Fisher et al., 1996). A plethora of pharmacological agents have been 
developed, and new drugs are constantly being designed that aim to circumvent drug 
resistance, yet pharmacokinetic interactions as well as dose-dependent toxicity in the 
patient present a recurring challenge that needs to be overcome (Gottesman et al., 2002).   
 
Identification of ABCB1-interacting partners that influence trafficking and/or function 
could provide alternative targets for therapy. Although a number of proteins have been 
shown to interact with ABCB1 (Section 1.11), to date there has been no systematic 
approach to identify the ABCB1 interactome to better understand its mechanistic 
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functions, and physiological role(s) and regulation. Consequently, the primary aim of this 
part of the project was to use the SU-YTH system to identify proteins that interact with 
ABCB1. 
3.1.1 Conventional techniques to study protein:protein interaction 
3.1.1.1 Co-immunoprecipitation 
Co-immunoprecipitation (co-IP) is one of the most valuable biochemical techniques used 
routinely in the lab for the identification of protein:protein interactions (Phizicky and 
Fields, 1995). It can either be employed to confirm an interaction between two known 
proteins or to identify unknown partners of a protein of interest. The basic principle 
involves the precipitation of a polypeptide from a whole-cell lysate using a specific 
antibody (Ab), washing away any non-specifically bound proteins while retaining those that 
bind directly to the protein of interest, elution of the precipitated complex and separation 
on a SDS-PAGE gel. The components of the complex can then be identified using mass 
spectrometry. The Ab used to precipitate the protein of interest (antigen) can either be a 
monoclonal Ab raised against a specific epitope or a preadsorbed polyclonal Ab. If an 
antigen is expressed heterologously in a cell system, the encoding vector can be designed to 
express the protein with a carboxy- or amino-terminal fusion to an epitope tag (such as c-
Myc or FLAG-tag) or to protein tag (such as glutathione-S-transferase (GST) (Vikis and 
Guan, 2004) providing more options when choosing a precipitating Ab. Weak or transient 
interactions are difficult to detect with co-IP although sometimes this can be overcome by 
covalent cross-linking of the proteins prior to immunoprecipitation. Although co-IP is an 
invaluable approach, it is technically difficult when used for membrane proteins because it 
requires the use of detergents to solubilise the proteins from the lipid membrane. The 
detergent used must be strong enough to solubilise the membrane protein but it should 
also allow the maintenance of its quaternary structure (le Maire et al., 2000). An array of 
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non-ionic or zwitterionic detergents can be used at a range of different temperatures and 
incubation times in order to optimise the conditions required for the isolation of the 
complex of interest. However, these methods require extensive optimisation for each 
complex and are therefore not suited for use in large-scale screens for the simultaneous 
identification of several uncharacterised protein:protein interactions.  
3.1.1.2 The yeast two-hybrid system 
The yeast Saccharomyces cerevisiae has proven to be an important tool for the identification of 
protein:protein complexes (Forsburg, 2001, Kumar and Snyder, 2001) due to the ease of 
handling yeast in the laboratory and the development of several reporter strains. Genetic 
methods involving the yeast two-hybrid (YTH) system (Fields and Song, 1989) were 
developed to detect interactions between insoluble proteins in the yeast cytosol and to 
verify interaction networks, but these require the translocation of the interacting complexes 
to the nucleus (Ito et al., 2001, Uetz et al., 2000). 
 
The classical YTH system is based on the reconstitution of an active transcription factor 
from the interaction of test proteins that are fused to the separated DNA-binding domain 
(BD) and transcription activation domain (AD) of a transcription factor such as GAL4 
(Fields and Song, 1989). The interaction of the test proteins reunites the BD with the AD 
and is detected via the expression of reporter genes such as lacZ (β-galactosidase) which 
contain an upstream activation sequence to which the BD binds (Fields and Song, 1989). 
 
The YTH system has been used successfully to detect interactions between particular 
membrane proteins (Bourette et al., 1997, Hellyer et al., 1998); however, in genome-wide 
YTH screens, the coverage of membrane proteins was shown to be poor (Ito et al., 2001, 
Uetz et al., 2000). Transmembrane proteins contain many strongly hydrophobic domains 
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and are therefore insoluble and tend to aggregate when in the cytosol. Furthermore, post-
translational modifications (such as glycosylation) hinder nuclear localisation even further. 
The potency of the original YTH system is therefore limited in the identification of integral 
membrane protein interactors, however modified YTH systems have been developed to 
address these problems (Stagljar and Fields, 2002).  
3.1.1.3 The “split-ubiquitin” yeast two-hybrid system 
Several yeast-based systems have been developed to allow for the detection of interaction 
between integral membrane proteins. These include the reverse Ras recruitment system 
(Broder et al., 1998, Hubsman et al., 2001), the G-protein-based YTH system (Ehrhard et 
al., 2000), the rUra3-based YTH system (Wittke et al., 1999) and the “split-ubiquitin” yeast 
two-hybrid (SU-YTH) system (Stagljar et al., 1998). 
 
In this chapter, the use of the commercially available SU-YTH system (Dualsystems 
Biotech, Zurich, CH) (Stagljar et al., 1998) to identify regulators of ABCB1 is described. 
The SU-YTH system has been used successfully to study ER (Scheper et al., 2003), 
vacuolar (Paumi et al., 2007) and plasma membrane proteins (Gisler et al., 2008, Stagljar et 
al., 1998, Thaminy et al., 2003). 
 
The system is based on the observation that ubiquitin (Ub), a protein which when used to 
modify a target protein can designate the target protein for proteasomal degradation by the 
26S proteasome (Hershko and Ciechanover, 1992), can be split into two parts; the N-
terminal (Nub) and the C-terminal (Cub) (Johnsson and Varshavsky, 1994). In the SU-
YTH system, the Cub moiety is linked to an artificial transcription factor (TF) fused to a 
transactivator protein. The two halves (Cub and Nub) can be autonomously expressed in 
the same cell, and retain their natural affinity for each other to re-assemble the “split-
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ubiquitin”. The reformed “split-ubiquitin” complex is recognised by ubiquitin-specific 
proteases (UBPs) which are recruited to cleave the Cub-linked TF which can translocate to 
the nucleus and activate expression of reporter genes. Thus, unlike the conventional YTH, 
the entire protein:protein interaction complex does not need to translocate to the nucleus 
to effect transcription of reporter genes. 
 
The innate attraction of Nub and Cub can be abolished by a point mutation in the wild-
type Nub (designated NubI) replacing an isoleucine at position 3 for a glycine (designated 
NubG) (Johnsson and Varshavsky, 1994). When co-expressed in the same cell, Cub and 
NubG do not innately re-assemble. If, however, a protein of interest X is fused to Cub and 
another protein of interest Y is fused to NubG, and X and Y interact, Cub and NubG are 
brought in close proximity to each other and reassemble the “split-ubiquitin” which can 
now be recognised by UBPs. 
 
Stagljar et al. (1998) and Thaminy et al. (2003) modified this system for the in vivo screening 
of membrane protein interactions. In this method, one integral membrane protein (the 
“bait”) is fused (N- or C-terminally) to Cub which is in turn fused to an artificial TF 
comprising the E. coli DNA-binding protein LexA and the activation domain of the Herpes 
simplex virus VP16. “Prey” are fused (N- or C-terminally) to NubG. If the “bait” and 
“prey” interact, “split-ubiquitin” is reconstituted, UBPs cleave the C-terminus of the Cub, 
the TF is released and this translocates to the nucleus to drive expression of the reporter 
genes independently of the membrane protein complex (Figure 3-1). A fundamental 
prerequisite for the detection of an interacting protein pair in the SU-YTH system is that 
the Cub-LexA-VP16 module fused to the N- or C-terminus of the bait and the NubG 
fused to the N- or C-terminus of the prey protein are both located on the cytosolic side of 
the membrane. The topology of ABCB1, based on primary sequence analysis, topological 
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analysis and the structures of homologues, shows that both the C- and the N-termini are 
cytoplasmic (Chen et al., 1986, Gerlach et al., 1986a, Gros et al., 1986b). Tagging ABCB1 
on either end should therefore make the Cub-LexA-VP16 module available for interaction 
with NubG. 
 
The interacting protein may be cytoplasmic or an integral membrane protein. Type I 
integral membrane proteins typically have a cytoplasmic C-terminus and a luminal N-
terminus whereas for type II integral membrane proteins the converse is true (Singer et al., 
1987) and for multiple transmembrane proteins, either, both or neither termini may be 
cytoplasmic. Two different cDNA libraries were therefore tested for candidates interacting 
with ABCB1. In a NubG-prey cDNA library (NubG-X), NubG is fused to the N-terminus 
 
 
Figure 3-1. The split-ubiquitin system for the detection of mbrane-protein interactions. 
(A). The integral membrane protein of interest X is fused to the Cub which is in turn fused to the 
artificial transcription factor LexA and the transactivation domain VP16. Another protein of interest 
is fused to the NubG. If X and Y do not interact, Cub and NubG will not re-constitute the “split-
ubiquitin”. (B). If X and Y interact, Cub and NubG are brought into close proximity to each other 
which enables them to interact and re-assemble the “split-ubiquitin”. This is recognised in-turn by 
Ubiquitin-specific proteases which cleave off the transcription factor. Consequently, the 
transcription factor translocates to the nucleus where it drives expression of reporter genes 
allowing the yeast expressing the interacting protein pair to survive on defined selective media by 
complementation of auxotrophic markers [modified from (Stagljar and Fields, 2002)]. 
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of the prey protein making it suitable for the screening of membrane proteins with an 
amino-terminal cytoplasmic domain. On the other hand, a prey-NubG (X-NubG) cDNA
library can be used for the screening of membrane proteins with a carboxy-terminal 
cytoplasmic domain. The topology of the candidates is an unknown factor. Furthermore, it 
is not possible to predict if a candidate will tolerate amino- or carboxy-terminal 
modifications or whether the quaternary interaction will survive either of these. For these 
reasons, it was deemed suitable to screen both libraries to ensure optimal recovery of 
putative interactors. 
3.1.2 Aim 
The overall aim of the project was to employ the SU-YTH system to identify proteins that 
interact with ABCB1. 
 
3.2 Results 
3.2.1 Expression of the ABCB1:bait construct in the reporter strain NMY51 
3.2.1.1 Efficient transformation of yeast cells and expression of bait protein 
Before the use of the SU-YTH system to identify putative ABCB1-interacting partners, it 
was important to verify the expression of the ABCB1:Cub fusion protein. The cDNA of 
human ABCB1 was cloned in-frame to the Cub in the pBT3-N (Dualsystems Biotech, 
Zurich, CH) bait vector (hereafter the ABCB1:Cub vector) and the correct sequence 
confirmed by DNA sequencing (Linton K. J., personal communication). 
 
The bait vector carries the LEU2 gene which will complement LEU2-deficient NMY51, 
allowing the cells bearing the bait vector to survive on defined selective media lacking 
leucine. Yeast cells are most competent when the culture used for the transformation is at 
an early log phase. In addition, use of freshly prepared transformation reagents (i.e., 50% 
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(w/v) PEG; poly[ethylene glycol]) as well as single-stranded carrier DNA increase the 
transformation efficiency by several-fold (Kawai et al., 2010). As shown in Figure 3-2, 
when NMY51 yeast cells were transformed with the ABCB1:Cub vector following the 
protocol described by Gietz and Schiestl (Gietz and Schiestl, 2007a), colonies appeared 
after three days of incubation at 30oC confirming that the yeast cells can be efficiently 
transformed: (125 colonies × 10,000 [dilution factor])/1.5 µg DNA = 8.0 × 105 cells µg-1 
“bait” DNA and should express the ABCB1:Cub fusion protein (Figure 3-2). This high 
transformation efficiency will also be sufficient to express a representative cDNA library. 
 
 
Figure 3-2. Representative growth on SD-Leu medium of NMY51 reporter strain transformed with 
1.5 μg pBT3-N (ABCB1) bait vector. 
Transformation was carried out using the LiAc/SS carrier DNA/PEG method. Dilution shown 
1:10,000 (100 μl plated, 125 colonies recovered). 
 
3.2.1.2 Confirmation of bait protein expression using the “NubI/NubG” test 
Following successful transformation of NMY51 cells with the ABCB1:Cub vector, the 
expression of the bait fusion protein was assayed. The yeast strain expressing the bait 
protein was co-transformed with the control prey plasmids pAI-Alg5 (NubI) and pDL2-
Alg5 (NubG) (Dualsystems Biotech, Zurich, CH). Co-expression of ABCB1:Cub with the 
wild-type NubI that retains affinity for the Cub resulted in reconstitution of the split-
ubiquitin and the activation of reporter genes allowing growth on selective medium by 
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complementation of auxotrophic markers HIS3 and ADE2 (Figure 3-3, panels B-C). Co-
expression of the bait together with NubG which has little or no affinity for the Cub did 
not activate either reporter gene (Figure 3-3, panels E-F). It should be noted that growth 
on SD-Trp-Leu plates is expected for both transformations confirming that both the bait 
and the prey vectors were taken up by the yeast cells (Figure 3-3, panels A and D). Growth 
on the selective media strongly suggests that the ABCB1:Cub protein is made by the cells 
and is able to interact with NubI. However, with this test it can only be assumed that the 
fusion protein folds correctly and inserts properly in the membrane. 
 
 
Figure 3-3. The “NubI/NubG” test. 
Panels A-C show growth of the yeast cells co-transformed with ABCB1:Cub and NubI on media of 
increasing stringency. Panels D-F show growth of yeast cells co-transformed with ABCB1:Cub and 
NubG on media of increasing stringency. The appearance of colonies on SD-Trp-Leu plates shows 
that the yeast were successfully transformed with both “bait” and “prey” vectors. Survival on SD-
Trp-Leu-His (panel B) and on SD-Trp-Leu-His-Ade (panel C) plates confirms that ABCB1:Cub and 
NubI interact allowing complementation of the auxotrophic markers. When yeast were co-
transformed with ABCB1:Cub and NubG, growth was only evident on SD-Trp-Leu plates. No 
survival was observed on the SD-Trp-Leu-His or on SD-Trp-Leu-His-Ade verifying the lack of 
interaction between ABCB1:Cub and NubG. 
 
3.2.1.3 Western blotting analysis of bait protein expression 
The expression of the ABCB1:Cub bait protein was also tested by western blot of total cell 
extracts, probed with antibodies specific for ABCB1 or LexA. The bait vector is 
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maintained at a very low copy number (1-2 copies/cell) and the expression of the fusion 
protein is under the control of a weak promoter (CYC1) in order to minimise the recovery 
of false positives during a library screen. The prey vector on the other hand, is maintained 
at a much higher copy number (20-50 copies/cell) and is under the control of a strong 
promoter (ADH1). To assay the differences in expression levels between the bait and prey 
vectors two additional control vectors (one bait and one prey) were employed that express . 
different membrane proteins unrelated to the ABC transporter family: (a) the multi-ligand, 
scavenger receptor CD36 (Greenwalt et al., 1992) which has been implicated in the
 
 
Figure 3-4. Western blot on NMY51 total-cell extracts. 
Trichloroacetic acid (TCA)-precipitated whole-cell protein extracts from ~2.4×10
7
 – 4.0×10
7
 yeast 
cells were loaded in each well and subjected to western analysis. [Lane 1] ABCB1:Cub + pAI-Alg5 
(control vector); [Lane 2] ABCB1:Cub + pPR3-STE:Caveolin (prey vector); [Lane 3] empty; [Lane 4] 
CD36:Cub + pPR3-STE:Caveolin (prey vector). (A). Mouse ABCB1-specific antibody (C219). (B). 
Mouse LexA-directed antibody. (C). Rabbit caveolin-1 specific antibody. Apparent molecular 
masses are indicated in kDa. In lanes 1 and 2 (panels A and B), a protein of approximately 208 kDa 
(ABCB1:Cub-LexA-VP16 fusion) was expected. No protein was detected using either of the two 
antibodies. In lane 4 (panel B), a protein of size between 120-130 kDa was expected (CD36:Cub-
LexA-VP16 fusion). In lanes 2 and 4 (panel C) a protein of approximately 22 kDa (Caveolin-1:NubG) 
was detected. 
 
development of atherosclerosis (Febbraio et al., 2000) and insulin resistance (Aitman et al., 
1999) and (b) caveolin-1, a structural component of lipid rafts (Galbiati et al., 2001, Simons 
and Ikonen, 1997) shown to act as a negative regulator of ABCB1 (Barakat et al., 2007, 
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Jodoin et al., 2003). The cDNA for CD36 was cloned into the pBT3-N bait vector (Linton 
K. J., and Wharton J., personal communication) and the cDNA for caveolin-1 was cloned 
into the pPR3-STE prey vector (Wharton J., personal communication).No ABCB1-fusion 
proteins were detected in the lanes where total cell extracts from the transformed yeast 
cells were loaded and probed with the mouse ABCB1-specific antibody (Figure 3-4; lanes 1 
and 2 on panels A and B). This contrasts with the result of the NubI/NubG test whereby 
expression of ABCB1:Cub was confirmed by auxotrophic complementation. 
 
The reason for this discrepancy may lie in the design features of the pBT3-N bait vector 
outlined earlier. As the bait vector is maintained at a very low copy number and the 
expression of the fusion protein is under the control of the CYC1 promoter, it is likely that 
ABCB1:Cub is expressed at levels below the detection threshold of the western. This is 
also likely to be true for the CD36:Cub fusion on the anti-LexA blot for which no signal 
was detected at the appropriate molecular weight (Figure 3-4; panel B, lane 4). Although 
CD36:Cub fusion protein was not detected on the western blot, the library screen with 
CD36 as bait (Snippe M., personal communication) provides evidence that the CD36:Cub 
is expressed as CD36:Nub interactors were recovered including CD36 itself (CD36 is 
known to dimerise; (Daviet et al., 1997, Thorne et al., 1997). The prey vector on the other 
hand, is maintained at high copy number and is under the control of the ADH1 promoter. 
As shown in Figure 3-4 (panel C, lanes 2 and 4) caveolin-1 was detectable as it is expressed 
at a higher level from the pPR3-STE vector. 
3.2.1.4 Analysis of ABCB1 functionality using the anti-fungal reagent FK506 
In the absence of detectable ABCB1:Cub by western analysis, the functional activity of the 
drug pump in yeast cells was tested to assess ABCB1:Cub expression. This assay was based 
on work carried out previously which showed that ABCB1 can be expressed and is 
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functional in yeast by measuring the resistance of ABCB1-expressing cells to the anti-
fungal drug FK506 (Raymond et al., 1994, Saeki et al., 1993). No difference was observed 
between the survival rates of ABCB1:Cub-expressing yeast cells and the control cells 
expressing CD36:Cub  at concentrations of FK506 between 10-100 μg ml-1 (see methods 
for details, data not shown). This observation could again be attributed to the low level of 
expression of the ABCB1:Cub fusion protein from the bait plasmid. 
3.2.2 Testing the interaction of ABCB1 with its putative interactors Caveolin-1 
and PKCα 
ABCB1 has already been suggested to interact with caveolin-1 (Barakat et al., 2007, Jodoin 
et al., 2003) and to be a substrate of PKCα (Fine et al., 1988, Germann et al., 1996, 
Goodfellow et al., 1996). To further confirm these interactions and to test the capacity of 
the SU-YTH system to be used with ABCB1, caveolin:Nub and PKCα:Nub fusion 
constructs were generated. 
3.2.2.1 Investigating the interaction of ABCB1 with Caveolin-1 
When the Cav:NubG was co-expressed with ABCB1:Cub no colonies were observed on 
SD-Trp-Leu-His/SD-Trp-Leu-His-Ade selective plates (data not shown), although growth 
was observed on the SD-Trp-Leu medium indicating uptake of both plasmids into the yeast. 
This lack of growth in the absence of histidine and adenine suggests that ABCB1 and 
caveolin do not interact in the yeast-based system at least under the screening conditions 
used. The possibility that the interaction is affected by the C-terminal fusion of the Cub on 
ABCB1 is unlikely as the proposed caveolin-binding motif (FTMFRYAGW) is located on 
the cytosolic N-terminus of ABCB1 (Demeule et al., 2000, Jodoin et al., 2003). The 
reason(s) for the lack of interaction in the yeast are presently unknown but perhaps is due 
to the carboxy-terminal modification of caveolin with NubG which may prevent 
interaction with ABCB1. 
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3.2.2.2 Investigating the interaction of ABCB1 with PKCα 
In order to test the interaction of ABCB1 with PKCα in vivo, the cDNA for PKCα first had 
to be fused to the cDNA for NubG in the pPR3-STE prey vector (Figure 3-5). 
 
 
Figure 3-5. Summary of the strategy followed to clone the PKCα cDNA into the pPR3-STE yeast 
expression vector. 
Initially the PKCα-ORF was amplified by mutagenic PCR introducing a 5’-PciI and a 3’-AgeI 
restriction site (Step 1). Next, the blunt-ended PCR product was introduced into the SmaI 
restriction site of the pGEM3 vector (Step 2). The ligated products were then transformed into 
bacteria and recombinants were selected in a blue/white screen. The sequence-verified 
pGEM3:PKCα vector was then digested with AgeI/PciI restriction enzymes to excise the PKCα 
sequence. At the same time, the pPR3-STE:Cav vector was digested with AgeI/NcoI to excise the 
caveolin sequence. PKCα and pPR3-STE were purified from an agarose gel, ligated (Step 3) and 
transformed into bacteria. The pPR3-STE:PKCα vector was confirmed by restriction digest with 
DraIII and transformed into the ABCB1:Cub-expressing NMY51 yeast strain (Step 4). Colony-
formation on defined selective media by complementation of auxotrophic markers aimed to test the 
interaction between ABCB1 and PKCα (Step 5). 
 
The caveolin cDNA was cloned between the NcoI and AgeI restriction sites introduced into 
the modified pPR3-STE vector (Linton K. J., and Wharton J., personal communication) to 
generate an in-frame fusion with NubG. In silico analysis of PKCα sequence identified an 
NcoI restriction site within its cDNA, however, PciI generates compatible cohesive ends 
suitable for cloning into an NcoI site. Mutagenic primers were therefore designed to amplify 
the PKCα-cDNA from a GFP-PKCα vector (obtained from A. Sardini) and simultaneously 
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introduce a PciI site at the 5’-end and an AgeI site at the 3’-end of the PCR product (Figure 
3-5; Step 1). 
 
Following successful amplification of the sequence of interest (Figure 3-6A), the blunt-ends 
of the PCR product were ligated to the pGEM3®-3Zf(-) vector cut with SmaI (Figure 3-5; 
Step 2), transformed into E. coli and plated onto LB (Lysogeny broth) agar plates 
supplemented with ampicillin (the selectable marker on the plasmid), IPTG (Isopropyl 1-
thio-β-D galactopyranoside) and X-gal (5-bromo-4-chloro-3-indolyl-beta-D-
galactopyranoside). The pGEM3®-3Zf(-) vector was chosen because it can offer α-
complementation when transformed into an appropriate bacterial host strain (e.g. XL10-
Gold® Ultracompetent cells) allowing blue/white screening for recombinants. When lacZ 
expression is induced by IPTG in the presence of the chromogenic substrate X-gal, 
colonies containing plasmids with inserts will be white, while colonies containing plasmids 
without inserts will be blue. After a 24 h incubation at 37oC, several white colonies (i.e. 
likely to carry the PKCα insert within the lacZ coding sequence) were selected. The plasmid 
DNA was recovered and digested with HindIII (Figure 3-6B; top panel) and XmnI (Figure 
3-6B; bottom panel) to identify recombinant plasmids carrying the PKCα cDNA. 
 
The restriction profiles indicated that “Clone#46” carried the PKCα cDNA (Figure 3-6B). 
The integrity of the insert was verified by DNA sequencing. “Clone#46” was then digested 
with PciI/AgeI to excise the PKCα-ORF, and the pPR3-STE:Cav with NcoI/AgeI to excise 
the caveolin-cDNA (Figure 3-5; Step 3 and Figure 3-6C). 
 
The pPR3-STE(NcoI/AgeI) vector and the PKCα-cDNA(PciI/AgeI) were purified and 
ligated (Figure 3-5; Step 3). The ligation product was transformed into XL10-Gold® 
ultracompetent cells and several colonies were selected for DNA extraction/purification.
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Figure 3-6. Cloning the the PKCα cDNA into the pPR3-STE expression vector. 
(A). Mutagenic PCR to amplify the PKCα-cDNA from the GFP-PKCα vector and introduce a PciI (5’-
end) and an AgeI (3’-end) restriction site. The reaction was carried out at a temperature gradient 
(48
o
C – 62
o
C) to identify the best annealing temperature for the primers. (B). Restriction digest 
profile of “clone#46” using HindIII (top panel) and XmnI (bottom panel). Sample DNA (400 ng) was 
digested and run on 1.0% (w/v) agarose gel. HindIII digest: for the pGEM3
®
-3Zf(-) empty vector only 
one fragment was expected of 3197 bp (top panel, lane 1) and for the pGEM3
®
-3Zf(-):PKCα a 
fragment at 5242 bp was expected (top panel, lane 2). XmnI digest: for the empty vector, a single 
fragment of size 3157 bp was expected (bottom panel, lane 1) and for the pGEM3
®
-3Zf(-):PKCα 
construct two fragments of size 3185 bp and 2057 bp were expected (bottom panel, lane 2). (C). 
Restriction digest profile of pPR3-STE:Cav (lane 1) and pGEM3:PKCα (lane 2) using the restriction 
enzymes NcoI/AgeI and PciI/AgeI respectively. The digested products (750 ng for pPR3-STE:Cav; 1 
μg pGEM3:PKCα) were run on 1.0% (w/v) agarose gel. NcoI/AgeI digest (lane 1): Two fragments of 
size 6591 bp (pPR3-STE [AgeI/NcoI]) and 533 bp (caveolin [AgeI/NcoI]) were expected. PciI/AgeI 
digest (lane 2): Three fragments of size 2788 bp (pGEM3 [PciI/PciI]), 2012 bp (PKCα [PciI/AgeI]) and 
442 bp (pGEM3 [PciI/AgeI]) were expected. (D). Restriction profiles of pPR3-STE:Cav (lane 1) and 
pPR3-STE:PKCα (lane 2). The constructs were digested with DraIII. As DraIII only cuts once within 
the vector sequence, only one fragment at 7124 bp was expected (lane 1). For the pPR3-STE:PKCα 
digest, two fragments of size 5817 bp and 2786 bp were expected (right lane). 
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The extracted DNA was digested with DraIII to verify the cloning of PKCα into the pPR3-
STE vector (Figure 3-6D). 
 
Finally, the NMY51 reporter strain was co-transformed with the ABCB1:Cub bait and the 
PKCα:NubG prey vectors and tested for an interaction by complementation of 
auxotrophic markers. Growth was detected on the SD-Trp-Leu plates (i.e. yeast cells had 
taken up both bait and prey vectors; data not shown), however, no colonies were visible on 
the SD-Trp-Leu-His-Ade plates indicating a lack of interaction between ABCB1:Cub and 
PKCα:NubG (data not shown). 
 
The lack of a good positive control for the library screen (i.e. no complementation of the 
auxotrophic markers on co-expressing ABCB1:Cub with either PKCα:Nub or Cav:Nub) 
was a concern, and indicated the SU-YTH system will not identify every protein interacting 
with ABCB1. However, there could be a perfectly reasonable explanation. For example, 
fusion of Nub to the C-terminus of PKCα or caveolin-1 could sterically hinder interaction 
with ABCB1, or perhaps PKCα requires stimulation to engage ABCB1. Nevertheless, the 
prior description of functional ABCB1 expression in yeast (Goodfellow et al., 1996, 
Raymond et al., 1994), and the behaviour of the ABCB1:Cub with the NubI positive 
control, suggested that a library screen was likely to be productive. 
3.2.3 Evaluation of the level of self-activation and determination of the optimal 
conditions for the library screen 
For a library screen the optimal screening conditions have to be determined. This was 
achieved by co-transformation of NMY51 with ABCB1:Cub and the pPR3-N NubG-X 
empty library vector. No interaction is expected between the ABCB1:Cub and NubG 
proteins therefore any colonies arising on plates of selective medium (SD-Trp-Leu-His/SD-
Trp-Leu-His-Ade) are non-specific background. To ensure that as few as possible false 
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positives arise on the selection plates, the medium was supplemented with 1-10 mM of 3-
AT, a competitive inhibitor of the HIS3 gene product that increases the stringency of 
selection. At a 3-AT concentration of 2.5 mM on SD-Trp-Leu-His-Ade plates all growth of 
yeast containing the ABCB1:Cub and the NubG vectors was inhibited. Transformation 
efficiency was also measured in this experiment; i.e., the number of colonies appearing on 
the SD-Trp-Leu plates. The total number of transformants on SD-Trp-Leu was 1.9×106 
clones per μg DNA (or a total of 4×107 colonies); a transformation efficiency almost 20× 
greater than recommended by the manufacturer (Dualsystems Biotech, Zurich, CH) for 
introducing the cDNA library. 
3.2.4 Library transformation and selection of interactors 
ABCB1 is highly expressed on the canalicular membrane of the hepatocyte (Thiebaut et al., 
1987). The ABCB1:Cub bait was therefore screened against two human adult liver libraries, 
NubG-X and X-NubG (Dualsystems Biotech, Zurich, CH). In NubG-X libraries the 
NubG is fused to the N-terminus of the prey. Any protein whose N-terminus is located in 
the cytoplasm and which tolerates an N-terminal fusion, will be available to interact with 
the Cub on the carboxy terminus of ABCB1:Cub. The X-NubG libray was also screened, 
in which NubG is fused to the C-terminus of the prey suitable for use with proteins when 
their C-terminus is cytoplasmic. 
3.2.4.1 Library characterisation 
The cDNA libraries from Dualsystems Biotech were derived from cells of an adult human 
liver. The company literature reports that the cDNAs were digested with SfiI, size-
fractionated and purified before cloning into the NubG-X or the X-NubG library vectors, 
as appropriate. 
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The NubG-X cDNA library should have a complexity of 1.5×106 independent clones 
ranging in size from 0.5 – 2.5 Kb (average size 1.3 Kb; see below) and the X-NubG library 
should have a complexity of 1.3×106 independent clones ranging in size from 0.3 – 4 Kb 
(average size 1.2 Kb) as stated by the supplier (Dualsystems Biotech, Zurich, CH). To 
achieve a reasonable likelihood of sampling each clone in the library a minimum of 1.3×107 
clones in the library screen was desirable (i.e., 10× the number of clone equivalents). 
 
To confirm the quality of the cDNA libraries employed; a qualitative test was performed 
on isolated plasmid DNA from randomly selected clones. As mentioned earlier the average 
insert size cloned between the SfiI sites of the library vectors should be between 1.2 and 1.3 
Kb (minimum 0.3 Kb and maximum 4.0 Kb). Consequently, digesting the vectors with SfiI 
should release an insert within this range. As shown in Figure 3-7, cDNA inserts covering a 
range of sizes were released from the NubG-X or the X-NubG vectors confirming the 
manufacturer’s description. On average, from ten clones from each library, the mean insert 
size was 1.3 Kb for both the NubG-X and the X-NubG. The insert sizes vary from 0.5 Kb 
to 3.0 Kb but most are within the range of 1.0 to 1.5 Kb (Figure 3-7). 
  
 
Figure 3-7. SfiI digestion of plasmid DNA from the NubG-X and the X-Nub-G libraries. 
Plasmid DNA (1 µg) was digested with SfiI and run on 1.0% (w/v) agarose gel. An array of insert 
sizes ranging from 0.3 – 4.0 Kb was expected. Average insert size from a total of 10 samples for 
each library: 1.3 Kb. Size of empty library vectors: 6.3 and 6.6 Kb for the NubG-X and X-NubG 
library vectors, respectively. 
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3.2.4.2 Library screen 
Using 28 µg of prey DNA and obtaining a transformation efficiency of ~9.7×105 and 
~8.2×105 clones per μg DNA (as detected by growth on SD-Trp-Leu plates) for the NubG-
X and the X-NubG libraries, respectively, a total of 18 clone equivalents were screened for 
each library. Since a cDNA library represents the expression pattern in the hepatocyte, 
highly expressed genes will be over-represented. Furthermore, since the digested cDNA 
fragments were separated according to size, genes smaller than the minimum insert size 
would be not represented in the library. For larger genes it is hoped that domains that fold 
independently will be represented. 
 
Interacting bait and prey are recognised by growth of their yeast host on the SD-Trp-Leu-
His-Ade plates supplemented with 2.5mM 3-AT, and also by colonies that are faint-pink to 
white in colour (see below for a more detailed account on the basis of the coloured shunt 
intermediate accumulation). Upon completion of the NubG-X and the X-NubG library 
screen, a total of 130 and 12 colonies were isolated from each library, respectively. Each 
colony should express a putative interacting protein pair.  
3.2.4.2.1 Clone identification 
To reveal the identity of each putative ABCB1 interactor, the library plasmid was isolated 
from the yeast colonies, transformed into E. coli, isolated from the bacterial colonies and 
sent for sequencing analysis. The bait and prey vectors are bifunctional and can therefore 
be maintained in both yeast and E. coli. Prey plasmids carry the β-lactamase gene so 
bacteria that have been transformed successfully can be propagated on LB agar plates 
supplemented with ampicillin. Bait plasmids encode only the kanamycin selectable marker, 
therefore only E. coli which have taken up the library plasmid grow in the presence of 
ampicillin. 
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From the 130 putative interactors isolated from the NubG-X library screen, fifteen (~12%) 
could not be transformed and amplified in E. coli and may well encode a product 
deleterious to the bacteria. 
 
Isolation of the plasmids which gave rise to bacterial colonies, sequencing and in silico 
analysis using the BLAST algorithm allowed for further sorting of the candidates. During 
transformation, yeast can take up more than one plasmid and it is possible that the 
recovered plasmid is not the one that is able to rescue growth on the selective yeast-
medium. Accordingly, twelve (~9%) appeared to be empty vectors i.e. not carrying a 
cDNA insert based on sequence analysis and five (~4%) of the isolated clones did not 
form colonies in the clone-confirmation assay (Section 3.2.4.2.2). Four (~3%) encoded 
ubiquitin which has been reported to be isolated occasionally from NubG-X libry screens 
(Iyer et al., 2005). 
 
Twenty (~15%) encoded proteins which, based on what is known for ABCB1 function and 
localisation, were not likely to interact. These included peroxisomal proteins such as enoyl 
CoA hydratase 1 (ECH1) which is involved in the β-oxidation of fatty acids (Hiltunen et 
al., 2003, Reddy and Mannaerts, 1994) as well as the mitochondrial malate dehydrogenase 2 
(MDH2) involved in the citric acid cycle (Musrati et al., 1998).  
 
A total of seventy four (~57%) encoded a potentially interesting candidate. Many clones 
were isolated more than once. Alignment of the sequence of the isolated clones originating 
from the same gene revealed that not all inserts were equal in length but all aligned to the 
3’-end of the respective gene’s coding sequence, as expected based on the strategy used to 
create the library (Dualsystems Biotech, Zurich, CH). For example, cDNA from the gene 
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STAT6 (signal transducer and activator of transcription 6) was the most prevalent in the 
screen (isolated 17 times; Table 3-1, column 1). All 17 clones aligned to the 3’-end of the 
STAT6 coding sequence but most of them had a different length of coding sequence 
meaning that they are likely the product of different cloning events rather than the result of 
the plasmid being amplified through a selective advantage in E. coli. In addition, some of 
the clones, such as those encoding for VKOR (vitamin K oxido-reductase), an enzyme 
involved in the recycling of oxidised vitamin K (Zimmermann and Matschiner, 1974, Li et 
al., 2004, Rost et al., 2004), carried the whole coding sequence of the gene. 
 
Sequence analysis of the twelve candidates isolated from the X-NubG screen revealed that 
they all encoded for the amino terminus of ubiquitin cloned from the liver library and were 
therefore considered false positives. Isolation of ubiquitin as an interacting partner is 
perhaps not surprising as ABCB1 is regulated via a ubiquitination-dependent pathway 
(Zhang et al., 2004). 
3.2.4.2.2 Clone retransformation and confirmation of interaction with ABCB1 
To confirm the findings of the NubG-X screen, isolated prey plasmids were re-
transformed into the ABCB1:Cub-bearing yeast strain. This was done in order to identify 
more false positives. As mentioned earlier, it is possible that during library transformation, 
the yeast cells take up more than one prey vector or the yeast may have survived due to an 
endogenous genetic change. 
 
Individual clones of retransformed NMY51 were grown on plates lacking tryptophan and 
leucine (SD-Trp-Leu), selecting only for the maintenance of the two plasmids. The clones 
were then spotted on SD-Trp-Leu-His-Ade plates supplemented with a range of 0-4 mM of 
3-AT. The clones were also spotted on SD-Trp-Leu plates at the same time for comparison 
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of colony growth. The control prey plasmids pAI-Alg5 (NubI) and pDL2-Alg5 (NubG; a 
control vector that codes for Cub fused to the endoplasmic reticulum transmembrane 
protein Alg5p) supplied by the manufacturer (Dualsystems Biotech, Zurich, CH), were also 
employed as positive and negative controls, respectively. 
 
Figure 3-8 is a representative example of the result obtained after 3-4 days of growth at 
30oC. All prey vectors were successfully transformed into the yeast complementing the 
auxotrophic markers on the SD-Trp-Leu plates (LEU2 for “bait”, TRP1 for “prey”; Figure 
3-8A). The lack of growth on the SD-Trp-Leu-His-Ade media for some of the 
transformants carrying both vectors (Figure 3-8B shows growth on SD-Trp-Leu-His-Ade 
plates plus 3 mM 3-AT but is comparable to plates with 2 mM and 4 mM 3-AT), indicates 
that some clones do not encode an ABCB1-interacting partner. For example clone 4i when 
co-expressed with ABCB1:Cub supports yeast growth on the SD-Trp-Leu-His-Ade plate 
suggesting that 4i is a true ABCB1 interactor. In contrast, when clone 25i was co-expressed 
with ABCB1:Cub, although the yeast cells were able to grow on SD-Trp-Leu plate (i.e., had 
taken up both bait and prey vectors) no growth was observed on the SD-Trp-Leu-His-Ade 
plate. Using this approach, 5 candidates (~4%) were discarded. 
 
 
Figure 3-8. Reconfirmation of the interaction between ABCB1 and candidate partner proteins in 
yeast. 
(A). Yeast growth on SD-Trp-Leu media. Growth on this plate denotes that both bait (ABCB1:Cub) 
and prey vectors were taken up by the yeast cells during the transformation. (B). Replicate SD-Trp-
Leu-His-Ade plate supplemented with 3 mM of 3-AT, an inhibitor of the HIS3 gene product. Growth 
on this plate indicates that the proteins encoded by bait and prey vectors interact and drive 
expression of the reporter genes (His and Ade). Clone numbers are indicated in the top row. NubI, 
positive control; NubG, negative control. 
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Following the elimination of all false positives 29 unique putative intetacting partners were 
recovered (Table 3-1; final 3 columns). 
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STAT6 
Clone(s): 23i, 37i, 39i, 41i, 48i, 52i, 62i, 65i, 69i, 
83i, 88i, 89i, 105i, 110i, 121i, 122i, 130i 
17 

  ++ +++ +++ 
EBP 
Clone(s): 27i, 29i, 34i, 40i, 42i, 49i, 58i, 81i, 91i, 
97i, 104i, 106i, 116i, 119i 
14    +++ +++ +++ 
IFITM3 
Clone(s): 10i, 24i, 46i, 54i, 71i, 75i, 77i, 82i, 85i, 
102i 
10    Ø ++ +++ 
SERP1/RAMP4 
Clone(s): 18i, 20i, 22i, 38i, 64i, 78i, 80i, 101i, 
112i, 126i 
10    ++ ++ +++ 
VKORC1 
Clone(s): 4i, 14i, 53i, 92i, 114i 
5    +++ +++ +++ 
TMBIM4 
Clone(s): 43i, 59i, 61i 
3    ++ ++ +++ 
ARL6IP5 
Clonse(s): 57i, 74i 
2    + ++ ++ 
ASGR2 
Clones(s): 44i, 111i 
2    + +++ +++ 
CYB5A 
Clone(s): 55i, 107i 
2    Ø +++ +++ 
PLP2 
Clone(s): 63i, 66i 
2    Ø Ø +++ 
VAPB 
Clone(s): 11i, 72i 
2    ++ +++ +++ 
acylCoA Dehydrogenase 
Clone(s): 7i 
1    ++ +++ +++ 
ATP6V0B 
Clone(s): 45i 
1    Ø Ø +++ 
Table 3-1. Phenotype of the 29 candidates isolated from the NubG-X library screen. 
The numbers highlighted in blue, indicate the putative interactors that were compared for 
specificity and strength of interaction with ABCB1:Cub in comparison with the FATP4:Cub and the 
Alg5p:Cub controls.  In cases where a candidate was isolated more than once, one was selected 
and used in the experiment. “+” indicates the degree of yeast cell growth on the selective plates 
(SD-Trp-Leu or SD-Trp-Leu-His-Ade) in the following order: +++ > ++ > + > Ø. Shaded boxes 
indicate the colour of the yeast colonies on SD-Trp-Leu plates: white= a strong interaction between 
the proteins encoded by the co-transformed “bait” and “prey” vectors, pink= intermediate 
interaction and red= lack of interaction. All the co-transformed cells gave rise to colonies on SD-
Trp-Leu selective plates indicating that they had taken up both “bait” and “prey” vectors. STAT6, 
signal transducer and activator of transcription 6; IFITM3, interferon induced transmembrane 
protein 3; SERP1, stress-associated endoplasmic reticulum protein 1; VKORC1, vitamin K epoxide 
reductase complex (subunit 1); TMBIM4, transmembrane BAX inhibitor motif containing 4; 
ARL6IP5, ADP-ribosylation-like factor interacting protein 5; ASGR2, asialoglycoprotein receptor 2 
(transcript variant 1); CYB5A, cytochrome b5 type A; PLP2, proteolipid protein  2; VAPB, vesicle-
associated membrane protein-associated protein B; ATP6V0B, ATPase H
+
 transporting lysosomal 
21kDa V0 subunit b. 
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CD63 
Clone(s): 128i 
1    ++ +++ +++ 
CD81 
Clone(s): 96i 
1    ++ +++ +++ 
CRP 
Clone(s): 108i 
1    Ø Ø Ø 
Ergic32 
Clone(s): 16i 
1    +++ +++ +++ 
Ferritin Light Polypeptide 
Clone(s): 13i 
1    Ø Ø Ø 
FXYD5 
Clone(s): 100i 
1    ++ +++ +++ 
HDAC6 
Clone(s): 73i 
1    +++ +++ +++ 
LASS2 
Clone(s): 99i 
1    +++ +++ +++ 
MDH2 
Clone(s): 51i 
1    Ø Ø Ø 
SERPINA1 
Clone(s): 125i 
1    Ø Ø +++ 
SOX4 
Clone(s): 113i 
1    Ø +++ +++ 
SSR3 
Clone(s): 32i 
1    +++ +++ +++ 
TM9SF4 
Clone(s): 56i 
1    Ø +++ +++ 
TMEM85 
Clone(s): 21i 
1    + + +++ 
TNFSF13B 
Clone(s): 90i 
1    ++ +++ +++ 
YIF1A 
Clone(s): 33i 
1    Ø ++ +++ 
          
UB 
Clone(s): 6i, 36i, 70i, 76i 
4    +++ +++ +++ 
Table 3-1. (continued) Phenotype of the 29 candidates isolated from the NubG-X library screen. ; 
CRP, C-reactive protein; Ergic32, ER-Golgi intermediate compartment protein 32; FXDY5, FXYD 
domain-containing ion transport regulator 5; HDAC6, histone de-acetylase 6; LASS2, ceramide 
synthase 2.MDH2, malate dehydrogenase 2; SERPINA1, serpin peptidase inhibitor member 1; 
SOX4, sex-determining region box 4; SSR3, signal sequence receptor gamma; TM9SF4, 
transmembrane 9 superfamily protein member 4; TMEM85, transmembrane protein 85; TNFSF13B, 
tumour necrosis factor superfamily member 13; YIF1A, Yip1 interacting factor homolog A; UB, 
ubiquitin. 
 
3.2.5 Determination of the specificity of interaction between ABCB1:Cub and its 
interactors 
The cDNA of the mouse long-chain fatty acid transporter FATP4 (Doege and Stahl, 2006, 
Hirsch et al., 1998, Gimeno et al., 2003) had been cloned into the pBT3-N bait vector 
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(Linton K. J., and Wharton J., personal communication). This construct has been used to 
screen a mouse heart expression library recovering prey proteins implicated in fat 
metabolism. Interaction has also been confirmed by co-IP, thus it is clear that FATP4:Cub 
expresses appropriately in yeast. 
 
In order to assess the specificity of interaction between the proteins identified from the 
library screen and ABCB1:Cub, each of the confirmed candidates was co-expressed in the 
NMY51 strain with (a) ABCB1:Cub, (b) FATP4:Cub and (c) pCCW-Alg5p:Cub. The 
rationale behind this experiment was that the FATP4:Cub and the Alg5p:Cub would act as 
more stringent negative controls as neither FATP4 nor Alg5p are related to ABCB1 but 
both proteins, linked to Cub, should be present in the membrane. No growth or 
dramatically reduced growth was therefore expected for cells co-expressing any of the 
candidates that specifically interact with ABCB1 and the two negative controls when plated 
on SD-Trp-Leu-His-Ade selective plates. 
 
For this experiment, colony colour was also monitored as this is related to the strength of 
bait and prey interaction. The NMY51 yeast strain carries a mutation in the ADE2 gene 
which codes for a key enzyme in the adenine biosynthetic pathway. This enzyme, 
phosphoribosylaminoimidazole carboxylase (or AIR carboxylase), catalyses the conversion 
of 5'-phosphoribosyl-5-aminoimidazole (AIR) to 5'-phosphoribosyl-4-carboxy-5-
aminoimidazole (CAIR). In the presence of low concentrations of adenine, AIR 
accumulates in the yeast cells and is oxidised into a red shunt intermediate (Roman, 1956, 
Dorfman, 1969, Gedvilaite and Sasnauskas, 1994, Stotz et al., 1993). Supplementation of 
high concentrations of adenine negatively inhibits the adenine biosynthetic pathway and 
the NMY51 strain fails to accumulate the red shunt product. This observation can be 
exploited to provide a measure of the strength of the interaction between the library 
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protein and ABCB1 on the SD-Trp-Leu medium containing low concentrations of adenine 
sufficient to allow growth, but insufficient to fully inhibit the adenine biosynthetic pathway. 
White colonies would result from the presence of an interacting pair inducing ADE2 gene 
expression via the released LexA-VP16 transcription factor. On the other hand, red 
colonies would be expected for cells co-transformed with FATP4:Cub or Alg5p:Cub and 
any of the putative interactors on the SD-Trp-Leu plates as the lack of interaction (for 
candidates that interact specifically with ABCB1) would be unable to drive expression of 
AIR carboxylase. AIR would therefore accumulate and be converted into the red shunt 
product. 
 
Figure 3-9 shows a representative result of such an experiment. The first observation is that 
all transformation experiments were carried out successfully as indicated by the visible 
growth of colonies on the SD-Trp-Leu plates (Figure 3-9, panels A and C) i.e. both “bait” 
and “prey” vectors were taken up by the yeast. The Alg5p:NubI and Alg5p:NubG  
transformants (respective positive and negative controls from Dualsystems Biotech) 
returned the expected result. Specifically, good growth was observed in the presence of 
Alg5p:NubI irrespective of the bait (Figure 3-9; column 8 on panel B and column 6 on 
panel D), and no growth, or markedly reduced growth, was observed in the presence of 
Alg5p:NubG on SD-Trp-Leu-His-Ade medium (Figure 3-9; column 9 on panel B and 
column 7 on panel D). 
 
The ideal ABCB1 interactor would be able to rescue growth on SD-Trp-Leu-His-Ade plates 
only when co-expressed with ABCB1:Cub and not with FATP4:Cub or Alg5p:Cub. 
Supplementing the plates with the 3-AT inhibitor should inhibit any non-specific growth. 
Surprisingly, at 3mM 3-AT growth is inhibited for some cells transformed ABCB1:Cub and 
some of the putative interactors whereas in the cells transformed with the equivalent 
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interactor and FATP4:Cub or Alg5p:Cub growth is less affected (for example see Figure 
3-9; clone 44i on panel B and clone 63i on panel D). This observation did not change at 
different concentrations of 3-AT (data not shown). Such clones were therefore considered 
not to interact specifically with ABCB1 and were discarded. 
 
If colony growth on the SD-Trp-Leu-His-Ade plates was not a good discriminating 
phenotype, then the colony colour on SD-Trp-Leu was used to gauge the specificity and 
strength of interaction. The colonies in the top row on panels A and C, where ABCB1 was 
co-expressed with its putative interactors or the positive control Alg5p:NubI, were 
expected to be white or faint pink, while colonies in which any of the candidate preys were 
co-expressed with either FATP4:Cub (second row on Figure 3-9 panels A and C) or 
Alg5p:Cub (third row on Figure 3-9 panels A and C) were expected to  be red because of 
the accumulation of the coloured, adenine shunt intermediate. A similar result is anticipated 
when any of the three baits (ABCB1:Cub, FATP4:Cub, Alg5p:Cub) is co-expressed with 
the negative control Alg5p:NubG (Figure 3-9; column 9 on panel A and column 7 on panel 
C; the variability in the colour phenotype is evident here with ABCB1 and Alg5p colonies 
turning red and the FATP4 remaining a paler colour, so results should be interpreted with 
care). In Figure 3-9A and C, the colonies transformed with ABCB1:Cub and any of its 
putative interactors were red or faint pink in colour (for example see Figure 3-9; clones 29i 
and 44i on panel A and clones 33i and 63i on panel C). Pale colouration may be indicative 
of a strong interaction but in the cases where this was observed it also occurred in the 
colonies transformed with the candidate interactor and either of the two negative control 
baits (for example see Figure 3-9; clone 4i on panel A and clone 33i on panel C). The 
results of this experiment for all 29 putative interacting proteins are summarised in the 
“colour” section of Table 3-1. 
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This experiment was designed to discriminate between specific ABCB1-interacting partners 
and candidates that would interact with any bait (i.e. “sticky” proteins or proteins generally 
involved in membrane protein translation, translocation and trafficking). 
 
A list of the “sticky” proteins that tend to come up in screens using the SU-YTH system is 
available online (http://www.dualsystems.com/support/highly-connected-interactors-in-
the-dualmembrane-system.html) but none of those isolated from the NubG-X screen 
presented here appears on this list. One could argue that the isolated interactors are 
involved in a translation, folding or trafficking pathway common to all the baits. Although  
 
 
Figure 3-9. Assessment of the specificity and strength of interaction between ABCB1:Cub bait and 
the putative interacting candidates (“preys”). 
Yeast cells were co-transformed with “preys” and either the original ABCB1:Cub bait or one of the 
negative control vectors FATP4:Cub and Alg5p:Cub. Growth was evaluated on SD-Trp-Leu-His-Ade 
plates supplemented with 3mM 3-AT. Accumulation of coloured shunt intermediate was examined 
on SD-Trp-Leu plates. NubI: positive control (Alg5p:NubI), NubG: negative control (Alg5p:NubG) as 
described in the text. 
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this is unlikely to be true of all candidates, VAPB (vesicle-associated, membrane protein-
associated protein B), SERP1/RAMP4 (stress-associated endoplasmic reticulum protein 
1/ribosome-associated membrane protein 4) and Ergic32 (endoplasmic reticulum-Golgi 
intermediate compartment protein 32) were among the putative interactors isolated and are 
all involved in the general folding and trafficking of proteins (Breuza et al., 2004, Hori et 
al., 2006, Lev et al., 2008, Nishimura et al., 1999, Yamaguchi et al., 1999a). Other “false 
positives” may include factors that drive the direct activation of genes in the nucleus. One 
such candidate could be STAT6 (signal transducer and activator of transcription 6) which 
was isolated several times from the NubG-X library screen. It is a member of a family of 
transcription factors that reside in the cytoplasm and accumulate in the nucleus upon 
activation/phosphorylation by tyrosine kinases in response to extracellular signals 
(Bromberg and Darnell, 2000, Levy and Darnell, 2002). STAT6 may therefore, directly or 
indirectly, influence transcription of the reporter genes independently of the bait protein. 
Even if this is not the case, STAT6 appears significantly less potent in the presence of 
ABCB1, where colonies are red on SD-Trp-Leu media, than with FATP4 or Alg5p which 
are much paler, indicating a distinct lack of specificity for ABCB1. 
 
The yeast system employed in this project proved to be unfruitful for identifying specific 
interaction partners for ABCB1 as all candidates have been ruled out as false positives or 
non-specific. However, it has been demonstrated that it can be used to screen for 
regulators of FATP4 and CD36 (Wharton J., and Linton K. J., unpublished data). In Figure 
3-10, an example of the system’s capacity to discriminate between a “true” and a “false” 
FATP4 putative interacting partner is shown. 
 
The yeast are red when co-expressing the LPL:NubG (lipoprotein lipase) “prey” and each 
of the three “bait” vectors (FATP4:Cub used as the bait for the library screen, CD36:Cub 
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used as a bait for the CD36 library screen (Snippe M., personal communication) and 
ABCB1:Cub used as a bait for the ABCB1 library screen described in this report) on the 
SD-Trp-Leu plates indicating that there is little or no interaction between LPL and each 
“prey” (Figure 3-10A). This is consistent with the lack of growth on the SD-Trp-Leu-His-
Ade medium. However, when cells co-express YIP1B:NubG (Yip1 interacting factor 
homolog B) “prey” and the “bait” vectors a different result was obtained. A white colony is 
apparent when FATP4:Cub and YIP1B:NubG vectors are co-expressed whereas a red
 
 
Figure 3-10. Specificity and strength of interaction between FATP4:Cub bait and two of the 
putatively interacting candidates (“preys”). 
Yeast cells were co-transformed with “preys” (LPL:NubG or YIP1B:NubG) and either the original 
FATP4:Cub bait or the negative controls CD36:Cub and ABCB1:Cub. Growth was evaluated on SD-
Trp-Leu-His-Ade plates supplemented with 3mM 3-AT. Accumulation of coloured shunt 
intermediate was examined on SD-Trp-Leu plates. LPL: lipoprotein lipase, YIP1B: Yip1 interacting 
factor homolog B. 
 
colony is observed with the YIP1B:NubG prey and the CD36:Cub or the ABCB1:Cub 
baits (Figure 3-10C) signifying a strong and specific interaction between FATP4 and 
YIP1B and a lack of interaction between YIP1B and either CD36 or ABCB1. Further 
confirmation is provided when the co-transformed cells were grown on SD-Trp-Leu-His-
Ade medium. Very good growth is achieved for the cells co-transformed with FATP4:Cub 
and YIP1B:NubG vectors but poor growth was observed for cells co-transformed with the 
 The ABCB1 “interactome” 
   
144 
 
YIP1B:NubG vector and either of the CD36:Cub or ABCB1:Cub vectors (Figure 3-10D). 
It was later shown that YIP1B could be co-immunoprecipitated from mammalian cells with 
FATP4 (Wharton J., and Linton K. J., personal communication). 
 
3.3 Discussion 
ABCB1, a multispecific efflux transporter, has a role in normal physiology to protect the 
body against the harmful effects of xenotoxins. Overexpression of this well-studied 
member of the ABC superfamily can confer MDR in cancer patients (Gottesman et al., 
2002, Higgins, 2007). The aim of this aspect of my project was to utilise the SU-YTH 
system to identify novel regulators of the MDR ABCB1 with a view to studying their 
effects on ABCB1 trafficking and function. Unfortunately, the candidates isolated from 
two adult mouse cDNA library screens proved not to interact with ABCB1 in a specific 
manner. 
 
Before screening for putative interacting partners it was considered important to 
demonstrate expression of the “bait” protein. The ABCB1:Cub fusion protein could not be 
detected by western blotting (Figure 3-4) or by function (i.e., resistance to the antifungal 
FK506; Section 3.2.1.4) but was shown to be expressed by the “NubI/NubG” test (Figure 
3-3). A plausible explanation for this ambiguity may lie in two of the main design features 
of the bait vector.  First, the vector is a centromeric plasmid that carries an ARS 
(autonomously replicating sequence) origin of replication and one CEN (centromeric 
locus) thus it is maintained at a maximum of two copies per cell. Second, CYC1 is a weak 
promoter which only allows for low levels of bait protein expression (Iyer et al., 2005). It 
has been demonstrated previously that overexpression of the bait protein can result in 
unstable and mislocalised fusion protein, and also to activation of the reporter genes in the 
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absence of an interacting prey (Miller et al., 2005). These two characteristics are therefore 
crucial to minimise the number of false-positives due to self-activation of the bait. 
Furthermore, ABCB1 has been expressed successfully in yeast by other groups and shown 
to function as a drug efflux pump, however in these prior experiments the ABCB1 protein 
was overexpressed (Goodfellow et al., 1996, Raymond et al., 1994, Saeki et al., 1993),  
 
There is evidence, both direct and indirect, that ABCB1 interacts with several different 
proteins (Elliott et al., 2005, Goodfellow et al., 1996, Jodoin et al., 2003, Ortiz et al., 2004, 
Sardini et al., 1994, Valverde et al., 1992). In an attempt to demonstrate the interaction of 
ABCB1 with caveolin-1 and validate the SU-YTH system, the ABCB1:Cub bait vector was 
co-expressed with the Cav:NubG prey vector in the NMY51 yeast strain. Unfortunately no 
interaction was detected. Caveolin-1 has been shown to function when fused, either N- or 
C-terminally, to GFP (Razani et al., 1999, Volonte et al., 1999) and to be able to interact 
with the Orf3a viral protein in the Y2H system (Padhan et al., 2007). The consensus N-
terminal caveolin-1-binding motif ΦXXXXΦXXΦ (where Φ = F, Y or W and X = any 
amino acid) has been proposed to be between amino acid residues 36 and 44 in ABCB1 
(36-FTMFRYAGW-44) indicating that an interaction between caveolin-1 and ABCB1 
likely occurs at the cytosolic N-terminus of ABCB1 (Demeule et al., 2000). Experiments 
performed in Cos-7 cells demonstrated that mutations in that domain do not affect the 
expression levels of ABCB1 but reduced its interaction with caveolin-1 by up to 48% as 
shown by co-immunoprecipitation assays (Jodoin et al., 2003). The Cav:Nub fusion protein 
was detected in the yeast by western analysis but whether or not the fusion protein is able 
to form functional caveolin in the yeast plasma membrane is not known. The available 
evidence suggests that it should have been possible to detect an interaction between 
ABCB1:Cub and Cav:Nub in the SU-YTH system, however, none was detected and it is 
difficult to reach a definitive conclusion from negative data.  
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ABCB1 has been shown to interact directly with PKCα (Goodfellow et al., 1996). In an 
effort to demonstrate this interaction, the PKCα cDNA was C-terminally fused to NubG. 
Fusion of large coding sequences to either end of PKCα has not proven to affect its 
normal folding and function (Ng et al., 1999, Prevostel et al., 2000) therefore the fusion of 
NubG to its carboxy-terminus was not expected to affect its behaviour. Similar to the 
caveolin-1 co-expression experiment, an interaction between PKCα and ABCB1 could not 
be demonstrated in the SU-YTH system. However, the interaction between ABCB1 and 
PKCα might be dependent on the activation of the latter, for example by phorbol ester 
(Castagna et al., 1982). Heterologous expression of functional mammalian PKC isoforms 
has been demonstrated in yeast in the presence of cell-membrane permeable activators 
such as phorbol esters (Parissenti and Riedel, 2003). The presence of such activators on the 
selective plates might have enabled the detection of an interaction between ABCB1 and 
PKCα but this was not tested. 
 
ABCB1 is highly expressed in the canalicular membrane of the hepatocyte (Thiebaut et al., 
1987). Screening of two liver cDNA expression libraries, NubG-X and X-NubG, identified 
a total 130 and 12 colonies, respectively, likely to express an interacting protein pair. The 
library plasmids encoding the putative interactors were isolated, sequenced and 
retransformed back into yeast cells already carrying the ABCB1:Cub vector in an attempt to 
replicate the findings (Figure 3-8). The sequence data from the candidates isolated from the 
X-NubG screen revealed that only ubiquitin was cloned from the expression library. 
Recurrent isolation of the N-terminal fragments of wild-type ubiquitin has been reported to 
be a common problem when using X-NubG libraries and is a much less frequent problem 
when using NubG-X libraries but the reason behind this is unknown (Iyer et al., 2005). It is 
not clear why no plausible candidates were picked out in the X-NubG screen but similar 
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screens with an X-NubG heart library have also provided few candidates for interaction 
with CD36 or FATP4 (Snippe M.; Wharton J., and Linton K. J.; personal communication). 
 
Sequence data of the putative interactors from the NubG-X libary screen, in silico analysis 
and retransformation into ABCB1:Cub-bearing cells (Figure 3-8) identified 29 possible 
ABCB1-interacting proteins. These proteins are listed in Table 3-1. One would have 
expected to detect PKCα, caveolin-1 or HAX-1 based on the evidence of a physical 
association between ABCB1 and PKCα (Goodfellow et al., 1996), caveolin-1 (Jodoin et al., 
2003) and HAX-1 (Ortiz et al., 2004). As discussed earlier, the association between ABCB1 
and PKCα may depend on activation of the latter. The library screen was not performed in 
the presence of a phorbol ester which may provide for a plausible explanation as to why 
PKCα was not detected. The downregulation of ABCB1 function by caveolin-1 was 
detected at the blood-brain barrier (Jodoin et al., 2003) whereas, here, an adult human liver 
cDNA library was used for the screen. Although caveolin-1 has been shown to be 
expressed in membrane microdomains (caveolae) at the canalicular membrane of rat 
hepatocytes (Ismair et al., 2009), it is possible that ABCB1 and caveolin-1 do not interact in 
hepatic cells. Interaction of HAX-1 and ABCB1 has been shown in rat liver cells by co-
immunoprecipitation (Ortiz et al., 2004). It is possible that this is species-specific and does 
not occur in human hepatocytes. It is also possible that other co-factors may be required 
for the correct trafficking of HAX-1 to the membrane which may not be present in the 
yeast or that the interaction may be indirect through a larger multiprotein complex. 
Furthermore, because of the way the cDNA libraries are constructed (Section 3.2.4.1), it is 
possible that only a part of HAX-1 was represented which may not be adequate for the 
interaction with ABCB1. 
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The strength and specificity of the interaction between ABCB1 and the 29 isolated 
candidates was assessed in comparison with two different control vectors (Figure 3-9 and 
Table 3-1). One encoding an unrelated FATP4:Cub fusion protein (Wharton J., personal 
communication) and the other a non-interacting Alg5p:Cub fusion protein (Dualsystems 
Biotech, Zurich, CH). The purpose of the controls was to ensure that the isolated prey 
proteins interact with the bait protein because of their specificity for ABCB1 and not 
simply due to their close proximity to any “bait” on the plasma membrane or in the 
ER/Golgi during folding and trafficking. The prey proteins did not discriminate between 
any of the bait controls and are therefore likely to be a mixture of proteins with a general 
role in protein folding and trafficking, such as VAPB, Ergic32 and SERP1/RAMP4, 
factors controlling gene transcription, such as STAT6, and proteins that based on our 
knowledge did not qualify as physiologically relevant regulators of ABCB1, for example the 
ferritin light polypeptide involved in the control of iron uptake/export in different tissues, 
or the Yip1 interacting factor (YIF1A) involved in the maintenance of the Golgi structure 
(Figure 3-9 and Table 3-1).  
 
A modified version of the SU-YTH system (iMYTH; integrated split-ubiquitin membrane 
yeast two hybrid) has been used successfully to screen for potential regulators of a member 
of the yeast ABCC subfamily (Ycf1p) in yeast (Paumi et al., 2007). In humans, the ABCC 
subfamily comprises 13 members, 9 of which (ABCC1-6 and ABCC10-12) are multidrug-
resistance associated proteins (MRPs) and are involved primarily in the export of anionic 
conjugates from cells (Borst et al., 1999, Kruh and Belinsky, 2003). The sulphonylurea 
receptors ABCC8 and ABCC9 (SUR1 and SUR2 respectively) act as ion channel regulators 
and control the gating of the K+ channel Kir6.2 (Nichols, 2006). ABCC7 (most widely 
known as CFTR) is expressed at the apical border of epithelial cells of exocrine glands 
where it functions as a chloride channel (Gadsby et al., 2006, Vankeerberghen et al., 2002). 
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Ycf1p is a vacuolar glutathione S-conjugate pump involved in the detoxification pathway in 
yeast cells (Li et al., 1996) which displays a 63% sequence similarity (at the amino acid level) 
to ABCC1 (Szczypka et al., 1994). Furthermore, it has been demonstrated that Ycf1p 
mutants can be complemented by heterologous expression of mammalian ABCC1 in yeast 
(Tommasini et al., 1996). In the approach undertaken by Paumi et al. (2007), Tus1p, an 
exchange factor for the small GTPase Rho1p involved in actin cytoskeleton remodelling 
during bud growth in yeast (Schmelzle et al., 2002), was isolated as a potential Ycf1p 
regulator. The authors were also able to show that the effect of Tus1p on Ycf1p was 
specifically through Rho1p demonstrating the modulation of an ABC transporter by a 
cytosolic factor.  Nevertheless, their modified iMYTH approach involved a native yeast 
protein and the bait was integrated into the yeast genome ensuring an endogenous level of 
expression to maintain the correct stoichiometry of protein complexes and avoid 
inappropriate interactions. 
 
The use of other proteins (FATP4 and CD36) to discriminate between specific and non-
specific interactors of ABCB1 (and preys that autoactivate) was useful in this study, 
providing a rapid approach to corroborate (or dismiss) interactions with ABCB1. Following 
a negative outcome, the decision was taken to discontinue this line of study as the 
likelihood of identifying a specific factor for ABCB1 maturation or regulation was remote.  
  
 
Chapter Four 
 
 
 
4 Expression of ABCB4 
wild-type and non-
synonymous genetic 
variants in HEK293T cells 
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4.1 Introduction 
Progressive familial intrahepatic cholestasis (PFIC) refers to a group of autosomal recessive 
liver disorders of childhood presenting with intrahepatic cholestasis within the first year of 
life which can lead to severe growth retardation and ultimately to death from liver failure. 
Progression to liver failure may occur within the first decades of life and in its most severe 
form, orthotopic liver transplantation represents the only treatment for patients (Davit-
Spraul et al., 2009). 
 
PFIC can be subdivided in three types which differ in their clinical presentation, liver 
histology and biochemical features (i.e. bile composition, serum gamma-glutamyltransferase 
activity and level of cholesterol in the serum) (Davit-Spraul et al., 2009, Jacquemin, 1999, 
Morotti et al., 2011). PFIC type 1 (or FIC1 deficiency) is due to mutations in ATP8B1 
(FIC1), PFIC type 2 (or ABCB11 deficiency) is due to mutations in ABCB11 (BSEP) and 
PFIC type 3 (or ABCB4 deficiency) is due to mutations in ABCB4 (or MDR3) (for a more 
detailed account on the identification of the three genes and their link to cholestatic liver 
disease see Chapter 1; Section 1.13.5.3). 
 
As described in Chapter 1 (Section 1.13.5.3.2), ABCB4 is a phosphatidylcholine (PC) 
translocase which functions at the canalicular membrane of the hepatocyte (Smith et al., 
1998, van Helvoort et al., 1996). Lipid secreted from the liver into the bile duct protects the 
liver from the detergent action of bile (Donovan et al., 1991). Consequently, mutations in 
ABCB4 are associated with a spectrum of liver diseases, ranging from the benign and 
episodic to the malign and fatal. In the rare and fatal condition, PFIC type 3 (PFIC3), the 
link between mutation and disease is clear, but in the majority of liver diseases the 
underlying causes are complex and include diet, physiological conditions such are 
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pregnancy or therapeutic drug use, as well as genetics (Oude Elferink and Groen, 2002, 
Oude Elferink and Paulusma, 2007, van Mil et al., 2005). In these cases, which include 
intrahepatic cholestasis of pregnancy (ICP or obstetric cholestasis), drug-induced 
cholestasis (DIC), low phospholipid-associated cholelithiasis (LPAC, a form of cholesterol 
gallstone disease), primary sclerosing cholangitis (PSC) and primary biliary cirrhosis (PBC), 
association with particular mutations in ABCB4 is implicated by human genetic studies and 
animal models, but critical evidence at the functional and mechanistic level of protein 
expression and floppase activity is lacking. 
 
Some insights into the functional consequences of ABCB4 mutation have been obtained by 
our group (Dixon et al., 2000) and more recently by the group of Michele Maurice in Paris 
(Delaunay et al., 2009) by mimicking clinically-relevant mutations in ABCB1 (the closest 
relative of ABCB4) and measuring the effect of the mutation on drug efflux by ABCB1. 
Although this approach can provide useful information on the possible effects of the 
mutations on ABCB4, it is limited and only relevant if the particular amino acid is 
conserved between the two proteins and performs the same function. Amino acid changes 
which influence PC binding or flopping, or responses to hormones of pregnancy, 
contraceptives or drugs are therefore ruled out. 
 
Critical evidence at the functional and mechanistic level of ABCB4 protein expression and 
floppase activity is lacking. This is because ABCB4 expression in vitro can be deleterious to 
recipient cells. This problem has been resolved recently, allowing for the transient 
expression of ABCB4 in naïve HEK293T cells. This is essential to analyse the phenotype 
of the large number of missense SNPs and has been achieved by co-expressing ABCB4 
with the ATP8B1/CDC50A flippase complex, which flips a different lipid, 
phosphatidylserine (PS), in the opposite direction to PC (Groen et al., 2011) [Chapter1; 
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Section 1.13.6.]. Co-expression of the ATP8B1/CDC50A PS flippase appears to stabilise 
the plasma membrane of the recipient cells in vitro (as it does the canalicular membrane in 
vivo), and allows expression and function of ABCB4 to be measured. I have exploited this 
method to analyse expression (by western blot), trafficking to the plasma membrane (by 
confocal microscopy) and lipid flopping activity (by bile salt-dependent extraction of 
radiolabelled PC into the culture medium) of 9 variant ABCB4 with missense SNPs that 
are implicated in the aetiology of liver disease (Table 4-1). 
 
a.a. 
Change 
Domain 
Relevant patient genotype 
where known 
Disease Class Reference 
A286V ICL2 S320F [on 2
nd
 allele] PFIC3 (Degiorgio et al., 2007) 
M301T MSH5 HET LPAC  (Rosmorduc et al., 2003) 
S320F MSH5 
A286V [on 2
nd
 allele] PFIC3 (Degiorgio et al., 2007) 
Y279X [on 2
nd
 allele] PFIC3 (Degiorgio et al., 2007) 
A953D [on 2
nd
 allele] + 
V444A [on ABCB11] (HET) 
LPAC to PFIC3 (Poupon et al., 2010) 
HOM LPAC (Rosmorduc et al., 2001) 
HOM LPAC (Rosmorduc et al., 2003) 
HOM ICP (Pauli-Magnus et al., 2004b) 
HET + V444A [on ABCB11] + 
-1G>T [on FXR] (HET) 
ICP  (Zimmer et al., 2009) 
HOM + V444A [on ABCB11] ICP (Keitel et al., 2006) 
HET ICP  (Bacq et al., 2009) 
E528D NBD1 
HET LPAC (Rosmorduc et al., 2003) 
HET LPAC (Nakken et al., 2009) 
HET ICP (Floreani et al., 2008) 
G535D NBD1 HET 
LPAC (juvenile) to 
ICP (2× pregnancy) to 
BC (at 47 years) 
(Lucena et al., 2003) 
R545C NBD1 Unknown PSC (Pauli-Magnus et al., 2004a) 
A546D NBD1 HET ICP (Dixon et al., 2000) 
L591Q NBD1 HOM LPAC (Rosmorduc et al., 2003) 
P1161S NBD2 
HOM LPAC (Rosmorduc et al., 2001) 
HET LPAC (Rosmorduc et al., 2003) 
Table 4-1. Summary of the 9 ABCB4 missense mutants analysed in this investigation. 
Where appropriate, additional mutations identified within the same patient(s) either on the other 
ABCB4 allele or on ABCB11, are indicated. a.a., amino acid; ICL, intracellular loop; MSH, 
membrane spanning helix; NBD, nucleotide-binding domain; PFIC, progressive familial intrahepatic 
cholestasis; LPAC, low phospholipid-associated cholelithiasis; ICP, intrahepatic cholestasis of 
pregnancy; BC, biliary cirrhosis; PSC, primary sclerosing cholangitis; HOM, homozygous; HET, 
heterozygous; c.HET, compound heterozygote; n/a, not available; FXR, farnesoid X receptor. 
 
These nine variants were chosen because they cover a wide range of liver disease 
phenotypes that have been linked to mutations in the ABCB4 gene. The S320F (c.959C>T) 
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variant has been implicated in three different disease phenotype; PFIC3 (Degiorgio et al., 
2007), LPAC (Rosmorduc et al., 2003, Rosmorduc et al., 2001) and ICP (Bacq et al., 2009, 
Keitel et al., 2006, Pauli-Magnus et al., 2004b). The E528D (c.1584G>C) variant has also 
been linked to more than one disease phenotypes; LPAC (Nakken et al., 2009, Rosmorduc 
et al., 2003) and ICP (Floreani et al., 2008). The A286V (c.857C>T) variant was identified 
in a PFIC3 patient as a compound heterozygous alteration with S320F (Degiorgio et al., 
2007). The M301T (c.902T>C), L591Q (c.1772T>A) and P1161S (c.3481C>T) variants 
have all been implicated in LPAC (Rosmorduc et al., 2003, Rosmorduc et al., 2001). The 
A546D (c.1637C>A) variant has been identified in an ICP patient (Dixon et al., 2000). The 
G535D (1605G>A) is unique in that it was found in a female patient presenting with 
juvenile cholelithiasis who then developed ICP during both of her pregnancies followed by 
biliary cirrhosis in adulthood (Lucena et al., 2003). Finally, the R545C (c.1633C>T) variant 
was identified as PSC-specific (Pauli-Magnus et al., 2004a). 
 
4.2 Results 
In this chapter the heterologous expression system for the transient expression of WT 
ABCB4 in HEK293T cells is described and optimised. In addition, the generation of the 9 
ABCB4 variants (summarised in Table 4-1), using site-directed mutagenesis, is outlined. 
Finally, the study of the expression level of the different variants in the HEK293T cell 
system is presented. 
4.2.1 Expression of wild-type ABCB4 in HEK293T cells 
Before attempting to characterise a number of ABCB4 variants in the heterologous 
expression system, it was important to demonstrate the expression of wild-type (WT) 
ABCB4 in HEK293T cells in the presence and in the absence of the ATP8B1/CDC50A 
PS flippase, recapitulating the results of a previous report to serve as a baseline for the 
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effect of the SNPs  (Groen et al., 2011). Success of the experiment is dependent on triple 
transfection of the recipient cells with high efficiency because each of the components is 
encoded on a separate plasmid. Cell density at the time of transfection can influence the 
transfection efficiency (i.e., the uptake of the PEI (polyethylenimine)-DNA complexes into 
the cells) and the expression levels of the genes of interest; therefore the optimal 
confluency at the time of transfection was investigated. 
4.2.1.1 Co-transfection of cells with ABCB4 and the ATP8B1/CDC50A PS flippase 
improves ABCB4 expression 
Initially, it was essential to confirm that the presence of the ATP8B1/CDC50A PS flippase 
improves the expression level of ABCB4 in HEK293T cells as previously reported (Groen 
et al., 2011). 
 
To this end, HEK293T cells were seeded on 6-well plates and transfected with the 
pcDNA3.1-ABCB4wt (coding for WT ABCB4) or pcDNA3.1-ABCB4_E558Q (coding for 
a Walker B motif mutant of ABCB4 that is likely to be deficient in ATP hydrolysis) 
mammalian expression vectors. Transfections were set up either in the presence (triple 
transfection) or in the absence (single transfection) of the pCI-neo-ATP8B1 (coding for 
ATP8B1) and pCI-neo-CDC50 (coding for CDC50A) mammalian expression vectors. In 
the case where cells were transfected with the ABCB4-expressing vector in the absence of 
the ATP8B1- and CDC50A-expressing vectors, the PEI:DNA ratio was kept constant by 
co-transfecting with the parental, empty form of the pcDNA3.1 vector. All vectors were 
kindly provided by Dr Marta Rodriguez-Romero (Groen et al., 2011). 
 
Both the pcDNA3.1 (Invitrogen) and the pCI-neo (Promega) vectors permit efficient and 
high-level expression of recombinant proteins in mammalian cells under the control of the 
human cytomegalovirus (CMV) immediate-early enhancer/promoter (Schmidt et al., 1990). 
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In addition, both vectors also contain the SV40 enhancer and early promoter region. The 
SV40 early promoter contains the SV40 origin of replication which induces transient, 
episomal replication of the vectors in cells constitutively expressing the SV40 large T 
antigen, e.g. HEK293T cells (Gluzman, 1981). 
 
The expression level of ABCB4 (WT or WB mutant) in the presence or in the absence of 
the ATP8B1/CDC50A PS flippase was assayed by western blotting using the monoclonal 
antibody C219 which recognises ABCB4 (Georges et al., 1990). C219 recognizes an 
internal, highly conserved amino acid sequence (VQEALD and VQAALD) found in 
ABCB4 (and ABCB1 and ABCB11). To allow comparison of the ABCB4 data, β-tubulin 
was employed as a loading control for the experiment. In the case where uneven loading is 
revealed (i.e., variations in the intensity of the signal detected for β-tubulin in the different 
samples), the level of ABCB4 detected was normalised against the level of β-tubulin. To 
achieve this, densitometry analysis was performed using the ImageJ image analysis software 
(http://rsb.info.nih.gov/ij/index.html). Initially, an arbitrary value for the level of intensity 
(i.e., density) of the bands was obtained by measurement of the number of pixels on a 
digital image of the loading control (β-tubulin) and ABCB4 blots (Figure 4-1; panel A). 
Next, the relative intensities of each of the loading control bands were calculated against a 
reference band. In this case the most intense band, based on its density, was selected as a 
standard and given the arbitrary value of 1. Finally, the density value of each of the ABCB4 
bands was multiplied by the relative value of the corresponding loading control to reflect 
the true band intensity which would have been detected for ABCB4 following equal 
loading of total protein. In doing so, a direct comparison between different samples was 
achieved. 
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No ABCB4 could be detected in the untransfected (UT) sample, indicating that HEK293T 
cells do not express endogenous ABCB4 (Figure 4-1; panel A, lane 5). WT ABCB4 was 
expressed 1.4-fold higher in the triple transfection as compared to the single (Figure 4-1; 
panel A, compare lane 1 with lane 2) when normalised against the loading control (Figure 
4-1; panel B). In contrast, the inactive WB mutant expressed 2.0× higher than WT ABCB4 
in the single transfection (Figure 4-1; panel A, lane 3) when normalised against the loading 
control (Figure 4-1; panel B). These data are in general agreement with previous results 
(Groen et al., 2011). Co-expression of ABCB4 with ATP8B1/CDC50A in HEK293T cells 
therefore increases the expression level of ABCB4, whereas it has little effect on the 
inactive WB mutant (Figure 4-1; panel A, lanes 3 and 4, and panel B).  
 
 
Figure 4-1. Expression of WT and mutant (WB, E558Q) ABCB4 in the absence or in the presence of 
the ATP8B1/CDC50A PS flippase. 
(A) HEK293T cells (3.0×10
5
) were seeded on 6-well plates and transfected 24 h post-seeding. The 
vectors encoding either WT or mutant/inactive (WB) ABCB4 were co-transfected with the vectors 
coding for ATP8B1 and CDC50A where indicated. Samples were harvested 48 h post-transfection 
and the level of ABCB4 was determined by western blotting using the anti-ABCB4 monoclonal 
antibody C219 (upper panel). No ABCB4 could be detected in the untransfected (UT) sample. β-
tubulin was used as a loading control (lower panel). Co-expression of ABCB4 and ATP8B1/CDC50A 
improves the level of ABCB4 in the samples (compare lanes 1 and 2). The presence of 
ATP8B1/CDC50A has little effect on the level of the WB mutant detected in the samples (compare 
lanes 3 and 4). The WB mutant expresses at a higher level than WT ABCB4 in the single 
transfection samples (compare lanes 1 and 3). Apparent molecular masses are indicated in kDa. (B) 
Densitometry analysis of ABCB4 in the samples shown in panel A. The relative density of ABCB4 
in each sample was corrected against the β-tubulin loading control and plotted using the WT 
ABCB4 single-transfected cell population as a reference. T1, single strasfection; T3, triple 
transfection. Densitometry was performed in ImageJ (http://rsb.info.nih.gov/ij/index.html) and 
plotted using GraphPad Prism 5.01. The experiment was performed three times (n = 3) for 
statistical analysis by one-way ANOVA (analysis of variance) in the GraphPad PRISM
®
 V5.0 
software. **P<0.01, ***P<0.005 (with respect to wild-type single transfection); error bars, standard 
error of the mean. 
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Together, these data confirm that the presence of WT ABCB4 is deleterious to HEK293T 
cells suggesting a negative selective pressure against ABCB4 function. In the presence of 
the ATP8B1/CDC50A PS flippase, the deleterious effect of ABCB4 function is alleviated 
allowing higher levels of ABCB4 in the cells (see also Section 1.13.6). The inactive form of 
ABCB4 (the WB mutant), is detected in the single- and triple-transfected cell population 
approximately 1.4-fold higher than WT ABCB4 achieved in the triple transfection. As the 
WB mutant is thought to be catalytically inactive, it is expected to have limited influence on 
the lipid composition of the plasma membrane. Consequently, in HEK293T cells the 
expression of this mutant is tolerated more than the expression of the WT protein even in 
the presence of ATP8B1 and CDC50A (Figure 4-1; panel B). 
4.2.1.2 Optimisation of HEK293T seeding density for efficient expression of ABCB4 
In the experiments described above, the expression of ABCB4 (WT or WB mutant) was 
tested in the absence or in the presence of the ATP8B1/CDC50 PS flippase which had 
been shown previously to increase the level of ABCB4 in HEK293T cells and improve 
plasma membrane localisation (Groen et al., 2011). Although the expression of WT 
ABCB4 was improved with concomitant expression of ATP8B1/CDC50A, it did not 
appear to be as high as reported by Groen et al. This could be due to inefficient 
transfection. Cell density at the time of transfection can have an important influence on the 
transfection efficiency. The expression of WT and WB ABCB4 in HEK293T cells was 
therefore tested at different cell densities. 
 
HEK293T cells were seeded on 6-well plates at 1.5, 3.0 or 6.0×105 cells per well, 24 h prior 
to transfection. The expression level of ABCB4 (WT or WB mutant) was assayed by 
western blotting using β-tubulin as a loading control (Figure 4-2; panel A). The results of 
this analysis were plotted as the relative level of ABCB4 in each well using the level of 
 Expression studies of ABCB4 missense variants 
 
159 
 
ABCB4 in the aliquot collected from the wells seeded with 1.5×105 cells as a reference 
(Figure 4-2; panel B). The analysis was achieved by means the densitometry method 
described in Section 4.2.1.1. 
 
As shown in Figure 4-2, the highest level for WT ABCB4 expression, when normalised 
against the β-tubulin loading control, was obtained at a seeding density of 3.0×105 cells per 
well (Figure 4-2; panel B), suggesting that wells can be over- and under-seeded. The 
optimal seeding density for transfection and efficient expression of ABCB4 variants in all 
future experiments was thus selected as 3.0×105 cells per well. As shown later, optimisation 
of the seeding density resulted in a high transfection efficiency of HEK293T cells (Figure 
4-3) and increased the ratio between the WT ABCB4 detected in the triple transfection 
over the single transfection (Figure 4-5).  
 
 
Figure 4-2. Optimisation of seeding density for efficient transfection of HEK293T cells. 
(A) HEK293T cells, 1.5×10
5
, 3.0×10
5
 or 6.0×10
5
, were seeded on 6-well plates and transfected 24 h 
post-seeding. The vectors encoding either WT or mutant/inactive (WB) ABCB4 were co-transfected 
with the vectors coding for ATP8B1 and CDC50A. Samples were harvested 48 h post-transfection 
and the level of ABCB4 was determined by western blotting using the anti-ABCB4 monoclonal 
antibody C219 (upper panel). No ABCB4 could be detected in the untransfected (UT) sample. β-
tubulin was used as a loading control (lower panel). The mature, fully glycosylated form of ABCB4 
migrates at 170 kDa. The second, lower molecular weight band (~140 kDa) detected in the WB 
sample corresponds to the immature, unglycosylated form of ABCB4 (see Section 4.2.4). Highest 
level of ABCB4 was detected in the samples collected from the wells seeded with 3.0×10
5
 cells. 
Apparent molecular masses are indicated in kDa. (B) Densitometry analysis of ABCB4 in the 
samples shown in panel A. The relative density of ABCB4 in each sample was corrected against 
the β-tubulin loading control and plotted using the sample collected from the wells seeded with 
1.5×10
5 
cells as a reference. Densitometry was performed in ImageJ 
(http://rsb.info.nih.gov/ij/index.html) and plotted using GraphPad Prism 5.01. 
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A high level of protein was also detected in the samples for the WB mutant (1.36× that of 
WT) when transfected at the same cell density (Figure 4-2). In the WB sample, two forms 
of the protein were evident which differed in their glycosylation status (Figure 4-2; panel 
A). The top, high molecular weight band, corresponds to the mature, fully glycosylated 
form of the protein, whereas the bottom, lower molecular mass band represents the 
unglycosylated form of the protein (see Section 4.2.4). 
4.2.1.3 The HEK293T cells are efficiently transfected at optimal seeding density 
Having determined the seeding density for optimal expression of the constructs, it was 
important to assay the transfection efficiency under the experimental conditions used for 
the triple transfection. This was performed using flow cytometric analysis. 
4.2.1.3.1 Flow cytometric analysis 
In a flow cytometer a cell suspension is taken up into the sample stream of the flow 
cytometer under negative pressure. This sample stream is then mixed with the sheath 
stream and injected into the flow manifold. Within the flow manifold, the cells are 
subjected to a laser beam which excites any fluorophores associated with the cell. Light 
emitted by the fluorophores passes through a series of filters onto photomultipliers, 
enabling the measurement of emissions at specific wavelengths. In addition, the forward- 
and sideways-scattering of the excitation light can be used to measure the size, granularity, 
and morphology of each cell that passes through the manifold. All these individual 
measurements are recorded by the data processing unit, and multiple scattering or 
fluorescence signals can be used to divide, or ‘gate’, the cells into subpopulations for 
further analysis, or to examine cellular physiology. 
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4.2.1.3.2 Measurement of HEK293T transfection efficiency 
Flow cytometry can be used to assess cell-surface expression of membrane glycoproteins. 
Lack of an antibody that specifically recognises an extracellular epitope of ABCB4 means 
that a direct measurement of the level of plasma membrane localisation of the protein 
would be difficult. A different experiment was therefore employed as a means of assaying 
the transfection efficiency of HEK293T cells. 
 
 
Figure 4-3. Transfection efficiency of HEK293T cells. 
HEK293T cells were transfected with a total 7.5 μg of plasmid DNA at a 1:1:1 ratio of pEGFP-
C1:pECFP-C1:pEYFP-C1. The cells were harvested 48 h post-transfection. Fluorescence data was 
acquired on a BD FACSAria II flow cytometer (Becton Dickinson). Cells (10,000) were gated for 
normal size and granularity. The EGFP fluorophore was excited at 525 nm, the ECFP fluorophore 
was excited at 582 nm and the EYFP fluorophore was excited at 450 nm. Emission spectra were 
measured using the FL-1 channel. Cells from the ECFP/EGFPexpressing population (left panel) 
were also gated for EYFP expression (blue trace; right panel) and compared to untransfected cells 
(grey trace; right panel). Flow cytometry data were analysed using the FlowJo software package 
(Tree Star, Ashland, OR, USA). Under these conditions, 70% of the cells were successfully 
transfected of which 100% were positive for all three fluorescent markers. 
 
HEK293T cells (3×105) were transiently transfected with 2.5 µg each of plasmids that 
express, respectvely, an enhanced green fluorescent protein (EGFP), an enhanced yellow 
fluorescent protein (EYFP), and an enhanced cyan fluorescent protein (ECFP) under the 
conditions used for the ABCB4/ATP8B1/CDC50A triple transfection. Forty eight hours 
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post-transfection, the cells were analysed by flow cytometry. The level of expression of 
each fluorophore was measured in 10,000 cells of normal size and granularity. Seventy 
percent (70%) of the analysed cell population was positive for ECFP and EGFP (Figure 
4-3; left panel). The ECFP/EGFP-positive (ECFP+/EGFP+) population was then gated 
for EYFP expression and compared to the untransfected population. One hundred percent 
(100%) of the ECFP+/EGFP+ population was also positive for EYFP (Figure 4-3; right 
panel). In this experiment, the conditions for efficient triple transfection of HEK293T cells 
have been demonstrated which should be sufficient to allow measurement of ABCB4 
function. 
 
These data, together with the expression difference of WT ABCB4 in the single and triple 
transfected cells suggests that a cell-based system for the transient expression of ABCB4 is 
achievable in the presence of the ATP8B1/CDC50A PS flippase. The difference in ABCB4 
expression in the single, compared to the triple transfection could also provide tentative 
insights into the functionality of the ABCB4 variants. Thus, variants that express equally 
well in single and triple transfections are likely to be relatively inactive for flopping PC. 
This system was therefore applied to the characterisation of ABCB4 variants involved in 
the development of cholestatic liver disease. 
4.2.2 Generation of ABCB4 mutants implicated in cholestatic liver disease 
The 9 ABCB4 variants selected for characterisation (Table 4-1) using the HEK293T 
heterologous expression system harbour missense mutations identified in patients suffering 
from one or more of the several forms of cholestatic liver. None of the mutations is 
located in TMD2. There is one mutation in NBD2 (P1161S) and five in NBD1 (E528D, 
G535D, R545C, A546D and L591Q). The rest of the mutations are centred on MSH5 
(M301T, S320F) and its preceding ICL (A286V).   
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The mutations were introduced into pcDNA3.1-ABCB4wt by site-directed mutagenesis. 
However, because the mutagenesis protocol is not 100% efficient, not all plasmid 
molecules in the reaction will be modified therefore generating both mutant and non-
mutant progenies. As a result, it is helpful to be able to quickly and conveniently identify 
the mutated plasmid DNA isolated from the bacterial colonies. 
 
Mutagenic oligonucleotides are often designed to introduce, along with the desired non-
synonymous mutation, a synonymous change in the same vicinity of the coding region. 
Although it does not change the encoded amino acid, the secondary change is designed to 
remove or introduce a restriction site. This alters the restriction digest profile of the mutant 
plasmid DNA. This type of manipulation allows for the rapid screening of putative mutant 
plasmids (isolated from transformed E. coli), using specific restriction endonucleases. In 
silico analysis of the expected DNA sequence of all mutants generated for the purpose of 
this study revealed that the non-synonymous mutation introduced to the WT ABCB4 
coding sequence, serendipitously resulted in a change of the restriction digest profile of 
each mutant, except for ABCB4_A286V (c.857C>T). Consequently, no further changes 
were introduced to the design of these mutagenic oligonucleotides to allow for rapid 
screening of putative mutants. In the case of ABCB4_A286V, no restriction analysis was 
performed and mutants were identified by DNA sequencing. Following the identification 
of plasmid DNA likely to harbour the desired mutation by restriction analysis (or 
sequencing over the mutation site), the integrity of the entire cDNA in the construct was 
validated by DNA sequencing to ensure no additional mutations were introduced during 
the mutagenesis or replication process in E. coli.  
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Figure 4-4 depicts an example of the screening process. Within the pcDNA3.1-ABCB4wt 
plasmid, there are four BstXI restriction sites (CCANNNNN▼NTGG; where N = A or C 
or G or T). When digested with the BstXI restriction endonuclease (NEB, UK) and the
 
 
Figure 4-4. Screening for putative ABCB4 mutant plasmids. 
(A). Restriction digest profile of plasmid DNA of WT ABCB4 (lane 1) and G535D (lanes 2-8) putative 
mutants. Each sample (1 µg) was digested with BstXI restriction endonuclease for 90 min at 37
o
C 
and run on 0.75% (w/v) agarose gel. For WT ABCB4, four fragments were expected: 7269, 1642, 356 
and 14 nucleotide bases in length. For the G535D mutants, three fragments were expected: 7269, 
1998 and 14 nucleotide bases in length. The candidates in lanes 2, 3, 5, 7 and 8 reveal the 
restriction digest profile expected for plasmid DNA carrying the desired mutation (c.1605G>A). The 
putative mutants in lanes 5, 7 and 8, highlighted by a red asterisk, were subjected to DNA 
sequencing. (B). Electropherogram of DNA sequencing of wild-type ABCB4 and the putative 
mutant in lane 8. A guanine (G) at position 1605 of the ABCB4 coding region (left panel) is replaced 
with an adenine (A) (right panel) following successful mutagenesis. The integrity of the whole 
ABCB4 G535D coding region was verified by careful inspection of the electropherograms. 
 
sample subjected to agarose gel electrophoresis, four fragments of different sizes are 
therefore expected: 7269, 1642, 356 and 14 nucleotide bases in length (Figure 4-4A; lane 1) 
 Expression studies of ABCB4 missense variants 
 
165 
 
[note: the smallest band (14 base pairs) is too small to detect]. The ABCB4_G535D codon 
change removes one BstXI restriction site from the ABCB4 coding region. Consequently, 
only three fragments are expected: 7269, 1998, 14. Out of the seven individual plasmid 
samples digested, five had the anticipated profiles (Figure 4-4A; lanes 2, 3, 5, 7 and 8) of 
which three (Figure 4-4A; lanes 5, 7 and 8) were sequenced to confirm the presence of the 
desired mutation. The amino acid change at position 535 of the ABCB4 polypeptide is a 
result of a point mutation whereby a guanine (G) at position 1605 of the ABCB4 coding 
region is replaced with an adenine (A). This results in the replacement of the wild-type 
glycine (Gly, G) residue with an aspartic acid (Asp, D) residue. DNA sequencing of the 
putative mutant depicted in lane 8 of Figure 4-4A confirmed that the c.1605G>A 
modification was present (Figure 4-4B; right panel). Following careful inspection of the 
whole ABCB4 coding region no further changes were detected, therefore this plasmid was 
selected for downstream applications. 
 
Mutant 
Change 
Introduced 
Screen with 
# of Restriction Sites Fragments 
WT 
Putative 
Mutant 
WT 
Putative 
Mutant 
G535D BstXI (-) BstXI 4 3 
7269, 1642, 356, 
14 
7269, 1998, 14 
M301T NcoI (-) NcoI 5 4 
3342, 3331, 1279, 
735, 594 
3342, 3331, 
1873, 735 
E528D BsmAI (+) BsmAI 9 10 
3136, 2460, 1503, 
776, 770, 328, 192, 
74, 42 
2460, 1776, 
1503, 1360, 776, 
770, 328, 192, 
74, 42 
L591Q AccI (-) AccI 5 4 
4324, 2185, 1420, 
1345, 7 
5669, 2185, 
1420, 7 
P1161S TthIIII (+) TthIIII 1 2 9281 7513, 1768 
R545C PmlI (-) PmlI & NheI-HF 1 (each) 1 (NheI) 7553, 1728 9281 
S320F BamHI (-) BamHI 2 1 8265, 1016 9281 
A546D SexAI (+) SexAI 2 3 7085, 2196 6234, 2196, 851 
A286V None n/a n/a n/a n/a n/a 
Table 4-2. Restriction digest profiles of WT and mutant vector (pcDNA3.1) DNA carrying the ABCB4 
coding region. 
DNA base changes introduced a restriction site change in all but one of the non-synonymous 
mutants. This change was used to screen for putative mutants during the mutagenesis 
experiments. Addition or removal of a restriction site is indicated with a (+) or a (-) sign, 
respectively, next to the change introduced. The expected fragments in the WT and putative 
mutants are also outlined. In the A286V variant, no alteration in the restriction profile was 
introduced by the mutation and putative mutants were confirmed by DNA sequencing of the 
ABCB4 coding region. WT, wild type; n/a, not applicable. 
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The same process was exploited to obtain all nine of the desired ABCB4 non-synonymous 
genetic variants. As stated earlier, eight of the mutations introduced to the ABCB4 coding 
region resulted in a change of the restriction profile. Specifically, the ABCB4_M301T 
(c.902T>C) codon change removes one of the five NcoI sites; the ABCB4_E528D 
(c.1584G>C) codon change inserts one BsmAI site resulting in a total of nine BsmAI 
restriction sites; the ABCB4_L591Q (c.1772T>A) codon change removes one of the five 
AccI sites; the ABCB4_P1161S (c.3481C>T) codon change inserts one TthIIII resulting in a 
total of two TthIIII restriction sites; and the ABCB4_R545C (c.1633C>T) codon change 
removes the unique PmlI site (Table 4-2). The ABCB4_A546D (c.1637C>A) and 
ABCB4_S320F (c.959C>T) were provided by Dr Marta Rodriguez-Romero (personal 
communication) and reconfirmed by DNA sequencing. 
4.2.3 Expression of ABCB4 mutants in HEK293T cells 
To investigate the role of ABCB4 in the development of cholestatic liver disease I have 
introduced a series of mutations into the transporter, that are found in the human 
population and linked to various liver conditions (Table 4-1). The 9 non-synonymous 
ABCB4 variants gave a range of different mutant phenotypes which could be divided into 3 
categories: 1. WT-like (active or unaffected) mutants, 2. WB-like (non-active/stable) and 3. 
non-active/unstable mutants  (Figure 4-5). 
4.2.3.1 WT-like (active or unaffected) mutants 
Mutants which display a similar expression profile to WT ABCB4 are designated here as 
WT-like and represent one third (3/9) of the total number of mutants studied [Figure 4-5; 
panel B (E528D and L591Q) and panel C (P1161S)]. E528D, P1161S and L591Q mutants 
are detected at a very low level when expressed in HEK293T cells in the absence of 
ATP8B1/CDC50A, but when these mutants are co-expressed with ATP8B1/CDC50A, the 
level of expression is dramatically improved (Figure 4-5F). These data, mimicking the
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Figure 4-5. Expression of ABCB4 mutants in HEK293T cells. 
HEK293T cells were transiently transfected with WT or mutant ABCB4-expressing vector in the 
presence (+) and in the absence (-) of the ATP8B1/CDC50A PS flippase. Samples were harvested 48 
h post-transfection and whole-cell lysate (2 μg of total protein) from each sample was subjected to 
western analysis. The level of ABCB4 was determined using anti-ABCB4 monoclonal antibody 
C219. β-tubulin was used to ensure equal loading for all samples. A representative blot for each set 
of mutants is shown in panels A-E. No ABCB4 could be detected in the untransfected samples. WT, 
wild type; UT, untransfected; WB, walker B (E558Q) mutant. Apparent molecular masses are 
indicated in kDa. Densitometry analysis of ABCB4 expression in the samples shown in panels A-E 
is presented in panel F. The relative density of ABCB4 in each sample was corrected against the β-
tubulin loading control and plotted using the WT ABCB4 single-transfected cell population as a 
reference. T1, single strasfection; T3, triple transfection. Densitometry was performed in ImageJ 
(http://rsb.info.nih.gov/ij/index.html). The experiment was performed three independent times (n = 
3) for statistical analysis in the GraphPad PRISM
®
 V5.0 software. *P<0.05, **P<0.01, ***P<0.005 (with 
respect to the single transfection); ns, not significant; error bars, standard error of the mean. 
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phenotype of WT ABCB4 shown as a control on each panel, suggests that the mutants are 
deleterious to the cells. These mutants are therefore expected to localise to the plasma 
membrane and flop PC similar to WT ABCB4 (see Chapter 5). 
4.2.3.2 WB-like (non-active/stable) mutants 
Mutants which display a similar expression profile to the E558Q (WB) mutant (Figure 4-5; 
panel D) are designated here as WB-like and also represent one third (3/9) of the total 
number of mutants studied [Figure 4-5; panel A (G535D), panel B (M301T) and panel D 
(A286V)]. All three mutants behave in a manner more comparable to the WB mutant than 
WT. Specifically, these are detected at a high level in the absence of ATP8B1/CDC50A. 
However, expression of each of the 3 mutants is improved by co-expression with 
ATP8B1/CDC50A suggesting that each may retain some PC floppase activity, but this is 
likely to be less than the WT activity (Figure 4-5F). In this type of analysis it is difficult to 
distinguish between non-functional mutants (i.e., those that reach the plasma membrane 
but are unable to flop PC) and trafficking mutants (i.e., those that fold inefficiently and 
therefore do not progress through the trafficking pathway although it is possible that these 
mutants may migrate faster through SDS-PAGE due to the presence of core rather than 
mature glycosylation). Both phenotypes likely result in protein that has limited influence on 
the lipid asymmetry, and hence the integrity, of the plasma membrane and therefore their 
expression is tolerated by HEK293T cells in the absence of the ATP8B1/CDC50A PS 
flippase. These two possible sub-phenotypes are addressed further in Chapter 5. 
4.2.3.3 Non-active/unstable mutants 
The remaining three mutants (S320F, A546D and R545C), are detected at a similar level 
both in the presence and in the absence of ATP8B1/CDC50A [Figure 4-5; panel A 
(S320F), panel D (R545C) and panel E (A546D)]. Notably none of the mutants reaches the 
level of expression of the WT ABCB4 achieved in the presence of ATP8B1/CDC50A 
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(although A546D consistently achieves about 70% of WT as indicated by densitometry 
analysis); but each is present at a higher level than WT ABCB4 in the absence of 
ATP8B1/CDC50A. These mutations may cause a folding defect which makes the protein 
unstable resulting in an increased rate of degradation. These proteins are also likely to have 
reduced activity hence expression is not improved in the presence of ATP8B1/CDC50A. 
Some insight into the effect of these mutations may be offered by studying the subcellular 
localisation of the recombinant protein by confocal microscopy, and measurement of its 
lipid flopping activity (by bile salt-dependent extraction of radiolabelled PC into the culture 
medium). The results of these studies are reported in Chapter 5. 
 
Of note, two forms of the R545C protein are evident which differ in electrophoretic 
mobility [Figure 4-5; panel D (R545C)]. This variation is likely due to a difference in the 
glycosylation status of the two protein species and this is tested and described below (see 
Section 4.2.4). 
4.2.4 Transient expression of ABCB4 R545C results in two protein forms which 
differ in their glycosylation status 
Western analysis of the expression levels of several ABCB4 variants following transient 
expression in HEK293T cells revealed that some mutants express as two forms with 
different apparent molecular weights [Figure 4-5; panel D (R545C, A286V and WB); panel 
B (L591Q)]. The peptide N-Glycosidase F (PNGase F; NEB, UK) cleaves mature and 
immature N-linked glycans present on a polypeptide and was used to test whether the two 
forms of ABCB4 detected differed in their glycosylation status.  In the untreated WT 
ABCB4 samples, the mature, 170-kDa is the main form present (Figure 4-6; lanes 1 and 3) 
although some immature 140-kDa form is detected when ABCB4 is overexpressed in the 
presence of ATP8B1/CDC50A (Figure 4-6; lane 3, black arrowhead). Enzymatic 
deglycosylation of the WT ABCB4 samples shows that the larger, 170-kDa band is 
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sensitive to the treatment (Figure 4-6; compare the untreated samples in lanes 1 and 3 with 
the treated samples in lanes 2 and 4). In the R545C samples, the higher molecular weight 
species is the mature form of the protein which migrates with the same mobility as the 
mature WT protein and which is sensitive to deglycosylation with PNGase F. The 
deglycosylated R545C migrates with the same mobility as the deglycosylated WT protein 
(Figure 4-6; compare lane 2 with lane 6 and lane 4 with lane 8). The lower molecular weight 
proteins present in the untreated R545C samples in the absence and in the presence of 
ATP8B1/CDC50A likely represent the nascent immature protein (Figure 4-6; lanes 5 and 
7). In addition, a small fraction of the deglycosylated R545C protein appears to migrate 
faster than the predominant 140-kDa deglycosylated form the PNGase F-treated samples 
and  likely represents a degradation product of the mature protein (Figure 4-6; lanes 6 and 
8, red arrowheads). This fraction is possibly present in the treated WT ABCB4 sample but 
is masked by the high signal detected from the deglycosylated protein (Figure 4-6; lanes 2 
and 4). 
 
 
Figure 4-6. Two forms of ABCB4 are expressed in HEK293T cells which differ in their glycosylation 
status. 
Aliquots (20 μg total protein) were subjected to PNGase F (lanes 2, 4, 6 and 8) digestion or left 
untreated (lanes 1, 3, 5 and 7), and processed for electrophoresis and immunoblotting using a 
monoclonal anti-ABCB4 antibody C219. Lanes 1-4: wild type ABCB4. Lanes 5-8: ABCB4_R545C 
mutant. Black arrowhead, nascent immature protein. Red arrowhead, degradation product of the 
mature ABCB4 protein. Apparent molecular masses are indicated in kDa. 
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4.3 Discussion 
ABCB4 is a PC floppase most abundantly expressed at the canalicular membrane of the 
hepatocyte (Smith et al., 1998, van Helvoort et al., 1996). Variations in the ABCB4 coding 
region cause PFIC3, a rare autosomal recessive disease characterised by the early onset of 
cholestasis that ultimately leads to liver failure at a young age (Jacquemin et al., 2001). 
There is now evidence that in addition to PFIC3, mutations in ABCB4 are involved in ICP, 
LPAC, DIC and PSC (Dixon et al., 2000, Jacquemin et al., 1999, Jacquemin et al., 2001, 
Lang et al., 2007, Lucena et al., 2003, Pauli-Magnus et al., 2004a, Pauli-Magnus et al., 
2004b, Rosmorduc et al., 2003, Rosmorduc et al., 2001, Poupon et al., 2010). Patients with 
these less severe conditions are generally heterozygous, in contrast to PFIC3 patients who 
are generally homozygous or compound heterozygous at the locus (Pauli-Magnus et al., 
2005). Although the genetic evidence describes a causative link between ABCB4 mutations 
and the disease phenotype, it is often not definitive for the complex conditions and the 
affect of these mutations on ABCB4 expression, membrane localisation and its PC-
flopping activity remains untested. 
 
The generation and expression in HEK293T cells of non-synonymous ABCB4 variants in 
the presence and in the absence of a PS flippase (ATP8B1/CDC50A) is reported. The 
mechanism notwithstanding, ATP8B1/CDC50A has a profound effect on the ability of the 
cells to tolerate ABCB4 function (Groen et al., 2011). Consequently, this heterologous 
triple expression system was used to analyse the ABCB4 mutations that have been linked to 
cholestatic liver disease by genetic studies. 
 
Nine non-synonymous ABCB4 variants were selected for testing. These have been 
associated with a range of phenotypes in cholestatic patients (Tables 4-1 and 4-3). The 
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mutations were introduced into the coding region of WT ABCB4 by site-directed 
mutagenesis and confirmed by DNA sequencing (Section 4.2.2). HEK293T cells were then 
transiently-transfected with mutant ABCB4-expressing vectors in the presence and in the 
absence of the ATP8B1/CDC50 PS flippase. Importantly, for each experiment, the WT 
ABCB4 and catalytically inactive Walker B mutant (E558Q) were included as controls. The 
level of expression of each mutant was then determined by western analysis of whole-cell 
extracts (Section 4.2.3). A range of different mutant phenotypes was observed (Figure 4-5) 
which could be divided broadly into 3 categories (Table 4-3). 
 
Allele 
Mutated 
domain 
Patient 
phenotype 
Expression level 
Implied impact on 
ABCB4 ABCB4 only 
ABCB4 
ATP8B1 
CDC50A 
WT n/a n/a + ++++ n/a 
WB (E558Q) NBD1 n/a ++++ ++++ Inactive 
E528D NBD1 ICP, LPAC ++ ++++ 
Apparently 
unaffected 
L591Q NBD1 LPAC + ++++ 
P1161S NBD2 LPAC + ++++ 
A286V ICL2 PFIC3 ++++ ++++ 
Loss of deleterious 
PC-flopping activity 
M301T MSH5 LPAC ++++ +++++ 
G535D NBD1 LPAC to ICP to BC ++++ +++++ 
S320F MSH5 PFIC3, ICP, LPAC +++ +++ 
Loss of activity and 
stability 
R545C NBD1 PSC ++ ++ 
A546D NBD1 ICP +++ +++ 
Table 4-3. Summary of the expression of WT and mutant ABCB4 in HEK293T cells. 
The expression of ABCB4 non-synonymous genetic variants was analysed following transient 
expression of ABCB4 in the presence and in the absence of ATP8B1/CDC50A in HEK293T cells. 
The level of expression is summarised here as: +++++ > ++++ > +++ > ++ > +. ABCB4 expression 
was detected in all samples tested but revealed different phenotypes which can be divided in three 
broad categories (far right column). ICL, intracellular loop; MSH, membrane-spanning helix; NBD, 
nucleotide-binding domain; n/a, not applicable; ICP, intrahepatic cholestasis of pregnancy; LPAC, 
low phospholipid-associated cholelithiasis; PFIC3, progressive familial intrahepatic cholestasis 
Type 3; BC, biliary cirrhosis; PSC, primary sclerosing cholangitis. 
 
One third of the mutants displayed an expression profile comparable to that of WT 
ABCB4; i.e. the level of ABCB4 detected was dramatically increased in the presence of 
ATP8B1/CDC50A (Figure 4-5F; E528D, L591Q and P1161S). These apparently 
unaffected variants have been associated mainly with LPAC (Floreani et al., 2008, Nakken 
et al., 2009, Rosmorduc et al., 2003, Rosmorduc et al., 2001) although the E528D mutation 
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has also been identified in an ICP patient (Floreani et al., 2008). LPAC is a multifactorial 
syndrome characterised by low phospholipid content in the bile and symptomatic and 
recurring cholestasis in young adults with an apparent prevalence in the female population 
(Rosmorduc and Poupon, 2007). Since all three variants display an expression profile 
analogous to that of the WT protein, it is unlikely that the disease phenotypes are a result 
of a defect in the PC-efflux activity of ABCB4 under normal conditions. However, it is 
plausible that the mutations predispose to the condition which only manifests under the 
influence of environmental and dietary factors. In the ICP patient carrying the E528D 
variant Floreani et al. only sequenced exons 14-16 of the ABCB4 gene, and additional 
mutations might have been missed (Floreani et al., 2008). Alternatively, since ICP is likely 
to be modulated by pregnancy hormones and their metabolites (Arrese and Reyes, 2006, 
Lammert et al., 2000), it is possible that E528D confers a genetic susceptibility to the 
disease which manifests during the third trimester of pregnancy when hormone levels are 
high. 
 
The second group of mutants revealed an expression profile similar to that of the WB 
(E558Q) mutant (an inactive derivative of ABCB4 carrying a point mutation in the Walker 
B motif likely rendering it unable to hydrolyse ATP) (Figure 4-5; panel D). These ABCB4 
mutants could be detected in the presence and in the absence of ATP8B1/CDC50A at 
comparable levels that were also similar to the level of WT ABCB4 when co-expressed 
with ATP8B1/CDC50A (Figure 4-5; G535D, M301T, A286V). However, these mutant 
phenotypes are not identical to one another. Both M301T and G535D reproducibly 
express at a significantly higher level in the triple transfection experiment suggesting that 
they retain a small level of PC-efflux activity that is deleterious in the absence of 
ATP8B1/CDC50A (a more modest increase in expression is observed with A286V). The 
low impact of these mutants on HEK293T cells in the absence of ATP8B1/CDC50A 
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compared to the effect of WT ABCB4 suggests a threshold effect under which low levels 
of PC-flopping activity are tolerated. These three ABCB4 variants (A286V, M301T and 
G535D) have been implicated in a variety of cholestatic phenotypes ranging from the most 
severe PFIC3 (A286V) to the milder LPAC (M301T) and to what appears to be a clinical 
continuum of diseases progressing from a mild (LPAC) to a progressive (biliary cirrhosis) 
phenotype (G535D) in a single patient. The western analysis suggests that these variants 
have lost their deleterious PC-flopping activity. Since they express at a level either 
comparable (A286V) or slightly elevated (M301T and G535D) compared to the WT 
protein in the triple transfection, and in the absence of core glycosylated fraction or 
degradation products, it is likely that they can adopt a normal conformation and traffic to 
the plasma membrane and that the mutation impacts their ability to flop PC. The M301T 
and G535D variants have been identified in the heterozygous state (Lucena et al., 2003, 
Rosmorduc et al., 2003). The expression of the normal allele in each patient probably 
compensates for the presumably reduced activity of the two variants resulting in the 
development of relatively mild phenotypes. The development of ICP and the slow, gradual 
progress to biliary cirrhosis (BC) in the patient expressing the G535D ABCB4 variant 
(Lucena et al., 2003) possibly reflects the complex, heterogeneous and multifactorial nature 
of ABCB4-related disease. Degiorgio et al. identified the c.857C>T (A286V) mutation in a 
PFIC3 patient as compound heterozygote with the recurrent c.959C>T (S320F) mutation 
on the ABCB4 locus (Degiorgio et al., 2007). The combination of a presumed loss-of-PC-
flopping activity variant (A286V) with another variant (S320F) which appears to lack PC-
flopping activity as well as stability (possibly due to a folding defect), would most likely 
result in a severe reduction in PC-efflux, failure of bile flow and  progressive liver disease.    
 
The final group of mutants displayed a unique expression pattern in that they do not 
resemble the profile observed for either WT ABCB4 or the WB mutant. The presence of 
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ATP8B1/CDC50A had little effect on their expression level. Although none of the 
mutants could be detected at a level approaching that of the WT expressed in the presence 
of the PS flippase (Figure 4-5S320F, A286V and A546D); all three are detectable at a 
higher level than WT ABCB4 in the absence of the PS flippase. The phenotype of these 
mutants suggests that they lack activity because they express at a higher level than WT 
ABCB4 in the absence of the PS flippase, and because they are unable to achieve the level 
of expression of the WB mutant, they may also fail to fold properly or may lack stability. 
The mutation c.959C>T (S320F) has been associated with a range of disparate phenotypes 
(PFIC3, LPAC and ICP) and identified in the homozygous, heterozygous as well as in the 
compound heterozygous states (Bacq et al., 2009, Degiorgio et al., 2007, Keitel et al., 2006, 
Pauli-Magnus et al., 2004b, Poupon et al., 2010, Rosmorduc et al., 2003, Rosmorduc et al., 
2001). Dixon et al. identified the A546D variant in an ICP patient heterozygous for this 
locus (Dixon et al., 2000). Finally, the R545C variant was only detected in a population with 
PSC although no correlation could be established between ABCB4 (or ABCB11) mutations 
and the development of PSC or PBC in this prior study (Pauli-Magnus et al., 2004a). 
 
In the earlier studies the level of expression of the S320F variant appeared to be low in 
western analysis, but immunostaining on liver sections identified the protein at the 
canalicular membrane suggesting that the variant can traffic to the plasma membrane and 
probably retains a level of PC-efflux activity (Keitel et al., 2006, Poupon et al., 2010). 
Several different cholestatic disease phenotypes have been associated with the S320F 
variant. These can probably be explained by the differences in zygosity in the patients 
(Degiorgio et al., 2007, Poupon et al., 2010) or the presence of additional mutations in 
other gene loci implicated in liver disease such as ABCB11 or the farnesoid X receptor 
(FXR) (Keitel et al., 2006, Poupon et al., 2010, Zimmer et al., 2009). The influence of 
endogenous (i.e., pregnancy hormones) or exogenous factors (i.e., environment and/or 
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diet), or a combination of the two, concomitantly with the S320F mutation may also play a 
role in the development of the disease phenotype (Bacq et al., 2009, Pauli-Magnus et al., 
2004b, Rosmorduc et al., 2003, Rosmorduc et al., 2001). 
 
Dixon et al. identified the A546D variant in an ICP patient (Dixon et al., 2000). When the 
equivalent residue (A544) was mutated in ABCB1, the closest homologue of ABCB4, it 
caused a trafficking defect in ABCB1 depleting the protein from the plasma membrane. 
However, the fraction that reached the plasma membrane could efflux drugs suggesting 
that this variant of ABCB1 was functional (Dixon et al., 2000). The results reported by 
Dixon et al. are in agreement with the reduced stability observed here (Table 4-3). In the 
triple transfection, the level of expression of the A546D variant is lower than that of WT 
ABCB4 suggesting that the mutation causes a folding defect which leads to the degradation 
of the A546D protein by the ERAD (ER-associated degradation) pathway (Meusser et al., 
2005, Vembar and Brodsky, 2008). Nevertheless, it is possible that a proportion of the 
expressed protein can reach the plasma membrane and efflux PC when stimulated by a bile 
salt. Likewise, the R545C variant could harbour a similar defect. Despite the lack of genetic 
association between ABCB4 mutations and the development of PSC and PBC (based on 
haplotype structure and variant segregation), the c.1633C>T (R545C) mutation was found 
to be PSC-specific (Pauli-Magnus et al., 2004a). It is possible therefore, that his non-
synonymous change has a functional impact on ABCB4 and is involved in the pathogenesis 
of PSC. 
 
In general, PFIC3 results from the most severe mutations to ABCB4, i.e. of nonsense or 
frame-shift mutations in the ABCB4 gene locus which result in truncation of the open 
reading frame (Chen et al., 2001, de Vree et al., 1998, Jacquemin et al., 2001, Pauli-Magnus 
et al., 2004b). mRNAs with a premature termination codon are recognised by the 
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nonsense-mediated mRNA decay (NMD) surveillance system and targeted for degradation 
(Chang et al., 2007). Consequently, ABCB4 canalicular staining was absent from liver 
biopsies of PFIC3 patients carrying nonsense or frame-shift mutations (de Vree et al., 1998, 
Jacquemin et al., 2001). In contrast, missense mutations cause a range of phenotypes with 
the type and severity of cholestatic disease usually dependent on the zygosity of the patient 
(Pauli-Magnus et al., 2005). As summarised in Table 4-3, some of the variants characterised 
in this report associate with a single disease phenotype (L591Q, P1161S, A286V, M301T, 
R545C and A546D) whereas others have been linked to more than one (E528D and 
S320F). Furthermore, one mutant (G535D) has been associated with a range of liver 
disease phenotypes within a single patient suggesting that ABCB4 mutations can result in a 
clinical continuum of diseases progressing from a mild to a severe phenotype. 
 
A more detailed biochemical and molecular analysis of mutant ABCB4 protein is required 
to further characterise the contribution of ABCB4 in the development of cholestatic liver 
disease. In the following chapter, the localisation of each mutant in HEK293T cells is 
studied by confocal microscopy providing insight into the trafficking of mutant ABCB4 
species to the plasma membrane, and the ability of mutant ABCB4 to efflux PC in a bile 
salt-dependent manner is measured in order to clarify the link between mutant protein 
phenotype and patient presentation.  
  
 
Chapter Five 
 
 
 
5 Localisation and 
phospholipid efflux activity 
of ABCB4 variants in 
HEK293T cells 
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5.1 Introduction 
In the previous chapter the generation and expression of ABCB4 non-synonymous 
missense mutants was described. HEK293T cells were transfected with the pcDNA3.1-
ABCB4wt or pcDNA3.1-ABCB4_X vectors, where X is any of the 9 ABCB4 variants 
summarised in Table 4-1, either in the presence (triple transfection) or in the absence 
(single transfection) of the pCI-neo-ATP8B1 and pCI-neo-CDC50A vectors. The level of 
expression of each mutant was then determined by western analysis of whole-cell extracts 
and compared with the phenotype of the WT and non-functional Walker B mutant 
(E558Q). This revealed a range of different mutant phenotypes (Figure 4-5) which could be 
divided broadly into 3 categories (Table 4-3). Although tentative conclusions could be 
drawn concerning the effect of the particular mutation on the folding, trafficking and even 
the function of the protein based on the western analysis, further biochemical evaluation 
was required. 
 
To this end, confocal laser scanning microscopy (CLSM) was employed to study the 
trafficking of mutant ABCB4 to the plasma membrane (Section 5.2.1) and the 3H-PC efflux 
assay (see below) was used to determine the level of PC-flopping activity retained in each 
variant (Section 5.2.2). Because all variants were shown by western analysis to be expressed 
following triple transfection (Figure 4-5), and because the co-expression of the PC-floppase 
alongside the PS-flippase is more physiologically relevant, both the CLSM analysis and the 
[methyl-3H]-PC efflux assay were performed in HEK293T cells co-transfected with the 
ATP8B1/CDC50A constructs. The basis of the [methyl-3H]-PC efflux assay is described in 
the following section. 
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5.1.1 Phosphatidylcholine biosynthesis 
The major structural lipids in eukaryotic membranes are the glycerophospholipids 
(phosphatidylcholine, PC; phosphatidylethanolamine, PE; phosphatidylserine, PS; 
phosphatidylinositol, PI; and phosphatidic acid, PA) and the sphingolipids (shingomyelin, SM 
and glycosphingolipids; GS). Within the lipid bilayer of the plasma membrane of eukaryotic 
cells, there is an asymmetric distribution of lipids with PS and PE predominantly facing the 
cytosolic side and PC and SM almost exclusively on the outer leaflet (Devaux and Morris, 
2004, van Meer et al., 2008). 
 
PC is the principal component of eukaryotic cellular membranes (>50% of the total 
phospholipid content) and in mammalian cells it is synthesised de novo via two different 
pathways residing in the ER: (i) the PEMT (phosphatidylethanolamine N-
methyltransferase) pathway (Vance et al., 2008); and, (ii) the CDP (cytidine diphosphate)-
choline (or Kennedy) pathway (Kennedy and Weiss, 1956). Although the PEMT pathway 
only accounts for a small fraction of PC synthesis in most tissues, in the liver it is 
responsible for ~30% of the total PC synthesis (Kent, 1995). In this pathway, PC is formed 
by a series of sequential methylations of PE by PEMT (Sundler and Akesson, 1975). In 
contrast, in the CDP-choline biosynthetic pathway (which occurs in all nucleated cells) PC 
formation requires the sequential conversion of dietary choline to phosphocholine, CDP-
choline and finally PC (Kennedy and Weiss, 1956). The rate-limiting step in this series of 
reactions requires CTP (cytidine triphosphate) to provide energy for the 
cytidylyltransferase-catalysed conversion of phosphocholine to CDP-choline which is in 
turn converted to PC by choline phosphotransferase (Kent, 1995, Vance et al., 2008).  
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5.1.1.1 The 3H-PC efflux assay 
A number of mutations have been reported, following genetic studies in cholestatic 
patients, which implicate ABCB4 in the manifestation of the disease. To establish cause 
and effect definitively would require an assay whereby the activity of ABCB4 could be 
demonstrated (and quantified) in an in vitro system to permit the characterisation of ABCB4 
variants with non-synonymous changes. Such an assay has been developed recently in our 
lab (Groen et al., 2011), in which HEK293T cells that have been co-transfected with 
vectors expressing WT ABCB4 and ATP8B1 and CDC50A, are fed [methyl-3H]choline (a 
radioactive labelled PC precursor for the Kennedy pathway). The cells are allowed to 
incorporate [methyl-3H]choline PC resulting in the generation of radiolabelled PC species. 
Forty-eight hours post-transfection, the cells are washed extensively and incubated with 
culture medium containing taurocholate (TC; 2 mM) to extract labelled PC flopped by 
ABCB4 to the outer leaflet of the plasma membrane of HEK293T cells. After 24 h 
incubation, the culture media is recovered and the radioactivity content is quantified. In 
addition, the cells attached to the culture dish are lysed and the radioactivity associated with 
the cellular fraction is also measured. The amount of labelled PC effluxed by ABCB4 (i.e., 
the radioactivity present in the recovered culture medium) is calculated as a percentage of 
the total radioactivity present in the dish (i.e., the radioactivity in the culture medium plus 
the radioactivity retained by the cells).  Quantification of the fraction of labelled PC 
effluxed to the culture medium mimics the situation at the canalicular membrane and 
provides a powerful tool to characterise ABCB4 variants. The results of this investigation 
are reported in Section 5.2.2.      
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5.2 Results 
5.2.1 Localisation of ABCB4 variants in HEK293T cells 
Most proteins adopt a particular three dimensional conformation to function. Failure to do 
so often has detrimental effects on the protein and misfolded membrane proteins are 
normally degraded by the ERAD (ER-associated degradation) pathway (Meusser et al., 
2005, Vembar and Brodsky, 2008). In fact, many inherited diseases such as cystic fibrosis 
(CF) are due to defective protein folding (Welch, 2004) caused by mutations that prevent 
the protein (ABCC7/CFTR in the case of CF) from adopting its native fold resulting in its 
retention in the ER and subsequent degradation. For example, the ΔF508 mutation in 
ABCC7 which is present in approximately 70% of patients with cystic fibrosis results in the 
loss of a phenylalanine residue at amino acid position 508 (Riordan et al., 1989, Kerem et 
al., 1989). Consequently, the protein is retained in the ER and rapidly degraded preventing 
it from reaching the plasma membrane (Cheng et al., 1990). Mutations in the ABCB4 
coding region could have similar effects on protein processing which would prevent its 
correct trafficking to the plasma membrane. 
 
To examine the cellular localisation of ABCB4, HEK293T cells were transiently-
transfected with plasmid DNA encoding WT ABCB4 or a non-synonymous missense 
variant in the presence of the ATP8B1/CDC50A PS flippase and studied by CLSM. Cells 
were seeded onto glass coverslips at a low density in order to observe some cells in 
isolation by microscopy. A transfection efficiency of 40 – 60% was therefore generally 
achieved. Immunofluorescence was studied 48 hours post-transfection after detecting 
ABCB4 using the monoclonal antibody P3II-26. The epitope of the P3II-26 antibody is 
located in NBD1 of human ABCB4 between the amino acid residues 629 and 692 and so 
all the variant ABCB4 proteins generated for this study should be detectable (Scheffer et 
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al., 2000). In the untransfected cells, no ABCB4 was present (Figure 5-1A); the low level of 
green fluorescent signal detected arises from endogenous fluorophores which emit light 
when excited at 499 nm, and is known as autofluorescence. In contrast, in the cell 
populations transiently-transfected with the ABCB4-expressing vector, a strong fluorescent 
signal could be detected in a number of the recipient cells (Figure 5-1B-L) demonstrating 
expression of ABCB4 in the presence of ATP8B1/CDC50A and that the protein can be 
detected by the P3II-26 primary antibody on fixed cell preparations. 
 
In the majority of cells transfected with plasmid DNA encoding WT or WB (E558Q) 
mutant ABCB4, the protein appears to be almost exclusively at the periphery of the cell 
consistent with plasma membrane localisation (Figure 5-1B and C). This observation is in 
agreement with previous results (Groen et al., 2011). The subcellular localisation of variant 
ABCB4 reveals two distinct phenotypes. For the majority of mutants (7/9) a fluorescent 
staining pattern analogous to that of WT and WB ABCB4 is detected which is consistent 
with plasma membrane localisation of the protein (Figure 5-1D-J). In contrast, in cells 
transiently expressing either the R545C or the A546D ABCB4 variants, a punctate 
intracellular signal is evident (Figure 5-1K-L). This is suggestive of a trafficking defect in 
these two mutants which causes the intracellular retention of a large fraction of the 
transporter protein. The precise intracellular localisation of variant ABCB4 was not 
determined but, colocalisation with an organelle-specific antibody such as calnexin and 
protein disulphide isomerase (ER) or Golgi matrix protein (Golgi), would likely identify the 
subcellular compartment of the protein. 
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Figure 5-1. Expression of ABCB4 WT and missense variants in HEK293T cells in the presence of the ATP8B1/CDC50A PS flippase. 
HEK293T cells transiently expressing WT or missense variant ABCB4 and ATP8B1/CDC50A, were fixed with 10% (v/v) acetone in ethanol. ABCB4 was detected by 
immunofluorescence using the P3II-26 monoclonal antibody and Alexa Fluor
®
 488 Dye-conjugated goat anti-mouse IgG. Nuclei were stained with DAPI (4’,6-diamidino-2-
phenylindole). Untransfected cells were used as a negative control to account for background fluorescence. WT ABCB4 and the WB (E558Q) mutant were employed as 
positive controls to confirm that P3II-26 is specific to ABCB4. Scale bars, 10 μm. Images representative of the whole population are shown in each case. 
(A). Untransfected (UT) HEK293T cells. A low level green fluorescent signal (autofluorescence) is detected in all cells. 
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Figure 5-1. (continued) Expression of ABCB4 WT and missense variants in HEK293T cells in the presence of the ATP8B1/CDC50A PS flippase. 
HEK293T cells transiently expressing (B) WT and (C) WB mutant (E558Q) ABCB4 in the presence of ATP8B1/CDC50A. The green signal (ABCB4) is consistent with plasma 
membrane localisation of the protein. 
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Figure 5-1. (continued) Expression of ABCB4 WT and missense variants in HEK293T cells in the presence of the ATP8B1/CDC50A PS flippase. 
(D). HEK293T cells transiently expressing the L591Q non-synonymous ABCB4 variant in the presence of ATP8B1/CDC50A. The green signal (ABCB4) is consistent with 
plasma membrane localisation of the protein. 
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Figure 5-1. (continued) Expression of ABCB4 WT and missense variants in HEK293T cells in the presence of the ATP8B1/CDC50A PS flippase. 
(E). HEK293T cells transiently expressing the E528D non-synonymous ABCB4 variant in the presence of ATP8B1/CDC50A. The green signal (ABCB4) is consistent with 
plasma membrane localisation of the protein. 
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Figure 5-1. (continued) Expression of ABCB4 WT and missense variants in HEK293T cells in the presence of the ATP8B1/CDC50A PS flippase. 
(F). HEK293T cells transiently expressing the P1161S non-synonymous ABCB4 variant in the presence of ATP8B1/CDC50A. The green signal (ABCB4) is consistent with 
plasma membrane localisation of the protein. 
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Figure 5-1. (continued) Expression of ABCB4 WT and missense variants in HEK293T cells in the presence of the ATP8B1/CDC50A PS flippase. 
(G). HEK293T cells transiently expressing the S320F non-synonymous ABCB4 variant in the presence of ATP8B1/CDC50A. The green signal (ABCB4) is consistent with 
plasma membrane localisation of the protein. 
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Figure 5-1. (continued) Expression of ABCB4 WT and missense variants in HEK293T cells in the presence of the ATP8B1/CDC50A PS flippase. 
(H). HEK293T cells transiently expressing the M301T non-synonymous ABCB4 variant in the presence of ATP8B1/CDC50A. The green signal (ABCB4) is consistent with 
plasma membrane localisation of the protein. 
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Figure 5-1. (continued) Expression of ABCB4 WT and missense variants in HEK293T cells in the presence of the ATP8B1/CDC50A PS flippase. 
(I). HEK293T cells transiently expressing the A286V non-synonymous ABCB4 variant in the presence of ATP8B1/CDC50A. The green signal (ABCB4) is consistent with 
plasma membrane localisation of the protein. 
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Figure 5-1. (continued) Expression of ABCB4 WT and missense variants in HEK293T cells in the presence of the ATP8B1/CDC50A PS flippase. 
(J). HEK293T cells transiently expressing the G535D non-synonymous ABCB4 variant in the presence of ATP8B1/CDC50A. The green signal (ABCB4) is consistent with 
plasma membrane localisation of the protein. 
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Figure 5-1. (continued) Expression of ABCB4 WT and missense variants in HEK293T cells in the presence of the ATP8B1/CDC50A PS flippase. 
(K). HEK293T cells transiently expressing the R545C non-synonymous ABCB4 variant in the presence of ATP8B1/CDC50A. The green signal (ABCB4) is consistent with 
cytosolic localisation of the protein suggesting a trafficking defect for this mutant. Lower panel; scale bar, 10 μm. 
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Figure 5-1. (continued) Expression of ABCB4 WT and missense variants in HEK293T cells in the presence of the ATP8B1/CDC50A PS flippase. 
(L). HEK293T cells transiently expressing the A546D non-synonymous ABCB4 variant in the presence of ATP8B1/CDC50A. The green signal (ABCB4) is consistent with 
cytosolic localisation of the protein suggesting a trafficking defect for this mutant. Lower panel; scale bar, 10 μm. 
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5.2.2 PC-efflux activity of ABCB4 variants in HEK293T cells 
The co-expression of WT ABCB4 with ATP8B1 and CDC50A allows HEK293T cells to 
tolerate the function of ABCB4 enabling the measurement of the efflux of PC in a bile salt-
dependent manner (Groen et al., 2011). As shown by pulse-chase experiments performed 
in rat hepatocytes, after a 30 min incubation with [methyl-3H]choline, more than 90% of the 
radioactivity was present as phosphocholine. Following a chase with unlabelled choline, the 
radiolabelled phosphocholine was converted to PC as determined by thin-layer 
chromatography of the various choline metabolites (Pelech et al., 1983). It should therefore 
be possible to measure the level of PC floppase activity of ABCB4, by “feeding” cells 
[methyl-3H]choline and analysing the amount of radiolabelled PC effluxed into the culture 
medium. To mimic the situation at the canalicular membrane (because there is no lipid flow 
unless there is there is bile salt flow) sodium taurocholate (TC) was added to the medium, 
to accept the PC flopped by ABCB4. The efficiency of [methyl-3H]choline uptake by the 
cells can vary within an experiment probably due to a combination of micropipetting errors 
and the efflux of PC by active ABCB4 within the first two days. To account for differences 
in [methyl-3H]choline incorporation between wells, the radioactivity effluxed to the medium 
in the presence of 2 mM TC was calculated as the percentage of the total radioactivity in 
each well; i.e. amount of radioactivity in the medium following the addition of TC divided 
by the sum of the radioactivity in the medium plus the radioactivity retained intracellularly. 
 
It is particularly important to have a healthy monolayer of cells because all cells contain PC 
in their outer leaflet and dying cells are relatively easily solubilised by a natural detergent 
like TC. It was crucial therefore to include in each experiment a positive control (WT 
ABCB4 co-expressed with ATP8B1/CDC50A) and a negative control (the non-functional 
WB mutant co-expressed with ATP8B1/CDC50A). The level of TC-dependent PC efflux 
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should be significantly different in these two conditions, as shown in Figure 5-2, signifying 
the health of the cells. Mock-transfected cells (parental, empty form of the pcDNA3.1 
vector co-expressed with ATP8B1/CDC50A) display a low level of TC-dependent PC 
extraction but it is significantly lower than the level observed when the WB mutant is 
expressed (Figure 5-2). 
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Figure 5-2. TC-dependent PC efflux in triple transfected HEK293T cells. 
HEK293T cells were triple transfected with plasmid DNA encoding for WT or WB (E558Q) ABCB4 or 
the parental empty vector pcDNA3.1 (mock) and the ATP8B1 and CDC50A-expressing vectors, and 
fed [methyl-
3
H]choline for 48 h. The radioactivity effluxed to the medium in the presence of 2 mM 
sodium taurocholate hydrate (TC) was calculated as the percentage of the total radioactivity in 
each well. Cells expressing WT ABCB4 efflux significantly more PC than cells expressing the WB 
mutant. Mock-transfected cells consistently display a low level of TC-dependent PC extraction 
which is significantly lower than the level observed in the WB-transfected cells. Statistical analysis 
by one-way ANOVA (analysis of variance) was performed in the GraphPad PRISM
®
 V5.0 software. n 
= 6; ***P<0.005; error bars, standard error of the mean. 
 
The effect of the E558Q mutation has not been characterised in ABCB4. However, it has 
been shown that when the equivalent glutamate residue (E556) in ABCB1 (the closest 
homologue of ABCB4) was mutated to a glutamine (Q), the catalytic activity of ABCB1 
was abolished (Sauna et al., 2002, Zolnerciks et al., 2007). This suggests that the presence 
of ABCB4 protein in the plasma membrane may cause some destabilisation of the 
membrane leading to extraction (rather than flopping) of radiolabelled PC. The E558Q 
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WB mutant was therefore used as a negative control to account for background 
radioactivity present in the culture medium. 
 
To measure the PC-efflux activity of variant ABCB4, HEK293T cells were transiently co-
transfected with plasmid DNA expressing variant ABCB4, and ATP8B1 and CDC50A. 
Cells were then fed [methyl-3H]choline for 48 h. The cell medium was subsequently replaced 
with fresh medium containing TC (2 mM) to drive the efflux of [methyl-3H]-PC from the 
triple-transfected cells. The background level of radioactivity (i.e., percentage of [methyl-3H]-
PC effluxed by the WB mutant in each experiment) was then subtracted from each sample 
and the corrected levels of radiolabelled TC-dependent PC efflux by the variant ABCB4 
were plotted and compared to the level of activity of WT ABCB4 (Figure 5-3). 
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Figure 5-3. TC-stimulated PC efflux by ABCB4 in the presence of the ATP8B1/CDC50A PS flippase. 
HEK293T cells transiently co-expressing WT ABCB4 and ATP8B1 and CDC50A were fed [methyl-
3
H]choline for 48 h. The radioactivity effluxed to the medium in the presence of 2 mM sodium 
taurocholate hydrate (TC) was calculated as the percentage of the total radioactivity in each well 
after subtraction of the background level from similarly treated cells transfected with the Walker B 
(E558Q) mutant. The experiment was performed six independent times (n = 6) for statistical 
analysis by one-way ANOVA (analysis of variance) using the GraphPad PRISM
®
 V5.0 software. 
**P<0.01, ***P<0.005 (with respect to wild-type); error bars, standard error of the mean. 
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The level of [methyl-3H]-PC effluxed by each variant in the presence of TC was then used to 
calculate the relative activity of each mutant protein when normalised to the 100% level of 
TC-dependent [methyl-3H]-PC efflux by WT ABCB4. 
 
The data show that the different mutations affect the ability of ABCB4 to efflux 
radiolabelled PC to varying degrees. Specifically, cells expressing the L591Q variant retain a 
very high level of PC-floppase activity comparable to cells expressing the WT protein. 
Although the E528D and P1161S variants appear, consistently, to have a lower activity 
than WT, these are not statistically different from that of the WT protein. The activity of 
cells expressing the S320F variant is reduced by 50% compared to WT ABCB4 (P<0.01). 
Both the M301T and A546D variants efflux PC at about one third of the level of activity of 
the WT protein (P<0.005) whereas the R545C variant has only 20% of the PC-efflux 
activity compared to cells expressing WT ABCB4 (P<0.005). Finally, the G535D and 
A286V variants confer little or no PC-efflux activity to the host cells. 
 
Cells expressing different variants of ABCB4 can therefore have distinct phenotypes. The 
phenotypes range from full (L591Q) or close to full (E528D and P1161S) activity, to no 
activity (G535D and A286V) to efflux PC. Some variants that confer an intermediate level 
of PC-floppase activity (S320F, M301T, A546D and R545C) that is significantly different 
compared to the efflux activity of WT ABCB4 in HEK293T cells are arguably the most 
interesting as these offer the best possibility for clinical intervention. 
 
5.3 Discussion 
In Chapter 4 it was demonstrated that a non-synonymous change in the ABCB4 coding 
region can affect the expression level of ABCB4 in HEK293T cells (Figure 4-1). This may 
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be due to the mutation preventing the protein folding efficiently and trafficking to the 
plasma membrane or in single-transfected cells it may be due to impairment of ABCB4 
function abrogating a deleterious effect on the host cell membrane, or a combination of 
both. 
 
To further characterise the molecular pathogenesis of ABCB4 missense mutations, the nine 
variant forms of the protein (Table 4-1) were transiently co-expressed in HEK293T cells 
with the ATP8B1/CDC50A PS flippase. Their subcellular localisation (Section 5.2.1) and 
their ability to efflux radiolabelled PC in a bile salt-dependent manner were studied (Section 
5.2.2). 
 
Allele 
Mutated 
domain 
Patient 
phenotype 
Predominant localisation 
(PM/IC) 
Efflux Activity 
(% of WT) 
WT n/a n/a PM 100 
WB (E558Q) NBD1 n/a PM n/a 
L591Q NBD1 LPAC PM 102 
E528D NBD1 ICP, LPAC PM 66 
P1161S NBD2 LPAC PM 61 
S320F MSH5 PFIC3, ICP, LPAC PM 49 
M301T MSH5 LPAC PM 36 
A546D NBD1 ICP IC 33 
R545C NBD1 PSC IC 21 
G535D NBD1 LPAC to ICP to BC PM 4 
A286V ICL2 PFIC3 PM 1 
Table 5-1. Summary of the subcellular localisation and relative bile salt-dependent PC-efflux 
activity of WT and mutant ABCB4 in HEK293T cells. 
The subcellular localisation and ability to efflux [methyl-
3
H]-PC in a TC-dependent manner of WT 
and mutant ABCB4 was studied following transient expression in HEK293T cells in the presence of 
the ATP8B1/CDC50A PS-flippase. n/a, not applicable; NBD, nucleotide-binding domain; MSH, 
membrane-spanning helix; ICL, intracellular loop; LPAC, low phospholipid-associated 
cholelithiasis; ICP, intrahepatic cholestasis of pregnancy; PFIC3, progressive familial intrahepatic 
cholestasis Type 3; PSC, primary sclerosing cholangitis; BC, biliary cirrhosis; PM, plasma 
membrane; IC, intracellular compartment. 
 
So far in the analysis none of the data has been corrected for expression level. The level of 
expression of the L591Q, E528D and P1161S variants was very low in the single 
transfection and dramatically improved in the triple transfection similar to levels 
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comparable to WT ABCB4 (Figure 4-5). This western blot data suggested that these 
mutants are able to traffic to the plasma membrane where they are likely to flop PC with 
high efficiency. When expressed in HEK293T cells and examined by CLSM, all three 
variants revealed a staining pattern consistent with efficient plasma membrane localisation 
of the protein (Table 5-1). Furthermore, in the [methyl-3H]-PC efflux assay all three variants 
maintained a high level of TC-dependent PC-flopping activity comparable to WT ABCB4 
(Table 5-1). Taken together, these data suggest that the mutations do not appear to affect 
protein expression, plasma membrane localisation or the lipid-translocase activity of 
ABCB4 per se under the test conditions.   
 
The expression of the M301T, A286V and G535D variants when analysed by western blot 
was high in the single transfection and slightly improved in the triple transfection (Figure 
4-5). From the localisation studies presented in this chapter, it is evident that these mutants 
traffic to the plasma membrane (Table 5-1). Their high level of expression in the single 
transfection, in combination with their apparent plasma membrane localisation, suggests 
that these variants have reduced lipid-flopping activity. In fact, the G535D and A286V 
missense alterations appear to have a dramatic influence on the level of TC-dependent PC-
efflux activity (i.e., 4% and 1% of WT ABCB4 activity, respectively, P<0.005) whereas 
M301T is only able to efflux PC at 36% of WT ABCB4 (P<0.005) (Table 5-1). In each of 
these three cases the non-synonymous mutation most likely affects the molecular 
mechanism of PC-flopping activity of ABCB4, but to different degrees. This is also 
reflected in the patient phenotypes with which the variants are associated. For example, it is 
not surprising, given the lack of activity of A286V ABCB4, that it is associated with PFIC3. 
The relationship between genotype and phenotype is discussed further in the general 
discussion (Chapter 6). 
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The remaining three mutants (S320F, A546D and R545C), were detected by western blot at 
a similar level in the presence and in the absence of ATP8B1/CDC50A (Figure 4-5). 
However, none of the mutants reached the level of expression of the WT ABCB4 achieved 
in the presence of ATP8B1/CDC50A, but each was present at a higher level than WT 
ABCB4 in the absence of the PS-flippase (Figure 4-5). The subcellular localisation of the 
S320F variant is consistent with efficient trafficking to the plasma membrane and when 
subjected to the [methyl-3H]-PC efflux assay, S320F was shown to efflux radiolabelled PC 
with half the efficiency of WT ABCB4 (Table 5-1). In contrast, the A546D and R545C 
variants accumulated in an intracellular compartment which indicates a trafficking defect 
most likely caused by inefficient folding of the polypeptide during the maturation steps in 
the ER and Golgi (Table 5-1). Nevertheless, it is likely that some A546D and R545C 
ABCB4 protein can reach the plasma membrane because cells harbouring these two 
mutants can efflux PC in a bile salt-dependent manner to 33% and 21% (P<0.005), 
respectively, of the WT activity (Table 5-1). 
 
Collectively, the data presented in Chapters 4 and 5 describe a novel approach undertaken 
to characterise a group of ABCB4 non-synonymous variants linked to cholestatic liver 
disease. Biochemical characterisation of the variant proteins has provided insights into the 
effect of each mutation on ABCB4 expression, localisation and PC-floppase function. 
Correlations between genotype and patient phenotype and future prospects for genetic 
screening and clinical intervention are discussed in the following chapter.    
 
  
  
 
Chapter Six 
 
 
 
 
 
 
6 General Discussion 
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his thesis encompasses the work undertaken to characterise two related members of 
the ATP-binding cassette superfamily of proteins, ABCB1 and ABCB4. In Chapter 
3, the use of the “split-ubiquitin” yeast two-hybrid system to screen for regulators of 
ABCB1 is described. This approach proved to be unfruitful as all the candidates isolated 
have been ruled out as false positives or non-specific. The underlying reasons for this 
unsuccessful attempt were discussed in Chapter 3 and are therefore not considered further 
here. In Chapters 4 and 5, the effect of ABCB4 missense mutations linked to abnormal bile 
flow is investigated. It was demonstrated that cells expressing different variants of ABCB4 
can have distinct phenotypes. The effect of the missense mutations on ABCB4 and 
possible genotype-phenotype correlations are discussed below. Future perspectives for 
clinical intervention are also considered. 
 
6.1 ABCB4 and cholestatic liver disease 
Impairment of bile flow into the small intestine is known as cholestasis and can cause a 
wide range of hepatic disease from the benign and episodic to the malign and fatal. The 
most severe phenotype, PFIC, is characterised by progressive cholestatic liver disease 
which eventually leads to liver failure and can only be treated by liver transplantation 
(Davit-Spraul et al., 2009). There are three types of PFIC (1-3), each caused by mutations in 
the genes encoding hepatic transporters involved in bile formation. The genes mutated in 
PFIC1, 2 and 3 are ATP8B1, ABCB11 and ABCB4 respectively (reviewed in van Mil et al., 
2005).  
 
Sequence analysis in PFIC3 patients has resulted in the cataloguing of approximately 40 
different mutations in patients with high level of serum γ-GT, a normal level of serum 
cholesterol and moderately raised concentrations of serum primary bile acids (Chen et al., 
T 
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2001, de Vree et al., 1998, Degiorgio et al., 2007, Jacquemin et al., 2001). The patient is 
usually homozygous for the mutation or compound heterozygous. Typically the mutation is 
a nonsense alteration that could encode only for a truncated protein, in line with the 
absence of ABCB4 staining in liver biopsies from PFIC3 patients (Jacquemin et al., 2001). 
The near absence of ABCB4 mRNA in northern blot analysis on liver samples from several 
patients indicates that the truncations result in instability of ABCB4 mRNA which is then 
degraded (de Vree et al., 1998, Deleuze et al., 1996) although this could be secondary to the 
progressive liver disease. In these cases the link between patient genotype and disease 
phenotype is clear. The lack of ABCB4 protein causes the accumulation of toxic bile acids 
in bile which is not neutralised by phospholipids, eventually leading to damage to the bile 
canaliculi and biliary epithelium (Jacquemin et al., 2001). 
 
It is becoming increasingly apparent that missense mutations in ABCB4 are also associated 
with PFIC3, ICP, DIC, LPAC, PBC and PSC and in these cases the link between the 
genetic alteration and disease outcome is less clear. Whether the patient phenotype is due 
to an affect on protein expression, or on the ability of the protein to reach the plasma 
membrane or efflux phospholipids, is addressed in this study. A total of nine ABCB4 
missense variants implicated in cholestatic liver disease were generated and their 
expression, trafficking to the plasma membrane and ability to efflux PC in a bile salt-
dependent manner was investigated using a heterologous expression system (Table 6-1). 
 
6.2 The expression system 
In a recent study, our group reported that ABCB4 expression was very poor in HEK293T 
cells and that this was due to cytotoxicity of ABCB4 function. In contrast, an inactive 
mutant form of the protein expressed very well in the cells and trafficked to the plasma
  
General Discussion 
 
205 
 
a.a. 
Change 
Base 
Change 
Domain 
Relevant patient genotype 
where known 
Disease Class Reference 
Expression Level Predominant 
Localisation 
(PM/IC) 
Efflux 
Activity 
(% of WT) 
ABCB4 
Only 
ABCB4 
ATP8B1/CDC50A 
WT n/a n/a n/a n/a n/a + ++++ PM 100 
E558Q 1672G>C NBD1 n/a n/a (Groen et al., 2011) ++++ ++++ PM n/a 
L591Q 1772T>A NBD1 HOM LPAC (Rosmorduc et al., 2003) + ++++ PM 102 
E528D 1584G>C NBD1 
HET LPAC (Rosmorduc et al., 2003) 
++ ++++ PM 66 HET LPAC (Nakken et al., 2009) 
HET ICP (Floreani et al., 2008) 
P1161S 3481C>T NBD2 
HOM LPAC (Rosmorduc et al., 2001) 
+ ++++ PM 61 
HET LPAC (Rosmorduc et al., 2003) 
S320F 959C>T MSH5 
A286V [on 2
nd
 allele] PFIC3 (Degiorgio et al., 2007) 
+++ +++ PM 49 
Y279X [on 2
nd
 allele] PFIC3 (Degiorgio et al., 2007) 
A953D [on 2
nd
 allele] + 
V444A [on ABCB11] (HET) 
LPAC to PFIC3 (Poupon et al., 2010) 
HOM LPAC (Rosmorduc et al., 2001) 
HOM LPAC (Rosmorduc et al., 2003) 
HOM ICP (Pauli-Magnus et al., 2004b) 
HET + V444A [on ABCB11] + 
-1G>T [on FXR] (HET) 
ICP (Zimmer et al., 2009) 
HOM + V444A [on ABCB11] ICP (Keitel et al., 2006) 
HET ICP (Bacq et al., 2009) 
M301T 902T>C MSH5 HET LPAC (Rosmorduc et al., 2003) ++++ +++++ PM 36 
A546D 1637C>A NBD1 HET ICP (Dixon et al., 2000) +++ +++ IC 33 
R545C 1633C>T NBD1 Unknown PSC (Pauli-Magnus et al., 2004a) ++ ++ IC 21 
G535D 1605G>A NBD1 HET 
LPAC (juvenile) to 
ICP (2× pregnancy) to 
BC (at 47 years) 
(Lucena et al., 2003) ++++ +++++ PM 4 
A286V 857C>T ICL2 S320F [on 2
nd
 allele] PFIC3 (Degiorgio et al., 2007) ++++ ++++ PM 1 
Table 6-1. ABCB4 non-synonymous mutations analysed in this study. 
The zygosity of index patients is indicated as: homozygous (HOM), heterozygous (HET) or compound heterozygous (c.HET). The data obtained from the experiments 
described here are outlined in the last four columns. The level of expression of WT and variant ABCB4 as obtained by western analysis is summarised as: +++++ > ++++ > 
+++ > ++ > +. The subcellular localisation and ability to efflux PC in a taurocholate-dependent manner of WT and variant ABCB4 are also indicated. ICL, intracellular loop; 
MSH, membrane-spanning helix; NBD, nucleotide-binding domain; n/a, not applicable; ICP, intrahepatic cholestasis of pregnancy; LPAC, low phospholipid-associated 
cholelithiasis; PFIC3, progressive familial intrahepatic cholestasis Type 3; BC, biliary cirrhosis; PSC, primary sclerosing cholangitis; PM, plasma membrane; IC, 
intracellular compartment. 
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membrane. The cytotoxicity of ABCB4 was reduced to a background level upon co-
expression of the ATP8B1/CDC50A complex. This led to a dramatic increase in the level 
of ABCB4 and permitted the localisation of the protein to the plasma membrane. 
Furthermore, ABCB4 was able to flop PC in a bile salt-dependent manner (Groen et al., 
2011). Most importantly, these observations were confirmed in an in vivo mouse model 
whereby the canalicular membrane of mice deficient in both Atp8b1 and Abcb4 expression 
was more resistant to bile salt-mediated damage than the membrane of mice deficient on 
only Atp8b1 or Abcb4 (Groen et al., 2011). These observations are the basis for the 
heterologous expression system employed here for the characterisation of nine ABCB4 
variants that had been linked to cholestatic liver disease by genetic studies. 
 
ABCB4 has been expressed successfully in polarised cells [human hepatocellular carcinoma 
(HepG2) and Madin-Darby canine kidney (MDCK) II cells (Delaunay et al., 2009), pig 
kidney epithelial cells (LLC-PK1) (van Helvoort et al., 1996), and HEK293 (Morita et al., 
2007)] and shown to translocate PC across the plasma membrane in apparent contradiction 
of the results reported by Groen et al. However, although HepG2 cells express ATP8B1 
endogenously (Martinez-Fernandez et al., 2009), the level of endogenous ATP8B1 
expression was not investigated in any of the other cell lines where ABCB4 function has 
been investigated. In addition, in these earlier and contemporaneous studies, ABCB4 
expression and function were studied in stably-transfected cells (rather than by transient 
transfection employed in the present study). This may have led to the selection of cells 
expressing low levels of WT ABCB4 or mutated ABCB4, due to negative selective pressure 
against ABCB4 function. It is also possible that compensatory secondary changes, for 
example upregulation of a PS-flippase, ensued allowing for the deleterious effect of the PC-
floppase to be tolerated. 
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HEK293T cells do not express ABCB4 endogenously (Figure 4-1) making them an ideal 
expression system to study the transporter. They are also highly transfectable and 
recombinant ATP8B1 and CDC50A can be expressed without deleterious effect on the 
cells (Groen et al., 2011). WT ABCB4 expression is significantly and consistently improved 
in the triple transfected cells (Figure 4-2) suggesting that endogenous ATP8B1 expression 
in HEK293T cells is limited. 
 
6.3 Variant protein phenotype 
The three lines of in vitro evidence, expression, localisation and function, described in this 
report are used to characterise variant protein phenotype. These are summarised here and 
related to the published patient phenotypes and genotypes. 
6.3.1 S320F and A286V ABCB4 
S320F and A286V have been linked to the most severe ABCB4-related liver disease, PFIC3 
(Degiorgio et al., 2007). S320F ABCB4 was identified in two patients, in one case as a 
compound heterozygote with the missense mutation A286V in the second allele and in the 
second case as a compound heterozygote with the nonsense mutation Y279X. Poupon et al. 
also reported the S320F variant in two siblings as a compound heterozygous alteration with 
A593D (c.2858C>A) (Poupon et al., 2010), a mutation previously linked to PFIC3 in the 
homozygous state (Keitel et al., 2005). In these two patients, a heterozygous alteration 
(V444A; c.1331T>C) affecting ABCB11 was also detected which is reported to predispose 
to cholestatic disorders (Lang et al., 2007, Meier et al., 2006, Meier et al., 2008, Pauli-
Magnus et al., 2004b). Both subjects were diagnosed with LPAC in their early twenties 
which progressed to PFIC3 several years later necessitating liver transplantation (Poupon et 
al., 2010). 
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According to the western analysis performed in this study (Table 4-3), the high level of 
expression of A286V in the single-transfected cells suggests that the protein has lost its 
deleterious PC-flopping activity. The improved expression of S320F compared to WT in 
the single-transfected cells, and its low level of expression in the triple-transfected cells 
suggested this variant to have lost activity as well as stability, possibly due to a folding 
defect. However, by CLSM, it was evident that both mutants are able to traffic to the 
plasma membrane (Table 6-1). In keeping, immunostaining on liver sections from two 
PFIC3 patients harbouring both the S320F and the A593D variants revealed normal 
canalicular membrane localisation of mutant ABCB4 (Poupon et al., 2010). However, the 
TC-dependent PC-efflux activity of the S320F variant was reduced to half the level of the 
WT protein whereas, the A286V was inactive (Table 6-1). Taken together, these data 
provide an explanation for the PFIC3 phenotype observed in compound heterozygous 
patients (Degiorgio et al., 2007, Poupon et al., 2010). The reduced expression of the S320F 
variant results in a 50% reduction in PC-efflux that when combined with the inactivity of 
the A286V or Y279X variants in the same patient, likely results in a severe reduction in PC 
efflux. The low lipid content of the bile would make the relatively high bile salt 
concentration toxic and this would plausibly lead to chronic and progressive liver disease 
eventually leading to liver failure, characteristic of PFIC3 (Davit-Spraul et al., 2009). The 
late onset of PFIC3 in these two patients is most likely due to the PC-efflux activity of the 
small amount of S320F variant present in the canalicular membrane. Given this 
interpretation it is most likely that the uncharacterised A593D variant in the patient 
identified by Poupon et al., will be unable to efflux PC. 
 
The S320F variant has also been reported in ICP (Bacq et al., 2009, Keitel et al., 2006, 
Pauli-Magnus et al., 2004b) and LPAC patients (Rosmorduc et al., 2003, Rosmorduc et al., 
2001). LPAC is characterised by low phospholipid content in the bile and symptomatic and 
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recurring cholestasis in young adults with an apparent prevalence in the female population 
(Rosmorduc and Poupon, 2007). The LPAC patients were all homozygous for S320F 
indicating that the affect of the S320F mutation on ABCB4 function is not so severe as to 
result in PFIC3. Indeed, a 50% TC-dependent PC-efflux compared to cells expressing the 
WT protein suggests that this residual PC-flopping activity permits adequate efflux of PC 
to partially alleviate the detergent effect of bile salts in the biliary tract preventing 
progressive deterioration of the biliary epithelium. 
 
ICP presents in the third trimester of pregnancy with maternal pruritus and abnormal liver 
function (Reyes and Simon, 1993). Mutations in the coding regions of ABCB4 and 
ABCB11 confer genetic susceptibility to the development of the disease (Geenes and 
Williamson, 2009). Although the genetic predisposition plays an important role in the 
occurrence of ICP, the expression of the disease is also likely to be modulated by 
pregnancy hormones such as progesterone and oestrogens as well as by environmental 
factors (Arrese and Reyes, 2006, Lammert et al., 2000). In ICP patients, the S320F variant 
has been identified both in the homozygous state (Keitel et al., 2006, Pauli-Magnus et al., 
2004b) and heterozygous with the WT allele (Bacq et al., 2009). In one ICP patient 
homozygous for the S320F mutation, ABCB4 localisation at the canalicular membrane did 
not seem to be affected as shown by immunostaining of ABCB4 in liver sections (Keitel et 
al., 2006). This is in agreement with the observations presented here following CLSM 
analysis of the variant in vitro, but the immunostaining data are unlikely to be sufficiently 
sensitive to demonstrate quantitative differences in the level of the transporter at the cell 
membrane. It is likely, therefore, that the elevated levels of pregnancy hormones or their 
metabolites during the third trimester negatively modulate S320F ABCB4 function or, 
transiently, further reduce the level of the transporter in the canalicular membrane allowing 
the condition to manifest. 
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6.3.2 M301T, P1161S, L591Q and E528D ABCB4 
The genetic contribution in the development of gallstones is still under investigation but 
ABCB4 gene defects are thought to impose a high risk factor in acquiring the LPAC 
syndrome. The ABCB4 variants M301T, P1161S, L591Q and E528D have all been 
identified in patients with LPAC (Nakken et al., 2009, Rosmorduc et al., 2003, Rosmorduc 
et al., 2001). 
 
The M301T variant was described as a heterozygous alteration (Rosmorduc et al., 2003). 
Based on the western analysis performed here, M301T is amongst the mutants that appear 
to have lost their deleterious PC-flopping activity (Table 4-3). CLSM analysis revealed a 
staining pattern consistent with plasma membrane localisation (Table 6-1) but, the TC-
dependent PC-efflux activity of M301T was only 36% of the level of WT ABCB4 (Table 
6-1). The expression of this variant along with the WT protein in the heterozygous patient, 
probably means that there is a significant amount of PC effluxed into the bile resulting in 
slow disease progression and the appearance of symptoms only later in life [mean age at 
presentation 38.1 years; (Rosmorduc et al., 2003)]. Environmental and/or dietary factors, 
are likely to play a role leading to the formation of bile with decreased PC content and 
increased lithogenicity, injury of the biliary membrane and eventually the development 
LPAC in patients with accompanying increased γ-glytamiltransferase (γ-GT) activity in the 
serum (Rosmorduc and Poupon, 2007). 
 
Western analysis of the L591Q, E528D and P1161S variants suggested a WT phenotype 
(Table 4-3) and CLSM analysis suggests normal plasma membrane localisation (Table 6-1). 
Moreover, all three variants maintain a high level of TC-dependent PC-efflux activity 
(Table 6-1). Although the E528D and P1161S variants consistently present with lower PC-
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efflux activity than the WT activity (means of 66 and 61%, respectively), they are not 
statistically different (Figure 5-2).  
 
Environment and/or dietary factors therefore, likely play an important role in the 
development of LPAC in patients with the P1161S, L591Q and E528D mutations. Of 
note, the E528D variant has also been linked to ICP in a study where only exons 14-16 of 
the ABCB4 gene locus was sequenced from each patient (Floreani et al., 2008). As 
discussed earlier, it is possible that the elevated hormonal levels during the third trimester 
of pregnancy lead to the development of ICP in this patient (Jacquemin et al., 1999) or that 
additional mutations were present on any of the exons which were not sequenced by 
Floreani et al. 
 
Another possibility is that these represent normal variants in the population and the LPAC 
has a different aetiology in these patients. It is also possible that additional mutations were 
present in other gene loci involved in bile synthesis and flow, such as ABCB11 or FXR, 
which were not identified in the analyses performed by Rosmorduc et al. and Nakken et al. 
but have been described in other patients with cholestatic syndromes (Keitel et al., 2006, 
Poupon et al., 2010, Zimmer et al., 2009). 
 
It is also becoming increasingly apparent that mutations which disrupt the splicing 
machinery can have a causative role in a number of human diseases (Wang and Cooper, 
2007). Byrne et al. recently reported the impact of 62 missense mutations and 21 SNPs in 
ABCB11 on pre-messenger RNA (pre-mRNA)-splicing that have been linked to cholestatic 
liver disease (Byrne et al., 2009). Mutant sequences were cloned into a minigene vector and 
differentially-spliced products were amplified and quantified by real-time polymerase chain 
reaction (RT-PCR). Using this technique, Byrne et al. demonstrated that a number of 
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mutations caused exon skipping and therefore decreased the amount of normally spliced 
product generated by the minigene construct (Byrne et al., 2009). Of note was the effect on 
pre-mRNA splicing of c.1445A>G (p.D482G), which results in a mRNA that introduces 
14 novel amino acids and a premature stop codon to the polypeptide (Byrne et al., 2009). 
 
In vitro studies on the subcellular localisation and bile salt-efflux function of the same 
D482G mutant expressed from a cDNA have reported inconsistent results and this could 
be attributable to differences in the assay systems used by each group or inter-species 
differences between the rat, mouse and human protein (Hayashi et al., 2005, Kagawa et al., 
2008, Plass et al., 2004, Wang et al., 2002). Expression of the human D482G ABCB11 in 
MDCK II cells revealed that the protein was mostly present in the immature 
unglycosylated form which accumulated intracellularly, however, the mutant protein 
displayed normal bile-salt transport function in isolated inside-out membrane vesicles from 
HEK293 cells (Hayashi et al., 2005). 
 
The altered pre-mRNA splicing identified by Byrne et al. offers a plausible explanation for 
the linkage of D482G in PFIC2 patients. If altered pre-mRNA splicing of the D482G 
mutant allele is the predominant allele in PFIC2 patients, very little, if any, D482G 
ABCB11 will be present at the bile canaliculi. This would be consistent with 
immunostaining patterns in the liver of PFIC2 patients with the D482G mutation where 
ABCB11 is severely reduced or completely undetectable (Strautnieks et al., 2008). It 
remains possible therefore that the ABCB4 variants, L591Q, P1161S and E528D, are 
indeed mutations that lead to altered pre-mRNA splicing which affects the abundance of 
full-length ABCB4 in these patients. 
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6.3.3 G535D ABCB4 
The G535D variant was identified in a patient with a heterozygous genotype and a complex 
phenotype (Lucena et al., 2003). The patient developed LPAC during adolescence which 
was followed by ICP in two pregnancies and finally biliary cirrhosis (BC) at the age of 47 
(Lucena et al., 2003). Immunostaining of liver sections from the patient revealed reduced 
staining for ABCB4 at the canalicular membrane compared to sections from a control liver 
(Lucena et al., 2003). Lucena et al. postulated that the affect of G535D on ABCB4 is 
relatively mild resulting in a slow progression of liver disease. From my data, recorded in 
vitro, the level of G535D ABCB4 at the plasma membrane of HEK293T cells was high in 
the single-transfected cells and higher still in the triple-transfected cells. CLSM analysis 
showed that this variant can traffic to the plasma membrane (Table 6-1). However, TC-
dependent PC-efflux showed that the G535D ABCB4 variant retains only 4% of the PC-
flopping activity of the WT protein (Table 6-1). Since the patient was heterozygous at the 
ABCB4 locus suggests that expression of the normal allele partially compensates for the 
reduced activity of the G535D variant. This would allow for the slow formation of 
cholesterol gallstones as a result of the high lithogenicity of the low PC-content bile. 
During pregnancy, negative modulation of ABCB4 by sex hormones would likely 
contribute to the development of ICP (Jacquemin et al., 1999) and the progressive damage 
caused by the built-up of cholesterol and the toxic effect of bile may eventually have led to 
BC in this patient. 
6.3.4 A546D and R545C ABCB4 
Another ABCB4 variant which has been implicated in ICP is A546D which was identified 
in a patient heterozygous for this locus (Dixon et al., 2000). The mutation was reproduced 
in ABCB1, the closest homologue of ABCB4, and shown to cause a trafficking defect 
because the protein failed to traffic efficiently to the plasma membrane. However, the 
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fraction that reached the plasma membrane was functional and could efflux drugs, the 
normal allocrites for ABCB1 (Dixon et al., 2000). The data presented here (Table 4-3) are 
in agreement with these earlier observations. The fact that the level of expression of the 
A546D variant does not achieve the level of expression of the WT protein in the triple 
transfection suggests difficulty with folding or trafficking; a folding defect would likely 
result in degradation of the A546D protein by the ERAD (ER-associated degradation) 
pathway (Meusser et al., 2005, Vembar and Brodsky, 2008). Indeed, when the subcellular 
localisation of A546D ABCB4 protein was analysed by CLSM, the majority of protein 
appeared to accumulate in an intracellular compartment which is consistent with the 
reduced TC-dependent PC-efflux activity (33% of the WT protein) observed for cells 
expressing this variant (Table 6-1). 
 
In a study by Pauli-Magnus et al., the role of ABCB4 and ABCB11 genetic variations in the 
pathogenesis of PBC and PSC was investigated (Pauli-Magnus et al., 2004a). Although the 
authors could not conclude definitely that ABCB4 (and ABCB11) genes co-segregate with 
the development of PSC or PBC in patients, the R545C variant was found to be specific to 
the PSC population (Pauli-Magnus et al., 2004a). Western analysis shows that the 
expression of R545C ABCB4 is greatly reduced and not influenced by the co-expression of 
ATP8B1 and CDC50A. The subcellular localisation of the R545C ABCB4 protein closely 
resembles the pattern observed for the A546D variant; i.e., intracellular accumulation, in 
line with the reduced TC-dependent PC-efflux activity (21% of WT ABCB4) (Table 6-1). 
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6.4 Modelling of the ABCB4 mutations on the structural data for Abcb1a 
and Sav1866 
A crystal structure of ABCB4 is currently unavailable. However, the crystal structures of 
related ABC transporters, drug-efflux pumps from mouse (Abcb1a) and bacteria (Sav1866) 
have been resolved, albeit at a medium resolution (Aller et al., 2009, Dawson and Locher, 
2006). Alignment of the primary sequence of ABCB4 with Abcb1a and Sav1866 in 
ClustalW (Appendix I) allowed specific ABCB4 amino acid residues to be mapped on the 
structural models to gain insight into how specific mutations affect the PC-floppase. 
ABCB4 was found to be 73% identical, 83% similar to Abcb1a, and 27% identical, 44% 
similar to Sav1866 (aligned to the amino-terminal half of ABCB4). 
 
The A546D, R545C, S320F, M301T G535D and A286V ABCB4 mutants, all displayed 
reduced cellular TC-dependent PC-efflux activity compared to the WT protein (Table 6-1). 
S320F, A545D and A546D appear to affect the protein primarily at the level of folding 
and/or trafficking, while M301T G535D and A286V appear to affect the PC-transport 
activity. 
  
The mutated amino acid residues in ABCB4 and their equivalent residues in Abcb1a and 
Sav1866 following sequence alignment are shown in Table 6-2. Some ABCB4 residues are 
perfectly conserved in all three transporters (e.g. G535 and R545), some are only conserved 
between the more closely related ABCB4 and Abcb1a (ABCB4A286, ABCB4M301 and 
ABCB4A546), whereas ABCB4S320 is represented by a semi-conservative change in Abcb1a 
(threonine) and in Sav1866 by another amino acid with a relatively small side-chain but no 
hydroxyl group (alanine).  
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Amino Acid Residue 
ABCB4 Abcb1a Sav1866 
A286V A280 F233 
M301T M295 F248 
S320F T314 A267 
G535D G529 G480 
R545C R539 R490 
A546D A540 I491 
Table 6-2. ABCB4 mutant amino acid residues and their equivalents in murine Abcb1a and bacterial 
Sav1866. 
 
6.4.1 ABCB4A546 
In Figure 6-1, a cartoon model of Abcb1a is presented in a colour-coded format: TMD1, 
yellow; NBD1, grey; TMD2, purple; NBD2, green. The ABCB4A546 equivalent is shown in 
Abcb1a (Abcb1aA540) as red spheres on NBD1 (Figure 6-1A) and as elemental spheres in 
close up in Figure 6-1B and C. The structural fold of NBD1 is given in Figure 6-1B and the 
comprising alpha (α) helices and beta (β) sheets are numbered in ascending order from the 
amino terminus of the domain. The order is as follows: β1-β2-β3-α1-β4-α2-β5-α3-α4-α5-
α6-α7-β6-α8-β7-α9-β8-β9-α10-α11. Abcb1aA540 is located in α7, the final α-helix of the α-
helical subdomain (Figure 1-3). All of the amino acid residues within 5Å of Abcb1aA540 are 
shown in stick format and include several in the adjacent β-strand, β5. In the Abcb1a 
model A540 is only involved in intra-helical hydrogen bonds that would be no different if 
replaced by an aspartic acid, so long as α7 adopts the same secondary structure. However, 
alanine has a volume of 88.6Å3 whereas the volume of aspartic acid is 111.1Å3 
(http://www.fli-leibniz.de/IMAGE_AA.html). Replacing an alanine (Ala; A) with the 
larger and negatively charged aspartate (Asp; D) is therefore likely to sterically and 
electrostatically hinder the approximation of α7 and β5 of NBD1 preventing the domain 
from folding efficiently resulting in its intracellular retention and increased likelihood of 
degradation in the proteasome. 
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Figure 6-1. Mapping the ABCB4
A546
 residue on Abcb1a (Abcb1a
A540
). 
(A). Cartoon model of Abcb1a (PDB: 3G5U). NBD1 is coloured grey and NBD2 is coloured green. 
TMD1 is coloured yellow and TMD2 is coloured purple. The horizontal dashed lines represent the 
approximate positioning of the lipid bilayer. Abcb1a
A540
 is represented by red spheres. (B). 
Secondary structure of NBD1. The α-helices and β-sheets of the NBD1 fold are numbered in 
ascending order from the amino-terminal of the domain as follows: β1-β2-β3-α1-β4-α2-β5-α3-α4-α5-
α6-α7-β6-α8-β7-α9-β8-β9-α10-α11. (C). Abcb1a
A540
 is shown in coloured elemental spheres (C, 
green; N, blue; O, red) in alpha (α)-helix 7. Amino acid residues within 5Å of Abcb1a
A540
 are shown 
in stick format. 
 
6.4.2 ABCB4R545 
Abcb1aR539 (ABCB4R545) is adjacent to Abcb1aA540 on α7 (Figure 6-2A). In Figure 6-2B, 
Abcb1aR539 is illustrated in stick format on α7 and coloured elementally. In this close up 
view the side chain of Abcb1aR539 can be seen to hydrogen bond (orange dashes) to the 
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carbonyl group of the peptide backbone of Abcb1aV474 in the loop region between β5 and 
α3 which includes the Q-loop (Hopfner et al., 2000). 
 
 
Figure 6-2. Mapping the ABCB4
R545
 residue on Abcb1a (Abcb1a
R539
). 
(A). Cartoon model of Abcb1a (PDB: 3G5U). NBD1 is coloured grey and NBD2 is coloured green. 
TMD1 is coloured yellow and TMD2 is coloured purple. The horizontal dashed lines represent the 
approximate positioning of the lipid bilayer. Abcb1a
R539
 is represented by red spheres. (B). 
Abcb1a
R539
 and Abcb1a
V474
 illustrated in stick format on α7 and the loop region between β5 and α3, 
respectively, and coloured elementally (C, green; N, blue; O, red). Abcb1a
R539
 hydrogen bonds 
(orange dashes) to the carbonyl group of the peptide backbone of Abcb1a
V474
. Alpha (α)-helices 
and beta (β)-sheets are numbered as per Figure 6-1B. 
 
The Q-loop contains a highly conserved glutamine (Q) residue in an eight-residue loop 
which links the “core” subdomain with the α-helical subdomain of the NBD (Figure 1-3). 
It has been proposed that conformational changes in the Q-loop during the catalytic cycle 
transmit information between the NBDs and the TMDs (Dalmas et al., 2005, Jones and 
George, 2002). The hydrogen bond between Abcb1aR539 and Abcb1aV474 likely stabilizes the 
tertiary structure of this region. When ABCB4R545 is replaced by a cysteine (ABCB4R545C) the 
absence of this hydrogen bond could make folding, and therefore stability and trafficking 
of ABCB4-R545C difficult. 
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6.4.3 ABCB4S320 
Abcb1aT314 (ABCB4S320) is shown as red spheres in the extracellular loop at the end of 
MSH5 (Figure 6-3A).  
 
 
Figure 6-3. Mapping the ABCB4
S320
 residue on Abcb1a (Abcb1a
T314
). 
(A). Cartoon model of Abcb1a (PDB: 3G5U). NBD1 is coloured grey and NBD2 is coloured green. 
TMD1 is coloured yellow and TMD2 is coloured purple. The horizontal dashed lines represent the 
approximate positioning of the lipid bilayer. Abcb1a
T314
 is represented by red spheres. (B). Close 
up view of the Abcb1a extracellular loops. Abcb1a
T314
 is shown as spheres coloured elementally 
(C, green; N, blue; O, red). All residues within 5Å of Abcb1a
T314
 are shown in stick format. 
 
Abcb1aT314 is the first of a threonine (T)-serine (S) dipeptide in Abcb1a, i.e. Abcb1aT314-S315. 
This dipeptide is reversed in ABCB4 as ABCB4S320-T321 perhaps suggesting that the side 
chain hydroxyls of these two residues form important inter-helical hydrogen bonds. In the 
model of Abcb1a, while Abcb1aS315 is close enough for its side-chain to form a hydrogen 
bond with Abcb1aN747 (asparagine) in MSH2, Abcb1aT314 appears to form only intra-helical 
hydrogen bonds. While side-chain interactions of Abcb1aT314 in other conformations of the 
transport cycle cannot be ruled out, it is possible to speculate that in the ‘inwardly open 
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conformation’ shown for Abcb1a, replacing Abcb1aT314 with a bulkier phenylalanine (F) 
would hinder the formation of the tight extracellular turn of MSH5 into MSH6 and may 
sterically hinder the close packing of MSH4 (all residues within 5Å of Abcb1aT314 are shown 
in stick format in Figure 6-3B). 
 
6.4.4 ABCB4G535 
Abcb1aG529 (ABCB4G535) is shown as red spheres in NBD1 of Abcb1a (Figure 6-4A; grey). 
This amino acid residue is part of the ABC signature motif. The ABC signature (LSGGQ) 
which is also known as the C-motif is unique to the ABC superfamily (Hyde et al., 1990). 
In a full ABC transporter, the NBDs align in a “head-to-tail” arrangement such that the 
Walker A motif of one NBD is in close association with the ABC signature motif of the 
apposing NBD allowing two ATP molecules to be trapped at the interface (Jones et al., 
2009, Rees et al., 2009, Zolnerciks et al., 2011). 
 
The importance of this residue is best illustrated in Sav1866 (color-coded elemental spheres 
of Sav1866G480 in grey NBD) which was crystallized in closed conformation with 2×ADP 
at the interface (Dawson and Locher, 2007) imaged from above (Figure 6-4B; top panel), 
and in the α-helical subdomain of the isolated Sav1866 NBD with ADP and with the rest 
of the ABC signature motif in stick format (L478S479G480G481Q482; Figure 6-4B; bottom 
panel). The two glycine (G) residues in the ABC signature motif are essential to form the 
tight α-helical turn leading in to α7. Replacing one of these glycine residues with a larger, 
negatively-charged aspartate as in the ABCB4-G535D mutant would likely alter the 
conformation of the ABC signature motif which is necessary for interaction with the 
juxtaposed ATP. With a misfolded ABC-signature motif the G535D mutant would likely 
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be unable to bind ATP in this pocket and would therefore be unlikely to function as a 
transporter. 
 
 
Figure 6-4. Mapping the ABCB4
G535
 residue on Abcb1a (Abcb1a
G529
). 
(A). Cartoon model of Abcb1a (PDB: 3G5U). NBD1 is coloured grey and NBD2 is coloured green. 
TMD1 is coloured yellow and TMD2 is coloured purple. The horizontal dashed lines represent the 
approximate positioning of the lipid bilayer. Abcb1a
G529
 is represented by red spheres. (B). 
Secondary structure of the NBD-NBD dimer in Sav1866 with 2×ADP trapped at the interface (PDB: 
2ONJ) (Dawson and Locher, 2007) imaged from above (top panel), and as an isolated NBD with 
ADP and with the ABC signature motif in stick format (bottom panel) coloured elementally (C, 
green; N, blue; O, red). The two glycine (Gly; G) residues (G529 and G530) in the ABC signature 
motif are essential to form the tight alpha helical turn leading in to α7. Alpha (α)-helices and beta 
(β)-sheets are numbered as per Figure 6-1B. 
 
6.4.5 ABCB4A286 and ABCB4M301 
Abcb1aA280 and Abcb1aM295, the equivalents of ABCB4A286 and ABCB4M301 respectively, are 
indicated as red spheres on MSH5 of TMD1 in Figure 6-5A. Neither residue is involved in 
inter-helical interactions; Abcb1aM295 is expected to be exposed to the lipid bilayer if the 
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Abcb1a conformation is correctly interpreted and Abcb1aA280 would be at the intracellular 
face of the membrane.  
 
 
Figure 6-5. Mapping the ABCB4
A286 
and ABCB4
M301
 residues on Abcb1a (Abcb1a
A280
/Abcb1a
M295
) 
and Sav1866 (Sav1866
F233
/Sav1866
F248
). 
(A). Cartoon model of Abcb1a (PDB: 3G5U). NBD1 is coloured grey and NBD2 is coloured green. 
TMD1 is coloured yellow and TMD2 is coloured purple. The horizontal dashed lines represent the 
approximate positioning of the lipid bilayer. Abcb1a
M280 
and Abcb1a
M295
 are represented by red 
spheres. Both residues are exposed  on the outside of MSH5. (B). Cartoon model of Sav1866 (PDB: 
2ONJ) with similar colour coding as in A. Sav1866
F233
 and Sav1866
F248
 on MSH5 are orientated to 
face the internal cavity. (C). As in (B) but with TMD2 removed for clarity and the structure rotated 
180
o
 clockwise through the central Y axis to show the side chains of the two phenylalanines 
pointing towards the centre of the protein. 
 
When modelled on the Sav1866 structure the equivalents of ABCB4 A286 and M301 
(Sav1866F233 and Sav1866F248, respectively) are positioned such that their side chains point 
towards the central cavity of bacterial drug efflux pump (Figure 6-5B and C). Replacing an 
alanine (neutral, non-polar side chain) with a valine (neutral, non-polar side chain), or a 
methionine (neutral, non-polar side chain) with a threonine (neutral, polar side chain) 
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introduces a subtle change in the polypeptide that appears unlikely to affect the secondary 
structure of ABCB4. It is not clear why these mutations (ABCB4-A286V and ABCB4-
M301T) have an impact on function but both are in the same MSH which may change 
conformation during the transport cycle and so it is possible that they are involved directly 
in the binding of PC. 
 
6.5 Future Work 
6.5.1 The ICP-associated ABCB4 variants. Are they influenced by hormones? 
ICP usually develops during the third trimester of pregnancy and is characterised by raised 
serum bile acids and γ-GT as well as severe pruritus. The condition persists until delivery 
after which the symptoms usually resolve within 48 hours (Geenes and Williamson, 2009). 
In addition to the genetic susceptibility conferred by mutations in the ABCB4, ABCB11 
and ATP8B1 gene loci (Dixon and Williamson, 2008), hormonal factors and environmental 
cues are thought to contribute to the pathogenesis of the disease (Geenes and Williamson, 
2009). 
 
Seasonal variation, dietary regime, geographical location as well as ethnicity, all appear to 
have an influence on the development of ICP (Pusl and Beuers, 2007). The fact that ICP is 
more common in twin pregnancies (Gonzalez et al., 1989), develops during the third 
trimester when oestrogen levels are at their maximum and resolves soon after delivery 
when pregnancy-related hormone levels return to their normal (Reyes and Simon, 1993), 
suggests that reproductive hormones play a role in the pathogenesis. 
 
Studies performed using estrogen (estradiol-17β-glucuronide; E217βG) and sulphated 
progesterone (5α-pregan-3α-ol-20-one; PM4-S and 5α-pregan-3β-ol-20-one; PM5-S) 
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metabolites have provided evidence that they can trans-inhibit ABCB11 and reduce bile 
flow (Stieger et al., 2000, Vallejo et al., 2006). In isolated vesicles from the canalicular 
plasma membrane of rat liver (cLPM), E217βG exhibited dose-dependent inhibition of TC 
transport into inside out cLPM vesicles but not in Abcb11-expressing vesicles from Sf9 
insect cells. However, co-expression of Abcc2 and Abcb11 in Sf9 cells restored the 
E217βG dose-dependent inhibition of TC transport prompting the authors to conclude 
that E217βG can only inhibit Abcb11 function, and thereby induce cholestasis, after it is 
excreted into the bile canaliculus by Abcc2  (Stieger et al., 2000). 
 
In experiments performed in isolated perfused rat liver, it was demonstrated that PM4-S 
could negatively modulate bile salt efflux (Vallejo et al., 2006). Vallejo et al. then used 
Xenupus laevis oocytes as an experimental model to investigate whether the reduction in bile 
salt efflux was due to an inhibition of Abcb11 function. Rat Abcb11 was expressed in X. 
laevis oocytes and the effect of PM4 and PM5 and their sulphated derivatives (PM4-S and 
PM5-S, respectively) as well as E217βG, on Abcb11-mediated efflux, was measured from 
bile salt loaded oocytes (Vallejo et al., 2006). It was shown that PM4 and PM5 had no 
effect on Abcb11-mediated efflux whereas PM4-S, PM5-S and E217βG had a significant 
negative effect (Vallejo et al., 2006). 
 
It is plausible therefore, that E217βG and/or progesterone metabolites induce a similar 
effect on ABCB4 function and increased effect on E528D, S320F, A546D and G535D. 
This is now testable for the ICP-related ABCB4 variants using the TC-dependent PC efflux 
assay described in this thesis. This may help to clarify the role of reproductive hormones in 
the aetiology of ICP.  
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6.5.2 The S320F, R545C and A456D ABCB4 mutants; candidates for therapeutic 
intervention? 
It seems likely that the apparently low level of activity of the S320F, R545C and A546D 
ABCB4 mutants is, at least in part, due to a folding defect which results in depletion of the 
protein from the membrane. The PC-efflux activity of cells expressing these three mutants 
[49% (P<0.01) for S320F; 33% (P<0.005) for A546D; and 21% (P<0.005) for R545C; 
compared to WT ABCB4] suggests that the fraction of the protein that is able to fold 
properly and reach the plasma membrane is able to efflux PC efficiently. 
 
For other proteins it has been demonstrated in vitro that some mutants can be fully 
functional provided they can escape the quality control machinery. This has been achieved 
by growth at reduced temperature or in the presence of pharmacological agents (Delaunay 
et al., 2009, Denning et al., 1992, Gautherot et al., 2012, Hayashi and Sugiyama, 2007, Plass 
et al., 2004, Wang et al., 2006). Pharmacological agents have also been used successfully in 
the clinic to improve disease outcome. In ABCC7 the ΔF508 mutation is a deletion of a 
phenylalanine at position 508 and it is the most common mutation amongst CF patients 
(Cutting et al., 1990). The mutation causes retention of the ABCC7 ΔF508 species in the 
ER and its subsequent degradation by the proteasome (Cheng et al., 1990). However, if it 
can escape degradation it can fold and traffic to the plasma membrane where it retains its 
chloride channel function (Li et al., 1993). Sodium 4-phenylbutyrate (4-PBA) is a clinically-
approved pharmacological chaperone that has been used successfully in patients 
homozygous for the ΔF508 mutation and shown to induce ABCC7 function in the nasal 
epithelia (Rubenstein et al., 1997). 4-PBA has also been used successfully in a patient with 
PFIC2 (with a homozygous ABCB11 mutation) and shown to improve liver function and 
reduce clinical cholestasis (Gonzales et al., 2012). 
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At present, there is limited evidence on the effect of pharmacological chaperones on 
ABCB4 mutants. ABCB4 I541F has been reported in a homozygous patient with PFIC3 
(Jacquemin et al., 2001) and shown to cause a folding defect that prevents the correct 
localisation of the protein at the canalicular membrane of hepatic HepG2 cells (Delaunay et 
al., 2009). The use of cyclosporin A (CsA) [better known as an immunosuppressant and a 
substrate and competitive inhibitor of ABCB1 (Tamai and Safa, 1990)], improved plasma 
membrane localisation of ABCB4 I541F in vitro (Gautherot et al., 2012). Although 
Gautherot et al. were not able to verify whether the rescued protein was functional at the 
cell surface, they postulate that because the equivalent I541F mutation in ABCB1 allowed 
the drug-efflux pump to localise to the plasma membrane and efflux calcein-AM from 
MDCK cells in the presence of low concentrations of CsA, the ABCB4 I541F variant is 
likely to be functional as well (Gautherot et al., 2012). 
 
The discovery and development of pharmacological agents that enhance the transport 
activity or the plasma membrane localisation of mutant ABCB4 associated with cholestatic 
liver disease poses a major challenge. Although the functional rescue of disease-related 
mutations by a pharmacological chaperone has been well documented for other membrane 
proteins (Morello et al., 2000, Ulloa-Aguirre et al., 2004, Bernier et al., 2004), until now 
only one such agent (CsA) has been tested on ABCB4 I541F (Gautherot et al., 2012). The 
systematic screening of ABCB4 mutants to determine which are likely to be amenable to 
chemical intervention would be a good place to start. 
 
The S320F, R545C and A546D ABCB4 mutants are characterised by reduced expression 
but all retain TC-dependent PC-efflux activity. It is likely that each causes a folding defect 
which results in reduced abundance of the transporter in the membrane. Restoration of the 
expression level therefore represents a route to therapeutic intervention in patients carrying 
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these mutations. The use of pharmacological or chemical chaperones such as glycerol, 
thapsigargin, 4-PBA or CsA, which have been used and shown to improve plasma 
membrane localisation of other membrane proteins (Delisle et al., 2003, Egan et al., 2002, 
Hayashi and Sugiyama, 2007, Rubenstein et al., 1997, Sobolewski et al., 2008, Tveten et al., 
2007), would be good candidates to demonstrate the efficacy of this approach in vitro 
before seeking small molecules suitable for use in the clinic. 
 
6.6 Concluding remarks 
The link between genotype and clinical phenotype is not straightforward as some 
mutations that are apparently innocuous (following in silico analysis of amino acid changes) 
can have a dramatic impact on the protein and result in the development of disease 
(Thorisson et al., 2009). In order to appreciate the contribution of ABCB4 in the 
development of cholestatic liver disease, a detailed biochemical and molecular 
characterisation of mutant ABCB4 proteins associated with disease phenotypes is required.   
 
As part of the work described in this thesis, the affects of nine ABCB4 variants on protein 
expression, subcellular localisation and phospholipid efflux activity were studied revealing a 
variety of phenotypes in vitro. Deciphering the molecular pathogenesis of cholestatic disease 
can establish the foundations for the development of new pharmacological treatments. 
 
The prospect of discovering and designing small-molecule chemical agents that can target 
specific mutations in cholestatic patients is an exciting one. Mutants which retain PC-
flopping activity but are limited by folding or stability to a low level of abundance at the 
plasma membrane (e.g. S320F, R545C and A546D) would be particularly suited to 
intervention. In the work presented here I have identified three ABCB4 mutants that fall 
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into this category; S320F, R545C and A546D. These mutants are implicated in all of the 
liver diseases linked to ABCB4 including the most debilitating PFIC3. They also represent 
one third of the variants tested and so there are likely to be more among the 1334 SNPs 
reported in the literature and on databases (http://www.ncbi.nlm.nih.gov/snp). Screens to 
identify modulators of these and similar mutants would be the natural extension to this work 
and should be possible using the in vitro expression system described herein. 
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